Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 1of 123Clinical Study Protocol
Study Intervention Tezepelumab
Study Code D5180C00031
Version 3.[ADDRESS_942755] of Tezepelumab on the Humoral Immune Response to 
Seasonal Quadrivalent Influenza V accination in Adolescent and 
Young Adult Participant s with Mod erate to Severe Asthma 
(VECTOR )
Sponsor  Name: [CONTACT_271160]: 151 85 Södertälje, Sweden
Regulatory Agency Identifier  Number(s)
IND number: [ADDRESS_942756] procedures. The Clinical Study  Protocol  is publicly  registered and the results are 
disclosed and/or published according to the [COMPANY_008] Global Policy on Bioethics and in 
compliance wi th prevailing laws and regulat ions.
Protocol Number: D5180C00031
Amendment Number: 2.0
Study Intervention :Tezepelumab
Study Phase: 3b
Short Title: Tezepelumab Hum oralImmune Response to Influenza V accine Study
Acronym: VECTOR
Parexel Medical Monitor Name [CONTACT_9352] [CONTACT_694986] u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D 5 1 8 0 C 0 0 0 3 1 
C O N FI D E N TI A L A N D P R O P RI E T A R Y 2of 1 2 3 N ati o n al c o -or di n ati n g i n vesti g at or 
 
E d m o n d, O K 7 3 0 3 4, U S A. P P D 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 3of 123PROTOCOL AMENDMENT S UMMARY OF CHANGES TABLE
DOCUMENT HISTOR Y
Document Date
Version 1.0 02 Jun 2021
Amendment 1 , Version 2.0 07Sep2021
Amendment 2, Version 3.0 22Feb2022
The Protocol Amendment Summary  of Changes table is provided below for the current 
amendment.
Amendment 2 ( 22Feb2022)
Overall Rationale for the Amendment:
The primary  rationale for thi s amendment is to introduce a primary  database l ockaftertheend 
of treatm ent at Visit 7(Week 16 ) and to update safety informat ion based on the most recent 
Invest igator ’s Brochure, V ersion 5.0, dated [ADDRESS_942757] ion, medical device deficiencies, and Appendix F Medical Device Adverse 
Events ( AEs)to align with In ternat ional Organi sation for Standardi sation [ZIP_CODE] and European 
Medical Device Regulat ion. In addit ion, the vaccine immunogenicit y analysis set definit ion
was updated to exclude patients who experience influenza infection prior to V isit 7(Week 16) . 
Other minor changes included clarificat ion of Schedule of Assessments for participants who 
prem aturely  discontinue study  interventi on.In addit ion, minor formatting and editorial 
administrative revisio ns were made throughout the protocol for clarificat ion purpos es.
The Clinical Study  Protocol  (CSP), V ersion 2.0, dated 07 Sep2021, was updated with the 
following changes:
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 4of 123Section # and Name [CONTACT_415588]/
Non-substantial
Synopsis, Safety  
Endpoints; Section 
6.3.4 Ensuring 
Blinding; Section 
6.3.5 Methods of 
Unblinding; Section 
9.3 Populations for 
Analy ses, Table 10; 
Section 9.4 Statistical 
Analy ses; Section 
9.4.1 General 
Considerations; 
Section [IP_ADDRESS] Safety 
Endpoint(s) ; 
Section 9.5 Interim 
Analy sesLanguage relat ingto primary 
and final database locks was 
added.To add primary analy sis of 
data at Visit 7 (Week 16) .Substantial
Section 1.3 Schedule 
of Activities, Table 2; Footnote ‘b’ was added 
explaining procedures which 
are to occur at the 
investigational product 
discontinuation (IPD) visit.To clarify that if the IPD or 
follow -up safety  visit were to 
occur at the scheduled Visit 6 
(Week 12 )or Visit 7 
(Week 16), that participants 
should have the flu vaccine 
and antibody assessments per 
Visit 6 (
Week 12 )andVisit 7
(Week 16) .Substantial
Section 2.[ADDRESS_942758] new 
information based on 
Investigator’s Brochure (IB) 
V5.0IB V5.[ADDRESS_942759] been reported .Substantial
Section 2.2 
Background; Section 
[ADDRESS_942760] Characteristics (SmPc) 
reference was updated to the 
curren t version.The SmPc was updated in 
2021.Non-Substantial
Section 6.1. 3Medical 
DevicesAdded section regarding 
sponsor manufactured medical 
device use in this study and all 
medical device deficiencies 
should be documented and 
reported by [CONTACT_694987] [ZIP_CODE] and 
European Medical Device 
RegulationSubstantial
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 5of 123Section # and Name [CONTACT_415588]/
Non-substantial
Section 6.2.[ADDRESS_942761] 
discontinuation (IPD) visit.To clarify that if the IPD or 
follow -up safety  visit were to 
occur at the scheduled Visit 6 
(Week 12 )or Visit 7 
(Week 16), that participants 
should have the flu vaccine 
and antibody assessments per 
Visit 6 (Week 12) or Visit 7 
(Week 16).Substantial
Section 7.1 
Discontinuation of 
study InterventionLanguage was added explaining 
procedures to be followed if the 
follow -up visit occurs on the 
same date as the scheduled 
Visit 7 (Week 16 ).To clarify the procedures to be 
followed at the Follow -up 
visit.Substantial
Section [IP_ADDRESS] 
Reversibility Test and 
Post-BD FEV1 
AssessmentSecond post-BD spi[INVESTIGATOR_694946] -BD 
spi[INVESTIGATOR_038].Correction of an error. Non-substantial
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 6of 123Section # and Name [CONTACT_415588]/
Non-substantial
Section 8.3.12 
Medical Device 
DeficienciesAdded Section 8.3.12 
definitions of medical device 
deficiency and requirements to 
fulfil regulatory reporting 
obligations worldwide and 
investigator’s responsibility for 
detection and documentation of 
events meeting the definition of 
device deficiency occur during 
the study .To align with International 
Organization for 
Standardization [ZIP_CODE] and 
European Medical De vice 
Regulation.Substantial
Section 9.3
Populations for 
Analy ses Table 10
and Table 11Vaccine immunogenicity 
analy sis set population updated 
to exclude participants w ho 
experience an influenza 
infection prior to Visit 7 
(Week 16) assessments.To reduce the potential to 
interfere with the generation 
or interpretation of an 
antibody response.Substantial
Section 9.4 Statistical 
Analy sesAdded wording to indicate 
selected safety objectives will 
be performed based on the 
primary  database lock data.To allow for review of 
selected safety outputs at 
primary  database lock.Non-substantial
Appendix D Actions 
Required in Cases of 
Increases in Liver 
Biochemistry and 
Evaluatio n of Hy’s 
LawInvestigational Medicinal 
Product was updated to study 
interventio n.To ali gn with other sections. Non-substantial
Appendix F Medical 
Device AEs, ADEs, 
SAEs, SADEs, US 
ADEs and Medical 
Device Deficiencies: 
Definitio ns and 
Procedures for 
Recording, 
Evaluating and 
Follow -upAdded Appendix F Medical 
Device AEs, ADEs, SAEs, 
SADEs, U S ADEs and Medical 
Device Deficiencies: 
Definitio ns and Procedures for 
Recording, Evaluating and 
Follow -up.To align with International 
Organization for 
Standardization [ZIP_CODE] and 
European Medical Device 
Regulation.Substantial
Appendix H 
Maintenance Thera py 
Equivalence TableReference to GINA 2018 was 
updated to GINA 2021 .Correction of footnote t o align 
with the current version.Non-substantial
Appendix I 
AbbreviationsNew abbreviations were added. To include all abbreviations in 
the document.Non-substantial
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 7of 123Section # and Name [CONTACT_415588]/
Non-substantial
Appendix J Protocol 
Amendment HistoryAppendix J was added. Appendix was added to 
include previous amendments 
summaries of changes.Non-substantial
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 8of 123TABLE OF CONTENTS
TITLE P AGE ........................................................................................................................ [ADDRESS_942762] ivities....................................................................................... 18
2 INTRODUCTION ............................................................................................ 22
2.1 Study  Rati onale ................................................................................................ 22
2.2 Background ...................................................................................................... 23
2.3 Benefit/Risk Assessment ................................................................................... 26
2.3.1 Risk Assessment ............................................................................................... 26
[IP_ADDRESS] Important Identified Risks ................................................................................. 26
[IP_ADDRESS] Important Potential Risks .................................................................................. 26
2.3.2 Benefit Assessment ........................................................................................... 28
2.3.3 Overall Benefit: Risk Conclusio n...................................................................... [ADDRESS_942763] yle Considerat ions................................................................................... 38
5.3.1 Meals and Dietary  Restri ctions......................................................................... 38
5.3.2 Caffeine, Alcohol, and T obacco ......................................................................... 38
5.3.3 Activity............................................................................................................. 38
5.3.4 Contraception ................................
................................................................... 38
5.4 Screen Fai lures ................................................................................................. 39
6 STUDY  INTER VENTION ............................................................................... 40
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 9of 1236.1 Study  Intervent ion(s) Administered ................................................................... [ADDRESS_942764] igational Products .................................................................................... 40
[IP_ADDRESS] Management of Study  Intervent ion Related Reactions ...................................... [ADDRESS_942765] ............................................................................. 41
6.1.3 Medical Devices ............................................................................................... 42
6.2 Preparati on/Handling/Storage/Accountabilit y................................................... 42
6.2.1 Tezepelumab ..................................................................................................... 42
[IP_ADDRESS] Preparati on and Handling .................................................................................. 42
[IP_ADDRESS] Dose Preparation
............................................................................................... 43
[IP_ADDRESS] Dose Administration ......................................................................................... 44
6.2.2 Influenza vaccine .............................................................................................. 46
[IP_ADDRESS] Preparati on and Handling .................................................................................. 46
[IP_ADDRESS] Dose Administration ......................................................................................... [ADDRESS_942766] ion............................................................... 47
6.3 Measures to Minimize Bias: Rando mizat ion and Blinding ................................ 48
6.3.1 Parti cipant Enrollment and Randomizat ion....................................................... 48
6.3.2 Procedures for Handling Incorrectly Enro lled or Rando mized Participants ........ 48
6.3.3 Methods for Assigning Treatment Groups ......................................................... 49
6.3.4 Ensuring Blinding ............................................................................................. 49
6.3.5 Methods for Unblinding .................................................................................... 50
6.4 Study  Intervent ion Compliance ......................................................................... 51
6.5 Concomitant Therapy ........................................................................................ 51
6.5.1 Resc ue Medicine ............................................................................................... 54
6.5.2 Asthma Medicat ion Restri ctions....................................................................... 54
6.6 Dose Modificat ion............................................................................................ 54
6.7 Interven tion After the End of the Study ............................................................. 54
7 DISCONTINUA TION OF STUDY  INTER VENTION AND PARTICIPANT 
DISCONTINUA TION/WITH DRA WAL........................................................... [ADDRESS_942767] to Follow -up............................................................................................. 56
8 STUDY  ASSESSMENTS AND PROCEDURES .............................................. 57
8.1 Efficacy Assessments ........................................................................................ 57
8.1.1 Humoral Response to Influenza V accine ........................................................... 57
8.1.2 Spi[INVESTIGATOR_038]........................................................................................................ 57
[IP_ADDRESS] General requirements ........................................................................................ 57
[IP_ADDRESS] Spi[INVESTIGATOR_694947] ....................................................................................... 58
[IP_ADDRESS] Post-bronchodilator Spi[INVESTIGATOR_96656]........................................................................ 59
[IP_ADDRESS] Order of Administration .................................................................................... 59
[IP_ADDRESS] Reversibilit y Test  and Post -BD FEV 1Assessment ............................................. 59
[IP_ADDRESS] Record Keepi[INVESTIGATOR_007] ................................................................................................ [ADDRESS_942768] u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D [ADDRESS_942769] ................................ .................................... 6 8 
8. 3. 7 H y ’s La w ................................ ................................ .......................................... [ADDRESS_942770] ical H y p ot heses ................................ ....................................................... 7 5 
9. 2 S a m ple Si ze Deter mi nat i o n................................ ............................................... 7 5 
9. 3 P o p ul at i o ns f o r A nal yses ................................ ................................................... 7 5 C CI 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 11of 1239.4 Statistical Analyses ........................................................................................... 78
9.4.1 General Considerations ..................................................................................... 78
9.4.2 Efficacy ............................................................................................................ 78
[IP_ADDRESS] Primary Endpo int(s).......................................................................................... 78
[IP_ADDRESS] Secondary  Endpo int(s)...................................................................................... 80
[IP_ADDRESS] Exploratory  Endpo int(s).................................................................................... 81
9.4.3 Safety............................................................................................................... 81
[IP_ADDRESS] Safety Endpo int(s)............................................................................................ [ADDRESS_942771] ivities (Screening) ........................................................... [ADDRESS_942772] ivities (Rando mizat ion, Treatment , and Fo llow-up) ......... [ADDRESS_942773] imands .................................................................... 76
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 12of 123LIST OF APPENDICES
Appendix A Anaphylaxis: Signs and Symptoms, Management .................................... 83
Appendix B Changes Related to Mitigation of Study  Disrupti ons Due to Cases of 
Civil Crisis, Natural Disaster, or Public Healt h Cri sis.............................. 87
Appendix C Regulatory , Ethical , and Study  Oversight Consi derati ons......................... 89
Appendix D Actions Required in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law ........................................................................... 94
Appendix E Adverse Events: Definit ions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ...................................................................... 100
Appendix F Medical Device AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs and Medical 
Device Deficiencies: Definit ions and Procedures for Recording, 
Evaluat ing and Follow -up...................................................................... 105
Appendix G Handling of Human Bio logical  Samples ................................................ 109
Appendix H Maintenance Therapy Equivalence Table ............................................... 111
Appendix I Abbreviat ions........................................................................................ 112
Appendix J Protocol  Amendment Hi story................................................................. 115
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 13of 1231 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Multicenter, Rando mized, Double -blind, Parallel Group, Placebo -
controlled, Phase 3b Study  to Eval uate the Potenti al Effect of T ezepelumab on the Humoral 
Immune Response to Seasonal Quadrivalent Influenza V accinat ion in Ado lescent and Y oung 
Adult Parti cipant s with Moderate to Severe Asthma (VECTOR )
Short Title: Tezepelumab Hum oral Immune R esponse to Influenza V accine Study
Rationale :The epi[INVESTIGATOR_1231]- derived cy tokine, thymic stromal lymphopoiet in (TSLP ), is 
produced i n response to proinflammatory  stimuli and drives allergic inflammatory  responses, 
primarily through its activit y on type 2 innate lympho id cells ( ILC-2), dendri tic and mast 
cells. Human TSLP expressio n is reported to be increased in asthmat ic airways correlating 
with disease severit y.
Owing to its immuno modulating effect, it is important to determine if tezepelumab affects 
functioning o f the immune system. In this study , a funct ional response of the immune system 
will be assessed by  [CONTACT_694988].
The rati
onale for sel ecting this popul ation is based on precedence fro m a similar study  with 
anti-IL5 bio logic drug benralizumab, in which humoral immune response was assessed in 
adolescents and y oung adul ts (12 to 21 years o ld) with severe asthma. In that study , the 
humoral ant ibody responses induced by [CONTACT_694989].
Objectives and Endpoint s
Please note : If influenza vaccine administration is delayed, so me participants ’ assessments at 
Visit 6 (Week12)andVisit 7 ( Week16)may be perform ed at l ater timepo ints.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 15of 123Disclosur e Statement : This is a parallel group treatment study  with [ADDRESS_942774] igator blinded. Number of Participants:
Approximately  135participants aged 12 to 21 y ears wi th moderate to severe asthma will be 
enrolledinto screening to provide a target sample size of approximately  
100 rando mized 
participants for the study .
Intervention Groups and Duration :
Parti cipants wi th moderate to severe asthma will be randomized 1:[ADDRESS_942775] 50% of the randomized participants are between the ages 
of 12 to 17 years. Treatment allocation will be stratified by [CONTACT_694990] o f informed 
consent/assent (12 to 17 years, and 18 to 21 y ears) to ensure equitable distribut ion of
tezepel umab and placebo treatment in each age group.
Please note: If influenza vaccine administration is delayed, the treatment period may be 
extended and therefore participants may be given an addit ional 1 to 2 study  intervent ion doses 
(as needed) every  4 weeks for a longer period than init ially planned.
Data Monitoring Committee: No
Statistical Methods
Primary Endpo ints
For the analysis o f the ant i-influenza ant ibody  response endpo ints, GMFRs and GMT s for 
HAI and MN ant ibody  measurements will be summarized by [CONTACT_694991] , 
and the least square geom etric mean rati o of GMFRs and GMT s between treatment groups 
(influenza vaccine divided by [CONTACT_694992]) will be calculated via an 
ANCOV A model on the l og-transform edvariable, adjusting for treatment group and age 
stratum  (adol escents aged 12 to 17 or young adults aged 18 to 21). The least square geometric 
mean ratio will be provided with associated 90% CI.
The ant ibody  response to the quadrivalent influenza vaccine strain is defined as a ≥ 4-fold rise 
in HAI or a ≥
4-fold rise in MN from pre-dose ant ibody  measure to post-dose antibody 
measure . The proportion of participants who experience a post -dose antibody response at 
Week16 (EOT) for HAI and the proportion of par ticipants who experience a post -dose 
antibody  response at W eek 16 (EOT) for MN and corresponding 90% Clopper -Pearson exact 
CIswill be summarized by  [CONTACT_694993] . 
The proporti on of  parti cipants who achieve a post
-dose HAI antibody  titer ≥ [ADDRESS_942776] -dose MN ant ibody t iter ≥ 40 at Week16 (EOT) 
and corresponding 90% Clopper -Pearson exact CI swill be summarized by [CONTACT_22058] t group
and by  [CONTACT_141599] .
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 16of 123Secondary  Endpo ints
Tezepelumab serum concentrations will be summarized using descriptive statist ics at each 
visit. ADA  to tezepel umab will  be summarized using descript ive statist ics at each visit.
Safety Endpo ints
Adverse events will be coded using the Medical Dicti onary  for Regulatory  Activities 
(MedDRA )versio n in force at the primary database l ock. The definit ion of on-treatm ent and 
on-study  for AE analyses will be given in the statisti cal analysis plan .
The numb er and percentage of participants with on -treatment and on -study  AEs will  be 
tabul ated separately by  [CONTACT_324706]. An event that occurred one or 
more times during a period will contribute 1 observat ion to the numerator of the propo rtion. 
The deno minator of the proportion will co mprise all part icipants in the safet y popul ation. On -
treatm ent AEs will also be summarized by [CONTACT_243696] y/severit y and separately , by 
[CONTACT_20084] y/relatedness (as determined by [CONTACT_3170]).
Laboratory  data w ill be summarized by [CONTACT_338428] (baseline 
to most extrem e post -baseline value) and by [CONTACT_694994] (means, medians, quartiles, ranges). The incidence of clinicall y 
notabl e laboratory  abnorm alities will  be summarized.
Vital signs data will be summarized by [CONTACT_324710]. The incidence of clinically notable vital signs abnormalit ies will be 
summarized. 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 17of 1231.2 Schema
Figure 1 Study Design
Abbreviations: n=number of participants .

Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 18of 1231.3 Schedule of Activities
Table1 Schedule of Activities (Scr eening)
Assessment/activity ScreeningDetails in CSP 
Section or Appendix
VisitV1
(Week -2 to -3)V2a
(V1 plus maximum 7 days)
Informed consent /assent X Section 5.1
Inclusion and exclusion criteria X X Sections 5.1and 5.2
Demography X Section 5.1
Medical and asthma historybX Section 5.1
Complete physical examination X Section 8.2.1
Weight, height, and BMI X Section [IP_ADDRESS]
Vital signs X X Section 8.2.2
Local 12 -lead ECG X Section 8.2.3
Serum chemistry X Section 8.2.4
Hematology X Section 8.2.4
Local urinalysis X Section 8.2.4
Serum concentration (theophylline)cX Section 8.2.4
Serology (hepatitis B, C; HIV -1; HIV -2) X Section [IP_ADDRESS]
Local SARS -CoV-2 viral diagnostic testdX Section [IP_ADDRESS]
Serum pregnancy testeX Section [IP_ADDRESS]
Pre-bronchodilator FEV 1fX X Section [IP_ADDRESS]
Post-bronchodilator FEV 1fX X Section [IP_ADDRESS]
Adverse Events X X Section 8.3
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 19of 123Assessment/activity ScreeningDetails in CSP 
Section or Appendix
VisitV1
(Week -2 to -3)V2a
(V1 plus maximum 7 days)
Concomitant medication X X Section 6.[ADDRESS_942777] not taken SABAs for 6 hours or their long -acting bronchodilator -containing therapy for 
12-24 hours. If spi[INVESTIGATOR_038]/reversibility procedures are actually planned at Visit 1 as a convenience, then the ICF/assent must b e signed prior to Visit [ADDRESS_942778] to be performed locally (local COVID -[ADDRESS_942779]) .
eFor women of childbearing potential only .
fPre and post -bronchodilator spi[INVESTIGATOR_620471] [ADDRESS_942780] reversibility at either Visit 1 or Visit 2 and this is needed 
to qualify the participant for randomi zation, the site should screen fail the participant .
Abbreviations: AE=adverse event; BMI=body mass index; CSP=clinical study protocol; COVID -19=Coronavirus disease 2019; ECG =electrocardiogram; FEV1=forced expi[INVESTIGATOR_184849] 1 second ; HIV=human immunodeficiency virus; ICF=informed consent form; SABA= short-acting β -agonist ; SARS -CoV-2= severe acute respi[INVESTIGATOR_18960] 2; V=visit.
Cli nical St u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D 5 1 8 0 C 0 0 0 3 1 
C O N FI D E N TI A L A N D P R O P RI E T A R Y 2 0 of 1 2 3 Ta ble 2 Sc he d ule of Acti vities ( R a n d o miz ati o n , T re at me nt, a n d F oll o w -u p) 
Assess me nt/ acti vit y Tre at me nt A nti b o d y res p o nse 
e v al u ati o n /
E O T aI P D bF U /
E n d of 
St u d y 
Visit U nsc h Det ails i n C S P Secti o n or 
A p pe n di x 
Visit V 3  V 4  V 5  V 6 V 7 V 8 
W 0  W 4  W 8  W 1 2  W 1 6 W 2 8 
Visit wi n d o w ( d a ys) c
± 0 ± 3 ± 3 ± 3 ± 3 ± 3 ± [ADDRESS_942781] ( di pstic k) eX  X  X  X X X  X Secti o n 8. 2. 5. [ADDRESS_942782] u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D 5 1 8 0 C 0 0 0 3 1 
C O N FI D E N TI A L A N D P R O P RI E T A R Y 2 1 of 1 2 3 Assess me nt/ acti vit y Tre at me nt A nti b o d y res p o nse 
e v al u ati o n /
E O T aI P D bF U /
E n d of 
St u d y 
Visit U nsc h Det ails i n C S P Secti o n or 
A p pe n di x 
Visit V 3  V 4  V 5  V 6 V 7 V 8 
W 0  W 4  W 8  W 1 2  W 1 6 W 2 8 
Visit wi n d o w ( d a ys) c
± 0 ± 3 ± 3 ± 3 ± 3 ± 3 ± [ADDRESS_942783] u d y i nter ve nti o n. 
bIf I P D visit occ urs at t he sa me ti me as t he sc he d ule d Visit 6 ( Wee k 1 2 ), partici pa nts s h o ul d perf or m all assess me nts, i ncl u di n g i nfl ue nza a nti b o dies 
f oll o we d b y i nfl ue nza vacci nati o n. Parti ci pa nts s h o ul d t he n ret ur n t o t he st u d y site f or Visit 7 ( Wee k 1 6 )a n d perf or m all assess me nts, i ncl u di n g i nfl ue nza 
a nti b o dies. Refer t o C S P Secti o n  7. [ADDRESS_942784] u d y 
i nter ve nti o n (see Secti o n 7. 1 f or  details). 
dE osi n o p hils, bas o p hil ,a n d m o n oc y te c o u nts will be re dacte d fr o m t he ce ntral la b orat or y re p orts e xce pt at Visit [ADDRESS_942785] u d y visit ( bef ore st u d y i nter ve nti o n a d mi nistrati o n o n 
Visit 3 t o V isit 6). 
fP K a n d A D A t o be c ollecte d P RI O R t o st u d y i nter ve nti o n d ose at V isit 3 a n d P K t o be c ollecte d P R I O R t o i nfl ue nza vacci nati o n at V isit 6. 
gBl o o d dra w f or ser u m a nti b o dies t o i nfl ue nza vacci ne s h o ul d occ ur pri or t o a d mi nistrati o n of i nfl ue nza vacci ne. If i nfl ue nza vacci ne a d mi nistrati o n is 
dela ye d fr o m Visit 6 ( Wee k 1 2 ), pre -i nfl ue nza vacci ne bl o o d dra w f or  ser u m a nti b o dies s h o ul d o nl y  occ ur o n t he wee k of i nfl ue nza vacci ne a d mi nistrati o n. 
hI nfl ue nza vacci ne is t o be a d mi nistere d at a differe nt site t ha n st u d y i nter ve nti o n a n d site of i njecti o n n ote d. Partici pa nt is t o be o bser ve d f or [ADDRESS_942786] u d y sites. All assess me nts d uri n g t he u nsc he d ule d visit ma y n ot be necessaril y c o m plete d. 
A b bre viati o ns:  A D A =a nti -dr u g a nti b o dies; A E =a d verse e ve nt; C S P =cli nical st u d y pr ot oc ol ; E O T =e n d of treat me nt; 
F U = f oll o w -u p; H C G = hu ma n c h ori o nic g o na d otr o pi n; I P D =i n vesti gati o nal pr o d uct disc o nti n uati o n ; P K = p har mac o ki netics; U n sc h = u nsc he d ule d; V = visit ; 
W = wee k .C CI 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 22of [ADDRESS_942787] of tezepelumab on ant ibody  responses fo llowing 
seasonal quadrivalent influenza virus vaccinat ion. 
2.1 Study Rationale
The epi[INVESTIGATOR_1231] -derived cy tokine , TSLP , is produced in response to proinflammatory  
stimuli and drives allergic inflammatory responses, primarily through its activit y on ILC -2, 
dendrit ic (Gilliet et al 2003 , Soumelis et al 2002, Reche et al 2001 )  and m ast cells 
(Allakhverdi et a l 2007). Hum an TSLP expressio n is reported to be increased in asthmat ic 
airways correl ating wit h disease severit y (Ying et al  2005 ).
Tezepelumab is a human mAb IgG2 λ directed against TSLP , expressed in a CHO CS -[ADDRESS_942788] ing of 2 heavy chains of the IgG2 subclass and 
2light chains o f the lambda subclass, which are covalent ly linked through disulfide bonds. 
Tezepelumab binds with human TSLP and prevents its interaction with TSLP receptor 
complex. As a result, targeting TSLP may inhibit mult iple bio logic pathways invo lved in 
asthma 
(Gauvreau et al 2014).
In the Phase [ADDRESS_942789] ive of baseline levels of T2 inflammatory bio markers (blood eosinophil 
counts, fractional exhaled nitric oxide , and serum total IgE) (Corren et al 2017, Menzies -Gow 
et al 2021 ). In these studies, tezepelumab also improved lung function, asthma control and 
patient heal th-related quali ty of life in the overall populat ion. In addit ion, in these studies, 
tezepel umab has been shown to decrease IgE levels ;however ,its administration did not affect 
IgG, IgM or IgA. In a preclinical toxico logy study  with cyno molgus monkeys the IgG 
response to keyho le limpet ant igen was suppressed but only at doses much higher than used in 
human studi es (50 mg/kg subcutaneously  [SC]weekly) (Invest igator ’s Brochure for 
tezepel umab ). 
Owing to its immuno modulating effect, it is important to determine if tezepelumab affects 
funct ioning o f the immune system. In this study , a funct ional response of the immune system 
will be assessed by  [CONTACT_694988] .
The influenza vaccine was chosen for this study  as GINA  Guidelines recommend yearly  
influenza vac cinat ion for asthm atics, in particular those with moderate to severe disease. The 
Center for Disease Control also recommends yearly  influenza vaccination for asthmat ics 
(GINA  , CDC Asthma 2021 ). Quadrivalent, inact ive influenza vaccine containing 4 strains ([ADDRESS_942790] u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D 5 1 8 0 C 0 0 0 3 1 
C O N FI D E N TI A L A N D P R O P RI E T A R Y 2 3 of 1 2 3 f o r i nfl ue nza A  a n d 2 f or i nfl ue nza B) selecte d f or t he i nfl ue nza seas o n 2 0 2 1/ 2 0 2 2 f or t he 
n ort her n he mis p here will be use d ( F D A 2 0 2 1 ).
I m m u n o ge nicit y will  b eassesse d usi n g 2 t y p es of  strai n -s pecific assa ys ( d ual pri mar y  
e n d p o i nt ) detecti n g vacci ne h u m oral res p o nse: 
H e m a g gl ut i ni n i n hi bit i o n ( H AI) assa y a n d micr o ne utralizat i o n ( M N) assa y. 
H e m a g gl ut i ni n i n hi bit i o n assa y meas ures t he a bilit y of  ser u m  t o bl oc k hae ma g gl uti nati o n, 
w hic h is t he a g gre gati o n of re d bl o o d cells ca use d b y i nfl ue nza vir us. T he res ult i n g 
hae ma g gl ut i nat i o n i n hi bit i o n a nti b o dies tit er is a c orrelate of pr otecti o n f or i nfl ue nza vir us 
t h at is acce pte d b y ma n y re g ulat or y  a ge ncies. Mi cr o ne utralizat i o n assa y  detect a nti b o di es t hat 
di rect l y ne utralize vir us (Ha n n o u n et al 2 0 0 4 , H o bs o n et al 1 9 7 2 , Kra m mer 2 0 1 9 ).
T he d ual pri ma r y  e n d p oi nt i ncl u des ser oc o n versi o n o utc o m e m eas ures ( 4- f o l d rise i n t it er a n d 
ti t er ≥ 1: 4 0) pr o vi de d as res p o nse rates , a n d ce ntral meas ures of  te n de nc y  f or t he i m m u ne 
res p o nse (ge o m etri c mea n f o l d rises [ G M F R ]a n d ge o m etri c m e a n ti ters [ G M T ]) f o r t he H AI 
a n d M N assa y res ults . F or t he I nfl ue nza A  H [ADDRESS_942791] of t he strai n (Si cca et al  2 0 2 0 ).
I n t hi s st u d y , a f u nct i o nal res p o nse of t he i m m u ne s yste m t o t he i nfl ue nza vacci ne will be 
assesse d i n a d o lesce nts a n d y o u n g a d ults wit h m o derate t o se vere ast h ma. T he rati o nale f or 
select i n g t hi s p o p ul at i o n is base d o n t he pre vi o us si milar st u d y  wi t h  a nt i- I L [ADDRESS_942792] u g 
be nraliz u ma b i n w hic h h u m oral i m m u ne res p o nse was assesse d i n a d o lesce nt a n d y o u n g a d ult 
( 1 2 t o 2 1 years o l d) se vere ast h mat ics ( Zei tl i n et al 2 0 1 8 ). A t otal  of  1 0 3 parti ci pa nts were 
ra n d o mize d a n d recei ve d be nraliz u ma b ( n = 5 1) or place b o ( n = 5 2). T here were n o c o nsiste nt 
differe nces i n H AI or M N a nti b o d y  res p o nses 4wee k s a ft er t he i nact i ve q ua dri vale nt 
i nfl ue nza vacci ne a d mi nistrati o n bet wee n part ic i pa nt s recei vi n g be nraliz u ma b or place b o. 
P arti ci pa nt e ntr y  will be stratifie d b y a ge ( 1 2 t o 1 7 -year a ge gr o u p a n d 1 8 t o 2 1 -year a ge 
gr o u p) t o e ns ure e q uita ble distri b uti o n of  treat m e nt all o c ati o n f o r a nal ysis. 
I n a d dit i o n t o t he i m m u ne res p o nse t o vacci ne, t h e teze pel u ma b i m pact o n 
n u m ber of e xacer bat i o ns, ser u m tr o u g h teze pel u ma b c o nce ntrati o ns ,a n d a nt i- dr u g a nt i b o dies 
( A D As) will be i n vest i gate d .
2. [ADDRESS_942793] ors. It is c haracteri ze d b y wi des prea d, varia ble, a n d re versi ble airfl o w 
o bstr ucti o n ,ai r w a y  i nfla m mat i o n, e xcessi ve m uc us pr o d ucti o n; a n d ai r w a y  
h y perres p o nsi ve ness t hat lea d t o rec urre nt e pis o des of w heezi n g, breat hless ness, c hest 
ti g ht ness, a n d c o u g hi n g ( C S G A  1 9 9 7 ). Pr o gressi ve pat h ol o gic ai r wa y r e m o deli n g a n d scarri n g C CI 
Clinical Stu dy Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 24of 123may occur in persistent asthma result ing in partially reversible or irreversible airway 
obstructi on (Pascual and Peters 2005 ). 
The eti ology of asthma is thought to be mult i-factori al, influenced by [CONTACT_694995]. The majorit y of cases ari se when a person beco mes 
hypersensit ive to allergens. Approximately [ADDRESS_942794] asthma ( Asthma and Allergy Foundation 
of America 2017). W orldwide, asthm a current ly affects approximately [ADDRESS_942795] e 
(Global Asthma Network 2018 ); yearly asthma accounts for an estimated 9.8 millio n 
physician office visit s, 1.6 millio n emergency room visits, and over 3500 deaths in the [LOCATION_003]  
(Asthma and Allergy Foundat ion of America )
.
Tezepelumab is being devel oped f or the treatm ent of moderate to severe, uncontrolled asthma. 
Approximately  5% to 10% of asthma patients have severe asthma (based on 2018 estimates 
[Global Asthma Network 2018]) , which may be inadequately controlled by [CONTACT_694996] [INVESTIGATOR_014] 
(Brightling et al 2008 ). These 
patients are at ri sk of asthma exacerbat ions (Tough et al 1998, Turner et al 1998) and have the 
greatest m edical need amo ng the asthmat ic populatio n today . Pati ents wi th severe asthma 
represent the greatest economic cost (> 50% of total asthma -related heal th care costs; 
Antoni celli et al 2004, Serra -Batlles et al 1998, Barnes and Kuitert 1996 ) . 
Study  D5180C00007 (NA VIGA TOR) was a Phase 3, mult icenter, glo bal, rando mized, 
doubl e-blind, placebo -controlled study  to assess the efficacy  and safet y of [ADDRESS_942796] spectrum of asthma phenoty pes as determined by  [CONTACT_694997] 300 cells/ μL, FeNO above and below 25 ppb, as well as 
allergic and non -allergic status. A total of 1061 participants were randomized in a 1:[ADDRESS_942797] acebo and 1059 participants (including 82 adolescents) received at least one 
dose of study  intervent ion. Tezepelumab treatment resulted in a statist ically significant and 
clinically meaningful red uction in annualised asthma exacerbat ion rate ( AAER )by 56% 
(p<0.001) compared with placebo in the overall populat ion and by 41% compared with 
placebo in participants with baseline blood eosinophils <300 cells/ μL (p < 0.001). The mean 
serum  trough concen tration of  tezepel umab increased over time and approached steady  state 
by 12 weeks. Treatment -emergent ADAs were detected at any  time during the study  in 4.9% 
(26) of participants treated with tezepelumab. Neutralizing ant ibodies to tezepelumab were 
detect ed in only one (0.2%) of the participants treated wi th tezepel umab. On -treatm ent AEs 
were similar between the placebo (80.8%) and the total tezepelumab (77.1%) dose groups and
themajorit y of participants had on -treatment AEs that were mild or moderate in severit y and 
not rel ated to the study  intervent ion. The percentage of participants who discontinued the trial 
regimen was 6.8% in the tezepelumab group and 10.7% in the placebo group. On -treatm ent 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 25of 123AEs that resulted in permanent discont inuat ion of study  interventi onwas 2.1% in the 
tezepel umab group and 3.6% in the placebo group. Overall, tezepelumab was well tolerated 
with an acceptable safet y profile and no safet y signals in both adul t and adol escent 
participants with severe, uncontrolled asthma ( Menzies -Gow et al  2021 , TEZSPI[INVESTIGATOR_694948] 2021 ).
For moderate to severe asthma patients who are uncontrolled on ICS, LABA  and other 
controllers ,biologic therapi [INVESTIGATOR_694949] t. Omalizumab may be suitable for a 
subgroup of patients with proven reactivit y to an aeroallergen and elevated s erum IgE levels 
who remain inadequately controlled wit h ICS pl us LABA  (XOLAIR US PI 2019, XOLAIR 
SmPC 2019 ). Four addit ional biologics, m epolizumab, reslizumab, benralizumab, and 
dupi[INVESTIGATOR_12458], have been approved for severe asthma with an eosinophilic phenoty pe and/or 
those requi ring oral corti costeroi d (OCS )therapy  (NUCALA  SmPC 2019 ,NUCALA  US PI 
2019, CINQAERO SmPC 2021, CINQAIR US PI 2020 , FASENRA  SmPC 2019 , FASENRA  
US PI 2019, DUPI[INVESTIGATOR_694950] 2020 , DUPI[INVESTIGATOR_694951] 2019 ). 
Biologics targeting IL- 4, IL -5, and IgE are now included in internat ional treatment guidelines 
(GINA  ) as add -on treatm ents to pati ents whose asthma remains uncontrolled wi th LABA/ICS 
treatm ent. However, even when using current ly available bio logics, substant ial proporti ons of 
patients continue to experience exacerbations and may benefit fro m agent s that target different 
molecular pathways ( Wenzel 2016 , Fro idure et al 2016, Swedin et al 2017). Therefore, despi[INVESTIGATOR_694952], there is st ill a clear unmet medical need amo ng patients 
with moderate to severe asthma, independent ly of IgE status or eosinophil level, who are 
unable to gain asthma control using current ly avai lable therapi[INVESTIGATOR_014].
Both GINA  and CDC recommend annual influenza vaccines for children and adults with 
asthma because they  are at hi gh risk of developi[INVESTIGATOR_694953], even if their 
asthma is mild or thei r symptom s are well -controlled by  [CONTACT_694998]. Influenza can result in 
airway and l ung inflammat ion which can contribute to acute asthma exacerbations. Asthma is 
the most comm on medical condit ion amo ng children hospi[INVESTIGATOR_215444] h influenza and one of 
the more comm on medical  condi tions among hospi [INVESTIGATOR_119800] (CDC Asthma 2021 ).Recent 
system atic review and meta -analysis that included observat ional studi es designs suggested 
that influenza vaccinatio n reduced the risk of asthma exacerbat ions (GINA  2021 ).
Tezepelumab is current ly being developed as a potent ial treatm ent option for the management 
of moderate to severe, uncontrolled asthma in adolescent and adult patients. By  [CONTACT_694999] , tezepelumab has been shown to have a broad erimpact on the inflammatory responses 
seen in asthma than other bio logics.
Addit ional studi es wi th tezepel umab have been completed. These include a mechanist ic study  
(D5180C00013; CASCADE ) conducted in adults wit h inadequately controlled asthma, an OCS 
sparing study  (D5180C00009 ; SOURCE) conducted in adults with OCS -dependent asthma, an 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 26of 123at-home use study in adults and adolescents with severe asthma study  (D5180C0001 1; PATH-
HOME), and a Japanese long -term safety study  in participants with inadequately controlled 
asthma (D5180C00019; NOZOMI) .
Adetailed descript ion of the above -ment ioned addit ional studies and chemistry , 
pharmaco logy, efficacy , and safet y oftezepel umab is provided in the current I nvest igator ’s 
Brochure .
2.3 Benefit/Risk Assessment
2.3.[ADDRESS_942798] ion was given, as well as headache (low grade), fever, muscle aches, 
nausea, and fatigue (CDC Influenza 2021) . Very rarely , as wi th all vaccines, anaphylaxis may  
occur .
[IP_ADDRESS] Important Identified Risks
To date there are no important identified risks in the tezepelumab clinical development 
program .
[IP_ADDRESS] Important Potential Risks
The m echanism  of action of tezepelumab suggests potential inhibitory  effects on immune 
responses mediated by  [CONTACT_78443]2 cells, leading to the possibilit y of diminution o f the host ’s 
protective response to infect ion.
Severe infect ions
Severe infect ions are defined as infect ions that are SAEs, requi re treatm ent wi th systemic 
antiviral medicat ions, intravenous antibiot ics or medicat ions for helmint h parasit ic infect ion, 
or requi re perm anent di scont inuat ion of study  intervent ion.
To mitigate the potential risk of seve re infecti ons eligibilit y criteria will  exclude vulnerable 
participants, and included participants will be monitored for infect ion with com plete bl ood 
counts, i ncluding different ial whi te cell count throughout the study; and through standard 
AE/SAE reporti ng. Participants using immunosuppressive medication wit hin 3 mo nths prior 
to screening; who have a history  of a known immunosuppressive disorder; who have a history  
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 27of 123of clinically significant infect ion prior to screening; and who have known active or suspec ted 
tubercul osis ei ther treated or untreated, will be excluded.
Parasi tic infestati on/infect ions
Tezepelumab may decrease the protective response to helmint h infect ion by [CONTACT_695000] . 
To decrease the risk of parasit ic infestation or infection, partic ipants who have a history  of 
clinically significant infect ion prior to screening and at screening, and participants with 
untreated sy stemic helmint h parasit ic infect ions or those at significant increased risk of 
systemic helmint h parasit ic infestations wil l all be excluded.
Serious h ypersensit ivity/allergic reactions (including immune co mplex disease)
As wi th any large mo lecule therapeutics, administration of tezepelumab may result in 
system atic and/or local reactions. Sy stemic react ions to large mo lecule therapeutics can be IgE 
or non -IgE-mediated and are generally  characteri zedby [CONTACT_695001], urti caria, pruri tus, l ocal or diffuse ery thema, angi oedema, fever, chills, cough, dy spnea, 
wheezing, bronchospasm, nausea/vo miting, di aphor esis, chest pain, tachy cardi a or 
bradycardia, and/or hy potensi on, which can all be severe or life -threatening. Effects typi[INVESTIGATOR_694954], but m ay be delayed.
To mitigate the potential risk of serious hypersensitivit y react ions, during and after 
administration of tezepelumab, specific requirements for observing participants for AEs/SAEs
and for monitoring vital signs before, during, and after administration of tezepelumab are 
included in the CSP . In addi tion, medical equipment to treat acute anaphylactic reactions will 
be immediately  available and site staf fwill be trained to recogni ze and treat anaphylaxis.
The administration of a mAb can result in the formation of ADA. The occurrence of ADA  
could resul tin immune co mplex disease (T ype [ADDRESS_942799] ions) with 
manifestations such as serum sickness, nephrit is, and vasculit is, or al tered tezepelumab levels 
or activit y.
To mitigate the potential risk of immune co mplex disease participants will be m onitored f or 
the presence o f AD A and confirmed immune complex disease through routine monitoring of 
AEs/SAEs. Participants with a prior history  of immune co mplex disease will be excluded.
More detailed informat ion about the known and expected benefits and potenti al risks of 
tezepel umab m ay be found in the current I nvest igator ’s Brochure .
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 28of 1232.3.[ADDRESS_942800] ion and asthm a control  metrics(Corren et al 2017 ).
Parti cipants in this study  may benefit fro m the continuous monitoring of all AEs arising 
during the clinical study , related or not rel ated to the study  intervent ion. In addit ion, 
participant s will be contribut ing to the development of new therapi[INVESTIGATOR_694955].
Benefit s of seasonal influenza vaccinat ion would include probable protection against 
developi[INVESTIGATOR_694956]. GINA  Guidelines recommend pat ients 
with moderate and severe asthma receive influenza vaccinat ion every  year to decrease risk of 
influenza and potenti al asthma exacerbat ion.
2.3.3 Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimiz erisk to participants enro lling in this study
(see Section [IP_ADDRESS] ), the potential risks identified in associat ion with tezepel umab are 
justified by [CONTACT_695002].
Cli nical St u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D 5 1 8 0 C 0 0 0 3 1 
C O N FI D E N TI A L A N D P R O P RI E T A R Y 3 0 of 1 2 3 Ta ble 3 O bjecti ves a n d E n d p oi nts 
O bjecti ves En d p oi nts 
A b bre viati o ns:  A Es =a d verse e ve nts; P K = p har mac o ki netic; 
S A E =seri o us a d verse e ve nts. C CI 
C CI 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 31of [ADDRESS_942801] of tezepelumab (210 mg SC Q4W) on 
antibody  responses fo llowing seasonal quadrivalent influenza virus vaccinat ion in the 
fall/winter 2021 -2022 in the [LOCATION_003] . 
Approximately  135participant s aged 12to 21 years wi th moderate to severe asthma will be 
enrolledinto screening to provide a target sample size of approximately 100 rando mized 
participants for the study . Parti cipants will be randomized 1:[ADDRESS_942802] 50% of the enro lled participants are between the ages of 12 to 17years . 
Treatment allocat ion will  be stratified by  [CONTACT_694990] o f inform ed consent/assent (12to 17
years , and 18 to 21 years ) to ensure equi table distribut ion of tezepelumab and placebo 
treatm ent in the [ADDRESS_942803] 50% of the enrolled part icipants are 12 to 
17years old, the IWRS/ IVRS will be set up wi th a 50% cap on the 18 to 21-year age group. 
Once this cap is reached, no more participants will be enro lled into the 18 to 21-year age 
group. Once an age group is closed, participants in the screening period in the closed age 
group will not be a llowed to be randomized and will be consi dered a screen failure
.
After enro llment and confirmat ion of entry  criteria, participant s will enter the screening period 
of a minimum of 2 weeks to allow adequate time for all of the eligibilit y criteria to be 
evaluated before being randomized. Participant s who meet the eligibilit y criteria will be 
rando mized at Visit3 [W eek0] and will receive eit her tezepelumab [ADDRESS_942804]
ivalent seasonal influenza vaccine 
IM at W eek12, prior to the fourth dose of study  intervent ion. Steady -state of tezepelumab is 
achieved at Week12. Serum samples for evaluation of ant ibody  response will be drawn at 
Week12 (pre -vaccinat ion) and at W eek16 ([ADDRESS_942805]-vaccination) when humoral response 
to the vaccination is expected to be fully developed.
The EOT Visit will be conducted at W eek16 and a final Follow
-up V isit and the End of Study  
Visit will be conducted at W eek28. 
Please note: If influenza vaccine administration is delayed, the treatment period may be 
extended and therefore participants may be given an addit ional 1 to 2 study  intervent ion doses 
(as needed) every  4 weeks for a l onger peri od than init ially planned .
Parti cipants will be maintained on their current ly prescribed ICS -
LABA  therapi[INVESTIGATOR_694957] – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 32of 123change from enrol lment throughout the screening and treatment period. If asthma 
exacerbations occur during the treatment period, participant s can be treated with oral or other 
syste mic corticosteroids or other asthma therapi[INVESTIGATOR_680218].
4.1.[ADDRESS_942806] Mitigation During Study Disruptions Due to Cases of 
Civil Crisis, Natural Disaster, or Public Health Crisis
The gui dance given below supersedes instructions provide d elsewhere in this CSP and should 
be implemented only during cases of civil crisis, natural disaster, or public healt h crisis (eg, 
during quarant ines and result ing site closures, regional travel restrict ions, and considerat ions if 
site personnel or study  partici pants becom e infected with SARS -CoV-[ADDRESS_942807] ion) which would prevent the conduct of study -related activit ies at study  sites, thereby 
[CONTACT_122591] f or the parti cipant’s abilit y to conduct the study . The 
investi gator or desi gnee shoul d contact [CONTACT_592724] d be implemented.
To ensure continuit y of the clinical study  during a civil  crisis, natural  disaster, or public healt h 
crisis, changes m ay be implemented to ensure the safet y of study  parti cipants, maintain 
compliance wi th Good Clinical Practice, and minimize risks to study  integrity. 
Where allowable by  [CONTACT_122593], ethi cs commi ttees, heal thcare provi der gui delines 
(eg, hospi[INVESTIGATOR_96626]) or l ocal government, these changes may include the following options: 
Obtaining consent/reconsent for the mit igation procedures (note, in the case of verbal 
consent/reconsent, the ICF should be signed at the participant’s next contact [CONTACT_476688]).
Re-screening: One addi tional re-screening to confirm eligibilit y to parti cipate in the 
clinical study  can be perform ed in previously screened participants. The investigator 
shoul d confi rm this wi th the designated Parexel Medical Monitor . 
Hom e or Rem ote vi sit: Perf ormed by  a site qualified HCP or HCP provided by  a TPV
only during safet y follow-up (after Vi sit 7).
Telemedicine visit: Remote contact [CONTACT_695003] y follow
-up 
(after Vi sit 7).
For further details on study  conduct during civil crisis, natural disaster, or public health crisis, 
refer to Append ixB.
4.[ADDRESS_942808] of tezepelumab on the antibody 
response to the quadrivalent seasonal influenza virus vaccine i n parti cipants 12 to 21 years of 
Clinical Study P rotocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 33of 123age wi th moderate to severe asthma (see Section 2.1).
4.[ADDRESS_942809] com pleted the study  if he/she has co mpleted all visits of 
the study  including the End of Study  Visit or the l ast scheduled procedure shown in the SoA.
The end o f the study  is defined as the date of the last visit of the last participant in the study  or 
last scheduled procedure for the last participant in the study .
5 STUDY POPULATION
Prospective approval o f CSP deviat ions to recruitment and enrollment criteria, also known as 
CSP waivers or exempt ions, is not permitted.
5.1 Inclusion Criteria
5.1.1 Study Eligibility
Parti cipants are eligible to be included in the study only if all of the f ollowing criteria apply:
Informed Consent
1Capable of giving signed informed consent /assent as described in Appendix Cwhich 
includes compliance with the requirements and restrictions listed in the ICF /assent and in 
this CSP.
Age
2Parti cipant m ust be 12to 21years of age inclusive, at the time of signing the ICF/assent .
Type of Participant and Disease Characteristics
3Docum ented physician -diagnosed asthma for at least 12 months pri or to Visit 1.
4Evidence of asthma as documented by  [CONTACT_5640]:
Post-bronchodilator airway reversibili ty (FEV 1 ≥ 12% and ≥ 200mL) demonstrated 
at Vi sit [ADDRESS_942810] u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D 5 1 8 0 C 0 0 0 3 1 
C O N FI D E N TI A L A N D P R O P RI E T A R Y 3 4 of 1 2 3 O R 
Air wa y  re versi bili t y  d oc u me nte d i n t he pre vi o us 1 2 m o nt hs pri or t o Visit 1. 
N ote: All part ic i pa nt s m ust ha ve re versi bilit y testi n g perf or m e d bef ore ra n d o mi zat i o n t o 
est a blis h a baseli ne c haracterist ic e ve n if hist orical d oc u me ntati o n is use d t o meet t his 
cri t eri o n. 
5D oc u m e nte d hist or y  of  sta ble treat m e nt wi t h  I C S a n d L A B A f or at least 3 0 da ys pri or t o 
Vi si t 1. 
T he I C S a n d L A B A ca n be parts of a c o m bi nat i o n pr o d uct or gi ve n b y se parate 
i n halers. F or I C S/ L A B A c o m bi nati o n pre parat i o ns, b ot h t he mi d a n d hi g h -stre n gt h 
mai nte na nce d oses a p pr o ve d i n t he U S Awill meet t his I C S criteri o n. 
T he I C S d ose m ust be > [ADDRESS_942811] y p o w der i n haler or 
e q ui vale nt dail y . Eq ui vale nt I C S d oses as detaile d i n  A p pe n di x H. 
A d dit i o nal ast h ma c o ntr oller me dicati o ns (e g, L T R As, s h ort a n d l o n g -act i n g 
a nt i- m u scari nics, t he o p h ylli ne, or al  c orti c oster oi ds, et c) t hat ha ve bee n use d f or at 
least 3 0 da ys pri or t o Visit 1 are all o we d. 
6M or ni n g pre -br o nc h o dilat or F E V 1of  > 5 0 % pre di ct e d n or mal val ue at Vi si t 1 or Visi t 2. 
Wei g ht 
7B o d y  wei g ht ≥ [ADDRESS_942812] u dies 
(see Secti o n 5. 3. 4 ).
5. 1. [ADDRESS_942813] y: 
1F or w o me n of c hil d beari n g p ote ntial , a ne gat i ve uri ne pre g na nc y test is re q uire d pri or t o 
a d mi nistrati o n of st u d y  i nt er ve nt i o n at Vi si t3 (ra n d o mi zat i o n). 
[ADDRESS_942814] ha ve ' n ot well -c o ntr olle d' ast h ma as d oc u me nte d b y ei t h er :

or 
A pea k e x pi r at or y  fl o w of  6 0 -8 0 % pre di cte d. 
or 
A n e xacer bat i o n, o ne or m ore, t hat re q ui re d oral  c or ti c oster oi ds i n t he pre vi o us 
1 2 m o nt hs. 
or C CI 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 35of 123Any one of the fo llowing assessed by  a parti cipant recall over the previous 
2-4weeks:
oAsthma symptoms > 2 days/week.
oNight
-time awakenings once or more per week.
oSABA use for symptom control (not for the preventi on of  exercise -induced 
asthma) > 2 days/week.
NOTE: A participant’s verbal history  suggest ive of asthma symptoms, but without supporting 
docum entati on, is not sufficient to satisfy  these inclusio n criteria.
5.2 Exclusion Criteria 
5.2.1 Study Eligibility
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
1Clinically important pulmonary disease other than asthma (eg, active lung infect ion, 
bronchiectasis, pulmo nary fibrosis, cystic fibrosis, hypovent ilation syndrom e associ ated 
with obesi ty, alpha 1 ant i-trypsin deficiency, and primary  ciliary  dyskinesia) or ever been 
diagnosed wi th pulm onary  or systemic disease, oth er than asthma, that are associated with 
elevated peri pheral  eosinophil counts (eg, allergic bron chopulm onary 
aspergillo sis/mycosis, eosinophilic granulo matosi s with polyangi tis (EGPA), 
hypereosinophilic syndro me), or pri or history  of immune com plex di sease .
2Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepat ic, renal,
neuro logical, muscul oskeletal , infect ious, endocrine, metabo lic, hematol ogical, 
psychiatric, or major physical impairment that is not stable in the opi[INVESTIGATOR_3078] n of the 
Invest igator and could:
Affect the safet y of the participant throughout the study .
Influence the findings of the studies or their interpretations.
Impede the participant 's abilit y to com plete the entire durati on of  study .
3Life-threatening asthma defined as epi[INVESTIGATOR_694958], respi[INVESTIGATOR_4047], hy poxic seiz ures, or asthm a-related syncopal  epi[INVESTIGATOR_1841].
4History  of cancer
Parti cipants who have had basal cell carcino ma, l ocalized squamous cell carcino ma 
of the skin, or in situ carcino ma o f the cervix are eligible provided that the participant
is in remissio n and have had their curative therapy  com pleted at l east 12 m onths pri or 
to Visit 1.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 36of 123Parti cipants who have had other malignancies are eligible provided that the 
participant is in remissio n and have had their curative therapy  com pleted at l east [ADDRESS_942815] ory ≥10 pack- years and participant s 
using vapi[INVESTIGATOR_96612], includin g electroni c cigarettes. Former smokers with a smoking 
history  of < [ADDRESS_942816] of the study .
Prior/Concomitant Therapy
13If on allergen immunotherapy , parti cipant s must be on a stable maintenance dose and 
schedule for at l east [ADDRESS_942817] of the study .
14Use of immunosuppressive medicat ion (including but not limited to methotrexate, 
troleando mycin, cyclosporine, azathioprine, tacrolimus, myco fenolate mofetil, 
intramuscular l ong-acting depot corticosteroid, or any experimental anti -inflammatory
therapy ) within 3 m onths prior to Vi sit 1.
15Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.
16Receipt of live attenuated vaccines 30 day s prior to the date of randomi zation.
17 Receipt of influenza vaccine for season 2021/22 prior to Visit 1.
18COVID -19 vaccinat ion within 6days pri or to randomi zation.
Prior/Co ncurrent Clinical Study Experience
19Parti cipants wi th a known history  of allergy  or reacti on to the study  intervent ion 
formulations or influenza vaccine.
20Receipt of any  marketed or invest igational biologic wi thin 16 weeks or 5 half -lives prior 
to Visit 1, w hichever is lo nger.
21Receipt of any  non-biologic investi gational medication within 30 days or 5 half- lives 
prior to randomi zation, whichever is longer.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 37of 12322Previously  received tezepel umab.
23Concurrent enrol lment in another drug -related intervent ional clinical tr ial.
Diagnostic Assessments
24Any clinically  significant abnormal findings in physical examinat ion, vital signs, baseline 
ECG, hem atology, clinical chemistry , or uri nalysis during screening period, which in the 
opi[INVESTIGATOR_3078] n of the invest igator, may put the participant at risk because of his/her participat ion 
in the study , or may  influence the results of the study , or the participant 's abilit y to 
complete ent ire durati on of  the study .
25Positive hepat itis B surface ant igen, or hepat itis C virus antibody serolog y, or a posi tive 
medical history  for hepati tis B or C. Participant s wit h a history  of hepat itis B vaccinat ion 
without history  of hepatitis B are allowed to enro ll.
26A history  of known immunodeficiency  disorder incl uding a posi tive HIV test at V1, or the 
participant is taking ant iretrovi ral medicat ions as determined by [CONTACT_96749]/or 
participant’s verbal report.
27Positive SARS -Cov2 test during the screening period.
28ALT or AST level ≥ [ADDRESS_942818] confirmed during screening period.
Other Exclusions
29For wom en only -current ly pregnant (confirmed wit h posi tive pregnancy test), 
breast feeding, or lactating women.
30Involvement in the planning and/or conduct of the study (applies to both [COMPANY_008] 
staff and/or staff at the study  site).
31Employees of the st udy cent eror any  other individuals invo lved with the conduct of the 
study  or immediate family  members of such individuals.
32Judgment by  [CONTACT_271089], restrict ions, and requirements.
5.2.2 At Randomi zation
Parti cipants are excl uded from  rando mization if any  of the f ollowing cri teria apply:
1Asthma exacerbation during the screening period that requires treatment with oral 
corticosteroi ds or a hospi[INVESTIGATOR_18543]/emergency room visit for the treatment of asthma .
2 Acute illness or evidence of significant active infection (eg COVID- 19) or known 
influenza infect ion during the current influenza season.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 38of 1235.[ADDRESS_942819] abstain from donating blood and plasma from the time of informed 
consent /assent , and for 16 weeks (5 half -lives) after last dose of study  intervent ion.
5.3.1 Meals and Dietary Restrictions
Parti cipants should avoid eat ing a large meal for at least 2 hours prior to all l ung f unction 
assessments at the study  site.
5.3.2 Caffeine, Alcohol, and Tobacco
Chronic alcoho l or drug abuse wit hin [ADDRESS_942820] of the study .
Smoking i s not allowed throughout the course of the study .
The use of e- cigarettes is also not allowed during the course of the study .
5.3.3 Activity
Parti cipants should avoid engaging in strenuous exertion for at least 30 minutes prior to 
all lung function assessments at the study  site.
5.3.4 Contraception
Female participants:
Female participants of childbearing potential who are sexually act ive with a non -sterilized 
male partner must use a highly effect ive method of contraception from screening, and 
must agree to continue using such precautions for 16 weeks after the final dose of study  
intervent ion. Cessat ion of contraception after this point should be discussed wit h a 
responsible physician. Periodic abstinence, the rhythm method, and the withdrawal 
method are not acceptable methods of contraception.
A highly effe ctive method of contraception is defined as one that results in a low failure 
rate (i e, less than 1% per y ear) when used consistent ly and correctly. Highly effect ive 
forms of birth control include: true sexual abst inence, a vasectomised sexual partner, 
Implanon™, female sterilizat ion by [CONTACT_310383] n, any effective intrauterine 
device/system, Depo -Provera™ inject ions, oral contraceptive, and Evra Patch™ or 
Nuvaring™.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 39of 123Adolescent specific information : 
If participant isfemale and has reached menarche, or has reached Tanner Stage [ADDRESS_942821] 
development (even if not having reached menarche), the participant will be considered a 
female of childbearing potential.
5.4 Screen Failures
Screen failures are defined as participant s who complete informed consent /assent to
participate in the clinical study but are not subsequent ly randomly assigned to study  
intervent ion. A minimal set of screen failure informat ion is required to ensure transparent 
reporting of screen failure participant s to m eet the Conso lidated Standards of Reporting Trials
(CONSOR T) publishing requirements and to respond to queries fro m regulatory  authori ties. 
Minimal informat ion includes demography , screen failure details, eligibilit y criteria, and any 
SAE .
These participant s should have the reason for study withdrawal recorded as ‘Screen Failure ’ 
(ie, participant does not meet the required inclusio n/exclusion criteria) in the eCRF . This 
reason for study  withdrawal  is only  valid for screen failures, and not randomized participant s.
Re-screening is allowed only  once under the follo wing circumstances:
If the reason for screen failure was transient (including but not limited to study -supplied
equipment failure, unforeseen personal events that mandate missed screening visit s), 
participant smay potenti ally be re -screened. These cases should be discussed with the 
Parexel Medical Monitor and documented in the investigator study  file.
Any re -screened participant will be re -enrolled and reassigned their originally assigned 
enrollment number after signing a new informed consent /assent form, and after all Visit [ADDRESS_942822] been performed as listed in Table 1(with the except ion of testing for 
HIV-1 and HIV-2, hepatit is B and C ). If the timefram e between screening and re -
screening is more than 30 days, then all Visit 1 assessments should be repeate d.
Parti cipants who experience an asthma exacerbat ion during the screening /run-inperiod 
will be screen failed and may be re-screened after [ADDRESS_942823] igator ’s discretion
(the extensio n of the screening period bey ond 14 days should be discussed wit h Parexel 
Medical Monitor) .
Re-screened participant s shoul d be assigned the same enrollment number as for the init ial 
screening.
However, re -screening should be doc umented so that its effect on study results, if any , can be 
assessed.
Cli nical St u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D [ADDRESS_942824] i gat i o nal i nt er ve nt i o n(s), m ar kete d pr o d uct(s) or 
pl ace b o i nte n de d t o be a d mi nistere d t o a st u d y  partici pa nt acc or di n g t o t he C S P .
I n t hi s st u d y , a d mi nistrati o n of  t he i nact i vate d qua dri vale nt i nfl ue nza vacci ne is c o nsi dere d a 
bac k gr o u n d i nter ve nt i o n, n ot a st u d y  i nt er ve nt i o n.
6. 1 St u d y I nter ve nti o n(s) A d mi nistere d 
6. 1. [ADDRESS_942825] b o 
D ose f or m ul ati o n  
  
 
 
U n it d ose stre n gt h(s) 2 1 0 m g N/ A 
D os a ge le vel(s) [ADDRESS_942826] u d y I nter ve nti o n will be pr o vi de d 
i n A P F S wit h 1. 9 1 m L fill v ol u me. 
Eac h s yri n ge will be la belle d i n 
acc or da nce wit h G M P. 
A b bre viati o ns: A P F S = access orize d pr e -f ille d syr i n ge; I M P =i n vesti gati o nal me dici nal pr o d uct; N/ A = n ot 
a p plica ble; NI M P = n o n i n vesti gati o nal me dici nal pr o d uct; S C =s u bc uta ne o us; Q 4 W =e ver y 4 wee ks ; U S A= U nite d 
States of A merica .
T he Access orize d Pr e - F ille d Syr i n ge (A P F S )is a si n gle use, dis p osa ble s yste m t hat is C CI C CI 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 41of 123designed to deliver the labelled dose to the SC space during one inject ion and automat ically 
provi de a safet y mechanism to reduce the occurrence of accidental needle sticks d uring 
disposal  of the system . The APFS consists of a pre -filled syringe sub -assembly (PFS -SA; 
2.25 mL syringe barrel  -pre-filled to 1.91 mL with a 1/2 -inch 27 -gauge thin wall staked in 
needle, rigid needle shield, plunger stopper) and safet y device.
[IP_ADDRESS] Manag ement of Study Intervention Related Reactions
Appropriate drugs (eg, epi[INVESTIGATOR_238], H 1and H 2antihistamines, and corticosteroids), and 
medical equipment to treat acute anaphylactic reactions must be immediately available. S ite 
staff must be trained to recog nize and treat anaphylaxis ( Kroger et al 2011 , Lieberman et al
2010). Management of anaphylaxis must be in accordance with current standard of care and 
clinical guidelines. Details on anaphylaxis management are provided in
 Appendix A.
Anaphylaxis will be defined as a serious reaction that is rapid in onset and may cause death 
(Simpson et al 2006). Anaphylaxis t ypi[INVESTIGATOR_96684] 1 of 3 clinical scenarios:
1The acute onset of a reaction (minutes to hours) with invo lvement of the skin, mucosal 
tissue, or both, and at least 1 of the fo llowing: a) respi[INVESTIGATOR_13521] y compromise or b) reduced 
blood pressure or symptoms of end
-organ dy sfuncti on.
2Two or more of the fo llowing that occur rapi[INVESTIGATOR_96685]: involvement of the 
skin/mucosal t issue, respi[INVESTIGATOR_33097], reduced blood pressure or associated 
symptoms an d/or persistent gastroi ntestinal symptom s.
3Reduced blood pressure after exposure .
At Visits [ADDRESS_942827] a pre -assessment (i e, vital signs) pri or to study 
intervent ion administration) and should be observed after study  intervent ionadmi nistrati on for 
a minimum of [ADDRESS_942828] ion.
In order to help understand the potential drug -relatedness of any acute reaction, a blood 
sample should be drawn as close as possible to the event for possible addit ional ADA  testing 
(if not already scheduled for this visit). Serum try ptase or other blood or urine testing relevant 
to the di agnosis of anaphylaxis may  be obtained at a l ocal lab at the di screti on of  the 
investi gator .
6.1.[ADDRESS_942829]
Intervention name [CONTACT_695034] – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 42of 123Dose formulation Pre-filled syringe
Unit dose strength(s) Background intervention
Dosage level(s) 0.5mLonce
Route of 
administrationIM injection
Use Background intervention
IMP and NIMP NIMP
Sourcing Provided centrally by [CONTACT_456].
Packaging and 
labellingProvided as per manufacturer’s packaging
Abbreviations: IM=intramuscular; IMP=investigational medicinal product; NIMP=non investigational medicinal 
product.
6.1.[ADDRESS_942830] ituent part, provided for use in this study  is:
Accessorised pre- filled syringe (APFS)
Instructions for m edical  device use are provided in study  intervent ionHandling Instructions.
All medical device deficiencies (including malfunction, use error and inadequate labelling) 
shouldbe docum ented and reported by  [CONTACT_695004] s tudy (see 
Secti on8.3.12 ) and appropriately managed by [CONTACT_3455] .
6.2 Preparation/Handling/Storage/Accountability
6.2.1 Tezepelumab
[IP_ADDRESS] Preparation and Handling
Blinded s tudy intervent ion will be supplied to the site in a kit containing APFS tezepel umab or 
matching placebo. The kit has a unique number that is printed on all labels within the kit (ie, 
the outer carton label and the label of the APFS within the carton).
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study  intervent ion.
The stu dy intervent ion is to be stored at the study center in a secured facilit y with limited 
access and controlled temperature. The temperature should be monitored on a daily basis and 
docum ented in the tem perature m onitoring l og while study  intervent ion is stor ed at the study 
center . The study  intervent ion must be kept i n the ori ginal  outer container and under 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 43of 123condi tions specified on the label (between 36 °F to 46 °F [2 °C to 8 °C], protected from light).
In the fo llowing cases neit her the center staff should us e the affected study intervent ion and 
shoul d immediately  contact a Parexel representative for further guidance:
Temperature excursion upon receipt or during storage at the study  center
Storage condit ions were not met (eg, frozen) or cannot be confirmed
Dam aged ki t upon recei pt
Dam aged APFSdevice
Securi ty seal on the carton has been broken
The expi[INVESTIGATOR_244802]
Other reason(s) that may  have affected the study  intervent ion
Dam aged study  interventi on shoul d be docum ented via IWRS/IVRS (please refer to 
IWRS/IVRS manual for further details).
[IP_ADDRESS] Dose Preparation
Prior to each study  interventi on administrati on at the study  site:
Invest igator/authorized delegate will assess inject ion site as per standards of medical care.
For wom en of childbearing potential, urine pregnancy test will be done; study  
intervent ion will be administered only when the result of the test is negative (see 
Secti on8.2.5.1 ).
The APFS shoul d be visually inspected prior to dose preparation. The study intervention will 
be provided to the study  sites as a cl ear to slight ly opalescent, col orless to li ght y ellow liquid, 
practi cally  free from parti cles contained in a pre -filled syringe to be stored between 36 °F to 
46 °F (2 °C to 8 °C) until used.
If defects are noted with the study  interventi on, the invest igator and site monitor should be 
notified immediately . Preparati on of  the study  intervent ion must be performed by  a qualified 
person ( eg, pharmacist, invest igator or nurse) at th e site.
The study  intervent ion does not contain preservatives and any unused portion must be 
discarded. T otal in-use storage time from removal of the study  intervent ion from the 
refrigerator to start of administration must not exceed [ADDRESS_942831] be prepared with a new study  intervent ion kit.
To prepare the participant ’s dose, a study  interventi on kit will be selected for administration 
according to the kit ident ification number assigned by [CONTACT_10966]/IVRS.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 44of 123Dose preparation steps:
1Allow the study  interventi on to equilibrate to room  temperature 68 °F to 77 °F (20 °C to 
25 °C) for at least [ADDRESS_942832] be di scarded immediately  after dose preparation as per the site ’s 
standard operating procedures, the kit boxes must be retained for study  interventi on 
accountabilit y.
[IP_ADDRESS] Dose Administration
The administration of all study  intervent ion should be recorded in the appropriate sections of 
the eCRF. The study  intervent ion will be administered at the study  center . The study 
intervent ion will be administered by [CONTACT_3170]/authorized delegate or qualified 
healt hcare professio nal (eg, pharmacist or study  nurse) as specified in the SoA  (Secti on1.3). 
Each participant will receive tezepelumab 210 mg (one 1.91 mL  injecti on) or m atching 
placebo administered SC Q4W  for [ADDRESS_942833] ion site rotation sequence 
is presented below (see Figure 2). In cases when rotation of the inject ion site is not favorable
forthe participant and/or invest igator , the reason should be recorded in the source documents. 
The inject ion site must be recor ded in the source documents and the eCRF at each treatment 
visit.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 45of 123Figure [ADDRESS_942834] be carried out in line with the 
instructi ons provi ded.
At Visits3 and 4(Weeks 0 and 4), participants should be observed by [CONTACT_695005] a minimum o f 2hours after study  interven tion administration for the 
appearance of any  acute drug reacti ons. For the remaining visits involving study  intervent ion 
administration , parti cipants will be observed by [CONTACT_695006] a 
minimum o f 1hour after study  intervent ion administration for the appearance of 
any such 
reacti on.
If any o f the following occur, the invest igator should reschedule the visit and the study  
intervent ion should not be administered until the rescheduled visit :
The parti cipant received allergen immunotherapy  inject ion on the same day as scheduled 
study  interventi on administrati on.
The parti cipant has an intercurrent illness that in the opi[INVESTIGATOR_694959] y of the parti cipant in the study  (eg, vi ral illnesses).
Theparticipant was febrile ( ≥ 100.4 °F; ≥ 38 °C) within 72 hours prior to study  
intervent ion administration.
The parti cipant is confirmed to have an active COVID -[ADDRESS_942835] results.
The parti cipant is suspected to have an active COVID -[ADDRESS_942836] ion based on assessment 
of COVID -19 symptom s.
The visit should be rescheduled within the allowed visit window and study  intervent ion shoul d 

Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 46of 123be administered at that rescheduled visit.
If the participant is suspected to have an active COVID -[ADDRESS_942837] ion or fever ( ≥100.4 °F; 
≥ 38 ° C) suspected due to COVID -[ADDRESS_942838] ion, the visit should be rescheduled (and study  
intervent ion administration deferred) and participant should be re- assessed for symptoms of 
COVID -19prior to re -scheduled vis it.
The Parexel Medical Monitor shoul d be contact[CONTACT_695007]:
The parti cipant has been diagnosed with an act ive COVID -[ADDRESS_942839] ion.
The parti cipant ski ps [ADDRESS_942840] igator or qualified designee will 
complete the AE eCRF page and an addit ional eCRF page with questions about the injection 
site reacti on.
1)The invest igator or designee must confirm appropriat e tem perature condi tions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study  intervent ion.
2)Only participants enro lled in the study  may receive study  intervent ion and only  
author ized site staff may  supply  or administer study  intervent ion. All study  intervent ion 
must be stored in a secure facilit y with limited access .
3)The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsibl e for study interventi on accountabilit y, reconciliat ion, and record maintenance 
(ie,recei pt, reconciliat ion, and final disposit ion records).
4)Further gui dance and information for the final disposit ion of unused study  interventi ons 
are provided in the inves tigator instructi ons document .
6.2.2 Influenza vaccine
[IP_ADDRESS] Preparation and Handling
Inact ivated q uadrivalent influenza vaccine will be provided to the study sites in the 
manufacturer ’s packaging and will be in Pre -Filled Sy ringes. Influenza vaccine will be stored 
in the refrigerator at 35 °F to 46 °F (2 °C to 8 °C).
[IP_ADDRESS] Dose Administration
The influenza vaccine will be administered by  a qualified heal thcare professio nal at the si te at 
Week12. The influenza vaccine should be injected IM, i n the deltoid muscle and should be 
administered prior to study  intervent ion. After influenza vaccine administration, the 
participant shoul d be observed for a minimum o f 15 minutes for the appearance o f any acute 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 47of 123drug reaction and prior to administratio n of study  intervent ion. A different injection site 
shoul d be used for SC inject ion of study  intervent ion on that day  (ie, not the same upper arm). 
The inject ion sites m ust be recorded in the source documents and the eCRF .
6.2.[ADDRESS_942841] be stored at 
labelled condit ions 2°C to 8°C (36°F to 46°F), separated from other study  intervent ionkits, 
unless otherwise instructed.
6.2.[ADDRESS_942842] complaints in these 3 categories in clude, but are not limited to:
Component Issue: Defect in the container or dosing mechanism of the study  
intervent ion. The com ponent may be damaged, missing, or broken. For the APFS, 
component examples include syringes and the accessory  housing the syringe.
Product Issue: Defect in the product itself. The product appearance has visual
imperfections such as foreign particles, cry stallizatio n, discoloration, turbi dity,
insufficient volume, or any thing that does not apply  to the product descri ption in the 
Parexel study -specific Investigator Manual .
Packaging/Labelling Issue : Defect in the packaging or labelling of the product. The
packaging (eg, carton, thermo -fitted tray , or tam per-evident seal) or labelling may be 
damaged or unreadable, or the label may  be missing.
6.2.5 Single Use APFS Device Malfunction
An AP FS m alfuncti on is when the APFS appeared normal during verificat ion of shipment and
then does not work during administration, eg, the safet y feature activated prematurely , part of 
the device (finger flange, p lunger rod, etc.) came off or broke, the needle shield could not be
removed ,only a partial dose was administered, the needle guard safet y feature di d not 
activate, needle bent or broke upon use.
Device m alfunct ions should be reported using the “Defect Malfunct ion Return Form ”and the
Study  Moni tor shoul d be notified.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 48of 123If a device malfunct ion is ident ified:
Before study  intervent ionadministration has started, another kit (replacement) should be 
dispensed to perform study  intervent ionadministration;
After study  interventi onadministrati on has started and participant has been administered 
partialdose of study  intervent ion, another ki t must not be di spensed, and the participant 
must not be administered with another study  intervent ionkit. The Parexel  Medi cal 
Moni tor and Study  Moni tor shoul d be notified.
The return a ddress and attention for malfunct ioning device is available in the Device 
Malfunct ion Return Instructions.
6.3 Measures to Minim izeBias: Randomization and Blinding
6.3.[ADDRESS_942843] igator(s) will:
1Obtain signed informed consent /assent fro m the potenti al participant , or their 
guardi an/legal representative, before any study  specific procedures are performed.
2Assign the potential participant a unique enro llment number via the IWRS/IVRS.
3Determine participant eligibilit y.
4Assign the eligible participant unique rando mization code via the IWRS/IVRS.
5Parti cipants will be allo cated to receive tezepelumab or placebo in a 1:[ADDRESS_942844] ion4.1. Randomi zation numbers will be 
grouped in blocks. If a participant withdraws fro m the study , then his/her 
enrollment/ran domizat ion code cannot be reused. Wit hdrawn participant s will not be 
replaced.
Specific information concerning the use of the IWRS/IVRS will be provided in a separate 
manual.
6.3.[ADDRESS_942845] igator should inform the Parexel  Medical  Moni tor
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 49of 123immediately , and a di scussio n shoul d occur between the Parexel Medical Monitor and the 
investigator regarding whether to continue or discont inue the participant from treatment. 
Study intervent ionmust be di scont inued in all cases where cont inued treatment is deemed to 
pose a safet y risk to the participant andthe Parexel Medical Monitor must ensure the decisio n 
is appropriately documented. Participant s that are discontinued fro m treatment should be 
followed up according to the options described in Section7.1.
In those cases where cont inuat ion of the study  intervent ionis judged not to present a concern 
related to safet y and disease management, the rati onale for continuing study  interventi onmust 
be clearly  docum ented.
6.3.[ADDRESS_942846] prepared by a 
computeri zed system  provi ded by [CONTACT_695008] o f [COMPANY_008] in accordance wi th the 
AZRand process . All participant s will be stratified at randomi zation by  [CONTACT_695009]/assent (12to 17 years and 18 to 21 years). The rando mizat ion will be set 
up to ensure that at least 50% of enro lled participant sare in the 12 to 17-year age group. This 
will be accomplished by [CONTACT_1299] a 50% cap on the 18 to 21-year age group in the IWRS/ IVRS 
such that enrollment in this age group stops once this cap is reached.
6.3.[ADDRESS_942847], study interventionwill be handled by a qualified person (e g, 
pharmacist or study  nurse) at the si te.
AParexel  site monitor will  perform study  interventio naccountabilit y. In the event that the 
treatm entallocation for a participant beco mes known to the invest igator or other study  staff 
involved in the management of study  participant s, or needs to be known to treat an individual 
participant for an AE, the sponsor m ust be notified immediately by  [CONTACT_41409], if 
possible, before unblinding.
The fo llowing person nel will have access to the randomizat ion list:
Those carrying out the packaging and labelling of study  interventi on
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 50of 123Those generat ing the randomi zation list (CALYX)
Supply  Chain Management department
Patient Safet y department at [COMPANY_008]
Bioanaly tical lab analyst performing the PK sample analysis
No other m ember of the extended study  team  at [COMPANY_008], or any contract research 
organizat ion (CRO )handling data, will have access to the rando mizat ionscheme during the 
conduct of the study  until aftertheplanned u nblinding at the primary database l ockafter the 
last parti cipant (enrolled in the 2021/2022 flu season) completes V isit 7 (Week 16) .
The informat ion in the randomization list will be kept from other personnel invo lved in the
conduct of the stud y and in a secure location unt il the end of the study .
Maintaining the blind to the participant’ s blood eosinophil counts
While not entirely  specific, parti cipants on active tezepelumab treatm ent are expected to have 
lower blood eosinophil counts than pa rticipants on pl acebo. Procedures to mit igate unblinding 
on this basis include:
From  Week4 onward , eosinophil, monocyte, and basophil counts will be redacted fro m 
central  laboratory  reports to prevent the investigator/designee fro m possibly deducing the 
eosinophil contribut ion to the com plete bl ood count.
If the invest igator orders any local safet y laboratory assessments, the requested tests 
shoul d be restri cted to the question at hand. For example, if a hemoglo bin is desired, the 
investi gator shoul d avoi dordering a com plete bl ood cell  count wi th different ial.
Handling of labs obtained during the treatment period but ordered outside of the clinical 
trial. Sitestaff who are direct ly involved in the parti cipant ’s management should remain 
blinded to any  eosi nophil, basophil, and mo nocy te resul ts included as part of outside 
laboratory reports. To hel p ensure this, each investigat ional sitewill designate an 
individual (eg, administrator or another ancillary  person) not di rectly invo lved in 
participant management, to receive and blind any  eosinophil, basophil , and m onocy te 
resul ts pri or to the report being handed over to the site staff invo lved in the pa rticipant ’s 
management and prior to filing as a source document. Similarly, eosinophil , monocy te,
andbasophil results must be redacted from all co mmunicat ions wit h the sponsor.
In cases where the invest igator requires an eosinophil, basophil, or monocyte count for 
managing safet y issues he/she may order these tests. [COMPANY_008] should be notified of all 
such cases.
6.3.5 Methods for Unblinding
Individual treatment codes, indicating the treatment randomi zation for each rando mized 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 51of 123participant , will be available to the investigator(s) and delegate(s) at the study sites fro m the 
IWRS/ IVRS. Routines for this will b e described in the IWRS/ IVRS user m anual that will be 
provi ded to each site.
The treatment code should not be broken except in medical emergencies when the appropriate 
management of the participant requi res knowledge of the treatment randomi zation. The 
investigator shoul d document and report the action to Parexel , without revealing the treatment 
given to participant to the [COMPANY_008] staff.
[COMPANY_008] retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally  related to a study  interventi on and that potentially require expedited 
reporting to regulatory  authori ties. Treatment codes will not be broken for the planned 
analyses o f data until all decisio ns on the evaluabilit y of the data from  each individual 
participant have been made and unt il the primary  database l ock -after the last participant has 
completed Visit 7(Week 16) -has been documented.
6.[ADDRESS_942848] igator/authorized delegate at each visit (as shown in SoA Sect ion1.3).
As theophylline has a narrow therapeutic window , please note that participants on 
maintenance treatment with theophylline should have blood concentration levels wit hin 
therapeuti c range docum ented before V isit 1. If this is not documented before signing the 
inform ed consent /assent , it can be obtained after informed consent /assent has been given or as 
part of the V isit [ADDRESS_942849] the results.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 52of 123Any medicat ion or va ccine (including over -the-counter or prescript ion medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrol lment or 
receives during the study  must be recorded along with:
Reason for use
Dates of administration including start and end dates
Treatment for any  exacerbat ion that occurred within 12 months prior to Visit 1 should be 
recorded
Dosage information including dose and frequency for asthm a medicat ions
The Parexel Medical Monitor shoul d be contact[CONTACT_695010] .
Table6 Permitted Medications
Type of medication/treatment Usage
The ICS and LABA can be parts of a combination 
product o r given by [CONTACT_310401].The ICS dose must be > 250 μg fluticasone 
propi[INVESTIGATOR_694960].
Additional asthma controller medications (eg, 
LTRAs, short and long -acting anti -muscarinics, 
theophylline, oral corticosteroids, etc).These must have b een used for at least 30 days prior 
to Visit 1.
Background controller regimen. Changes are discouraged throughout the study unless 
judged medically necessary by [CONTACT_695011] ’s health care practitioner.
Oral or other systemic cortic osteroids or other asthma 
therapi[INVESTIGATOR_014].Asthma exacerbations can be treated according to 
standard practice.
Abbreviations: ICS= inhaled corticosteroids; LABA= long-acting β2 agonist ; LTRA= leukotriene receptor 
antagonist.
Table7 Restricted Medications
Type of medication/treatment Usage
Allergen therapy . These should not be administered within 7 days of 
study intervention administration.
Medication with narrow therapeutic range. The level of theophylline or other drugs with a 
narrow therapeutic range should not exceed the upper 
limit of therapeutic range at the time of enrollment.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 53of 123Table7 Restricted Medications
Type of medication/treatment Usage
Scheduled inactivated/killed vaccines, including the 
COVID -19 vaccinationThese are allowed, provided they are not 
administered within 6days before or after study 
interventio n administration.
Scheduled influenza vaccination at Visit 6 is not 
allowed within 6days after the COVID -19 
vaccination.
Administration timing of COVID -19 vaccination 
should be discussed with P arexel Medical Monitor.
Abbreviations: COVID -19= Coronavirus disease 2019; OCS=oral corticosteroids .
Table8 Prohibited Medications
Type of medication/treatment Usage
Influenza vaccine. Not allowed for the fall/winter 2021/22 season prior 
to randomi zation or throughout study period (except 
for the influenza vaccine given at Visit 6 per CSP).
Any immunomodulators or immunosuppressives. Not allowed [ADDRESS_942850]. Not allowed 16 weeks or 5 half -lives prior to Visit 1, 
throughout the treatment period or until the End of 
Study Visit at Week 28 is complete.
Other investigational products (including 
investigational use of an approved d rug).Not allowed 30 days, or 5 half -lives (whichever is 
longer), prior to Visit 1, or throughout the treatment 
period.
Blood products or immunoglobulin therapy. Not allowed [ADDRESS_942851] dose 
of study intervention , PRN use is allowed if needed ;
however ,attention should be paid to the fol lowing 
restrictions.
SABA should be withheld for at least 6 hours prior to 
scheduled spi[INVESTIGATOR_694961].
Abbreviations: CSP=clinical study protocol ; SABA= short- acting β2 agonists .
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 54of 1236.5.1 Rescue Medicine
Short -acting bronchodilators may be used as rescue medicat ion during the study  in the event 
of a worsening of asthma symptoms.
6.5.2 Asthma Medication Restrictions
Changes to the participant’s background controller regimen are discouraged during 
the study unless judged medically necessary by [CONTACT_695012]’s HCP; 
ideally such changes should be discussed wit h the Parexel Medical Monitor . All changes 
in the part icipant’s background medicat ion shoul d be docum ented in source along with 
rational for change and recorded in the eCRF.
Asthma exacerbations can be treated with oral or other sy stemic corti costeroi ds or other 
asthma therapi[INVESTIGATOR_680218].
Asthma medication restrictions on the days of scheduled spi[INVESTIGATOR_694962]/or post -dose spi[INVESTIGATOR_694963] (see SoA, Section 1.3). Restrictions to the parti cipant’s background 
medicat ion are required prior to the spi[INVESTIGATOR_694964] (also see 
Secti on8.1.2 ).
Screening Visit 1 or 2: Participants will be asked to withho ld their usual bronchodilator 
medicat ions on the morning of scheduled spi[INVESTIGATOR_23952] (see Section [IP_ADDRESS] ). 
The parti cipant’s usual asthma medicat ions may be administered fo llowing com pletion of 
the screening lung funct ion procedures.
6.[ADDRESS_942852] of care asthm a 
medicat ion at the di scret ion of the investigator .
7 DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL
7.1 Discontinuation of Study Intervention
An individual participant will not receive any further study  intervent ion in the fo llowing 
situations.
Parti cipant decisi on. The parti cipant i s at any  time free to di scont inue study  intervent ion, 
without prej udice to further treatment.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 55of 123An AE considered to jeopardi ze the safet y of a parti cipant in the study .
Pregnancy.
Severe nonco mpliance with the CSP.
Development of any study specific criteria for discontinuat ion, including:
An anaphylact ic react ion to the study intervent ionrequi ring administration of 
epi[INVESTIGATOR_238] .
A helmint h parasit ic infestation requiring hospi[INVESTIGATOR_059] .
An asthma -related event requiring intubat ion.
Any mal ignancy  except participant s who develop basal cell carcino ma or l ocalized 
squamous cell carcino ma of the skin, provided that the malignancy is excised and 
determined to have clean margins .
Development of one or more of the fo llowing:
Confirmed ALT or AST i ncrease of ≥ 8 × ULN .
Confirmed ALT or AST increase of ≥ 5 × ULN for more than 2 weeks .
Confirmed ALT or AST increase of ≥ 3 × ULN and total bilirubin of ≥ 2 × ULN .
ALT or AST of ≥ 3 × ULN with the appearance of fat igue, nausea, vo miting, right 
upper quadrant pain or tenderness, fever, rash, and/or eosinophilia ( ≥ 5%).
Note that discontinuation fro m study  intervent ion is NOT the same thing as a withdrawal fro m 
the study .
Parti cipants who di scontinue study  interventi on shoul d return to the study  center and complete 
the procedures described for the IPD visit (refer to Secti on 1.3, SoA, IPD vi sit) at 4 weeks ( ±3 
days) post last study intervent ion administration. If the IPD vi sit occurs on the sam e date as 
the scheduled V isit6 (Week 12 ), all IPD assessments should be performed, in addit ion to 
influenza antibodies and influenza vaccine administration. The participant should t hen return 
for the scheduled V isit7 (Week 16 )visit and have all scheduled assessments performed, 
including the influenza antibodies, as per the SoA.
All participants who discont inue study  intervent ion shoul d be encouraged to return for all 
regul arly sche duled visi ts for safet y and efficacy assessments.
The parti cipant shoul d return for a Follow -up Visit  16 weeks ( ±3 day s) post l ast study  
intervent ion administration (refer to Section
 1.3, SoA, V8 –Week 28). If the fo llow-up visit 
occurs on the same date as the scheduled V isit 7 (Week 16 ), all fo llow-up assessments should 
be perform ed, in addi tion to influenza antibodies.
See the SoA for data to be collected and for any  further eval uations that need to be completed
in case o f discontinuati on from study  intervent ion.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 56of 1237.2 Participant Withdrawal from the Study
A participant may withdraw from  the study  at any  time at hi s/her own (parent or le gal 
guardi an) request, or m ay be withdrawn at any  time at the di scret ion of the investigator
for safet y, behavi oral,compliance, or administrative reasons .This is expected to be 
unco mmo n.
A participant who considers wit hdrawing fro m the study  must be informed by  [CONTACT_122610]-up opti ons (eg, telephone contact, a contact [CONTACT_4490] a 
relative or treating physician, or information fro m medical records).
At the time of withdrawal  from the study , if possible, an IPD Visitshoul d be conducted, 
as shown in the SoA (Section 1.3). See SoA for data to be collected at the time of study  
withdrawal and for any  further evaluat ions that need to be completed.
The parti cipant will discont inue the study  interventio n and be wit hdrawn from the 
study  at that time.
If the participant (parent or legal guardian) withdraws informed consent /assent for 
disclosure of future informat ion, the s ponsor m ay retain and continue to use any  data 
collected before such a withdrawal o f informed consent /assent .
If a participant withdraws fro m the study ,it shoul d be confirmed if he/she (parent or l egal 
guardi an)still agrees for exist ing samples to beused in line with the original informed 
consent /assent . If he/she (parent or l egal guardian) request s withdrawal of informed 
consent /assent for use of samples, destructi on of  any samples taken and not tested should 
be carri ed out in line wit h what was stated in the informed consent /assent and local 
regul ation. The invest igator must document the decision on use of exist ing samples in the 
site study  records and inform the Global Study  Team .
7.[ADDRESS_942853] be taken ifa participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_78778] m issed visit as soon as 
possible and counsel the participant on the importance o f maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or sh ould continue in 
the study .
Before a participant is deemed lost to f ollow-up, the invest igator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and ,
if necessary ,a certified letter to the partici pant’s last known mailing address or local 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 57of 123equivalent m ethods). These contact [CONTACT_13140] ’s 
medical record .
Shoul d the participant continue to be unreachable, he/she will be considered to have 
withdrawn from  the study . 
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Appendix C.
8 STUDY ASSESSMENTS AN D PROCEDURES
Study  procedures a nd their timing are summar ized in the SoA (Secti on1.3).Protocol
waivers or exempt ions are not allowed.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  interventi on.
Adherence to the study  design requi rements, including those specified in the SoA, is 
essent ial and required for study  conduct .
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al 
participant s meet all eligibilit y criteria. The invest igator will maint ain a screening log to 
record details o f all partici pants screened and to confirm eligibilit y or rec ord reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg,blood 
count) and obtained before signing of the informed consent/assent may be utilize d for 
screening or baseline purposes provided the procedures met the protocol -specified criteria 
and were performed within the t ime frame defined in the SoA .
The m aximum  amount of  blood collected from  each parti cipant over the duration of the 
study , including any  extra assessments that may be required, will not exceed 150mL. 
Repeat or unscheduled samples may be taken for safet y reasons or for technical issues 
with the sam ples.
8.1 Efficacy Assessments
8.1.1 Humoral Response to Influenza Vaccine
Serum  HAI and MN ant ibody  testing for antibody  responses will  be perform ed on bl ood 
samples taken at Week12 
(pre-dose antibody measure) and at Week16(EOT) from all study 
participants . Methods for these analyses will be described in the Laboratory  Manual .
8.1.2 Spi[INVESTIGATOR_038]
[IP_ADDRESS] General requirements
Lung funct ion (reversibilit y, FEV 1and FVC) at the study  center will be measured by  
[CONTACT_15209][INVESTIGATOR_694965]. Spi[INVESTIGATOR_694966] d be perform ed by [CONTACT_695013] – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 58of 123or authori zed delegate according to ATS/ERS or local guideline recommendat ions .
The PI/authorized delegate is responsible for assuring that the spi[INVESTIGATOR_667750], calibrated and meets the A TS/ERS or l ocal guidelines recommendat ions, and that 
the study  center personnel who will p erform the test are properly  certified.
IMPOR TANT:Parti cipants shoul d withhol d thei r usual maintenance therapi[INVESTIGATOR_96665] (s) 
when lung funct ion testing is being performed as below:
SABAs or SAMAs should be withheld at least 6 hours prior to scheduled spi[INVESTIGATOR_694967].
Twice daily LABA or LAMA -containing therapi[INVESTIGATOR_244838] 
12hours prior to scheduled spi[INVESTIGATOR_96653] . 
Once daily  LABA or LAMA -containing therapi[INVESTIGATOR_244838] 24 hours 
prior to scheduled spir ometry at si te.
LTRA should be restricted for at least 24 hours prior to scheduled spi[INVESTIGATOR_96620].
Twice daily theophylline should be wit hheld for at least 12 hours prior to scheduled 
spi[INVESTIGATOR_96666].
Once daily  theophylline shoul d be wi thheld for at least 24 hours prior to scheduled 
spi[INVESTIGATOR_96666].
If Visit s 1 and 2 are combined, bronchodilator therapy (ies) wi th or wi thout ICS shoul d be 
withheld for [ADDRESS_942854] ion6.5.2.
[IP_ADDRESS] Spi[INVESTIGATOR_694968] d avoi d engaging in strenuous exertion for at least [ADDRESS_942855] not be t ilted during m aneuvers and the 
thorax shoul d be able to m ove freely; hence, tight clothing should be loosened. A nose-clip 
shoul d be used for the m aneuver . Mouthpi [INVESTIGATOR_694969] n and shape should be 
used by [CONTACT_2299] .
The forced expi[INVESTIGATOR_75043] (FEV 1and FVC) should start with a maximal inspi[INVESTIGATOR_667756]  a fast and forceful expi[INVESTIGATOR_694970] 6 seconds. It is 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 59of 123important to encourage the participant to con tinue the expi[INVESTIGATOR_694971] . Ensure that none of the following has occurred: coughing during the 
first second, gl ottis closure, l eak or obstructi on of  the m outhpi[INVESTIGATOR_13959] (by [CONTACT_243285]).
Multiple forced expi[INVESTIGATOR_667758] (at l east 3 but no more than 8) will be performed for each 
center spi[INVESTIGATOR_667759] [ADDRESS_942856] efforts that meet the American Thoracic 
Society/European Respi[INVESTIGATOR_694972] y criteria will be 
recorded. The best efforts will be based on the highest FEV 1.
The abso lute measurement (for FEV 1and FVC), and the percentage of predicted normal value 
will be recorded using the local spi[INVESTIGATOR_694973], eg, NHANES III [ADDRESS_942857] FVC 
will also be reported regardless of the effort in which it occurred (even if the effort did not 
resul t in the hi ghest FEV 1).
[IP_ADDRESS] Post-bronchodilator Spi[INVESTIGATOR_694974] n criterion3either by [CONTACT_695014] y or by  [CONTACT_695015] y either at V is
it1 or V isit2. Even if documented 
histori cal reversibilit y is available, the post- BD spi[INVESTIGATOR_694975] m ust be perform ed at 
Visit1 to categori ze parti cipants (establish baseline characterist ic) prior to randomizat ion. The 
docum ented histori cal reversibili ty must be recorded in the eCRF/spi[INVESTIGATOR_694976]. 
The post -BD spi[INVESTIGATOR_694977] 30 ± [ADDRESS_942858] ion8.1.2.5 and Figure 3.
[IP_ADDRESS] Order of Administration
Order  of administration of usual asthma contr oller  medication and study intervention 
relative to scheduled pre and post
-bronchodilator  spir ograms.
The parti cipant ’s usual m orning asthma controller therapy  must not be given unt il after the 
initial pre -medicat ion, pre -BD spi[INVESTIGATOR_680230]; usual 
asthma con troller m ay be given after the post -BD spi [INVESTIGATOR_244916] .
[IP_ADDRESS] Reversibility Test and Post- BD FEV 1Assessment
The procedure described in this section refers to the reversibilit y testing at V isit 1 or V isit 2. 
Bronchodilatation can be induced using albuterol (90 μg metered dose), salbutamo l (100 μg 
metered dose) or levalbuterol (45 μg metered dose) up to a maximum o f 8 inhalations. It is 
highly  recommended to use a spacer device for this procedure. The algorithm for reversibilit y 
testing is outlined in Figure 3.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 60of 123Figure 3 Reversibility Testing Algorithm
Abbreviations: BD=bronchodilator; FEV 1=forced expi[INVESTIGATOR_3741] 1 second; SABA= short-acting β2 
agonists.
1Verify wit h the participant that the m edicati on restri ctions to allow the reversibilit y 
assessment have been met (Section 6.5.2 ).
2After a gent le and co mplete expi[INVESTIGATOR_1516], albuterol, salbutamo l or levalbuterol is inhaled in 
one breath to total lung capacit y from  a spacer device. The breath is then held for [ADDRESS_942859] -BD spi[INVESTIGATOR_244914] d be perform ed 15 to 20 
minutes l ater.
3If the pa rticipant has not m et reversibilit y criteria, an addit ional 2 inhalat ions of albuterol, 
salbutamo l, or levalbuterol can be administered as single inhalat ions, 30 seconds apart 
(for a total of 6 inhalat ions). Second post -BD spi[INVESTIGATOR_244914] d be perform ed [ADDRESS_942860] u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D 5 1 8 0 C 0 0 0 3 1 
C O N FI D E N TI A L A N D P R O P RI E T A R Y 6 1 of 1 2 3 4If t he parti ci pa nt still has n ot met re versi bilit ycri t eri a, a n a d dit i o nal 2 i n halat i o ns of 
al b uter ol , sal b uta m ol , or l e val b uter ol  ca n be a d mi nistere d as si n gle i n halat i o ns, 
3 0 sec o n ds a part (f or a t otal of 8 i n halat i o ns). T hi r d p ost -B D s pi r o m etr y  s h o ul d be 
perf or m e d [ADDRESS_942861] o n t he partici pa nt ’s heart rate, tre m or, or safet y .  T he 
br o nc h o dilat or al g orit h m ca n be st o p pe d at a n y  ti me o nce a partici pa nt has met re ve rsi bilit y 
cri teria. 
T he hi g hest pre a n d p ost -B D F E V 1s h o ul d be use d t o deter mi ne re versi bilit y. 
Re versi bilit y is calc ulate d as f o ll o ws: 
% Re versi bilit y = ( p ost -B D F E V 1-pre B D F E V 1) × [ADDRESS_942862] u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D 5 1 8 0 C 0 0 0 3 1 
C O N FI D E N TI A L A N D P R O P RI E T A R Y 6 2 of 1 2 3 8. 2 S afet y Assess me nts 
8. 2. 1 P h ysic al E x a mi n ati o ns 
P h ysical e xa mi nat i o n will be perf or me d at ti me p oi nts as s pecifie d i n t he S o A  ( Secti o n 1. 3 ). 
Baseli ne data will be c ollecte d at V isit 1. A n y ne w fi n di n g(s) or a g gra vate d e xist i n g fi n di n g(s), 
j u d ge d as cli nicall y  si g nifica nt b y  t he i n vest i gat or , will be re p orte d as a n A E as descri b e d i n 
Secti o n 8. 3 .
A c o m p lete ph ysical e xa mi nat i o n will be perf or m e d a n d i ncl u de assess me nts of  t he 
f o ll o wi n g; ge neral a p peara nce, res pi r at or y ,car di ovasc ular , a b d o me n, s ki n, hea d a n d nec k 
(i ncl u di n g ears, e yes, n ose ,a n d t hr oat), l y m p h n o des, t h y r oi d, m usc ular -s keletal  
(i ncl u di n g s pi [INVESTIGATOR_050] a n d e xtre mit ies) a n d ne ur ol o gical s yste m s. C CI C CI 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 63of 123A brief physical examinat ion will include, at a minimum, assessments of the general 
appearance, abdo men, cardi ovascular, and respi[INVESTIGATOR_36517] . For the bri ef physical  
examinat ion only informat ion on whether the assessment was performed or not is to be 
recorded .
8.2.2 Vital Signs
Pre-dose vital signs (pulse, blood pressure, respi[INVESTIGATOR_39870] n rate, and body  temperature) are to be 
obtained in accordance with the SoA  (Secti on1.3).
Body  temperature i s to be recorded in degrees Fahrenheit/ Celsius .
8.2.3 Local Electrocardiograms
An ECG will be performed at Visit 1 as specified in the SoA (Section 1.3).
A single [ADDRESS_942863] 5 minutes. The assessment should be performed before intervent ions wi th the 
participant (eg, spi[INVESTIGATOR_96656]).Measurements will be performed on sitesupplied equipment.
A standard ECG with a recommended paper speed of 25 or 50 mm/second covering at least 
6sequent ial beats will be used. The invest igator or authorized delegate will be responsible for 
the overall interpretation and determinat ion of clinical significance of any  potential  ECG 
findings. In case of discrepancy between the investigator ’s interpretation and that provided by 
[CONTACT_325387] m achine (if applicable), the invest igator ’s interpretati on takes precedence and should 
be noted on the printout and recorded in the eCRF . Two ident ical copi[INVESTIGATOR_694978], qualit y checked, and kept in case of further need for re -evaluat ion. The ECG 
printouts will be signed and dated by [CONTACT_695016] .
ECG data and evaluat ion will be recorded in the eCRF .
8.2.[ADDRESS_942864] be conducted in accordance with the 
Laboratory  Manual and the SoA (Section 1.3).Fasting before blood draw is recommended but 
not m andatory .
Addit ional safet y samples (repeated or scheduled) may be collected if clinically indicated at 
the discret ion of the invest igator .
The clinical chemistry andhematol ogy will be perform ed at a central laboratory . Urinalysis , 
theophylline level,and SARS -CoV-[ADDRESS_942865] will be performed at a local 
laboratory  atthe investigator site. Sample tubes and sample sizes may vary d epending on 
laboratory  method used and routine practice at the site.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 64of 123The invest igator should make an assessment of the available results with regard to clinically 
relevant abnorm alities. The l aboratory  resul ts should be si gned and dated and retained at sit e 
as source data for laboratory  variables.
The fo llowing laboratory  variables listed in Table9will be measured .
Table9 Laboratory Safety V ariables
Hematology / Hemostasis (whole blood) Clinical Chemistry (serum or plasma)
B-Hemaglobin S-ALP
B-Leukocy te count S-ALT
B-Leukocy te differential count (absolute count)aS-AST
B-Platelet count S-Bilirubin, total
B-Hematocrit S-BUN
B-MCV S-Calcium, total
B-RBC count S-Chloride
Urinalysis (dipstick) –local laboratory S-Creatinine
U-Hemaglobin/Erythrocytes/Blood S-Creatinine kinase (CK)
U-Protein/Albumin S-CRP
U-Glucose S-GGT
S-Glucose
U-Microscopy and culture as requiredbS-Phospho rus
S-Potassium
SARS-Cov -2 (swab) –local laboratory S-Sodium
SARS -CoV -[ADDRESS_942866] S-Total cholesterol
S-Ur ic acid
S-Theophylline level (local laboratory )c
aEosinophil, basophil and monocyte counts will be redacted from the central laboratory reports, except for 
Visit 1 and Visit 3 (see Section 6.3.4 ).
bUrine samples will be analyzed locally and sent to the central laboratory only for analysis when a positive 
dipstick result for any parameter is observed.
cFor participants on theophylline see Se ction 6.5.
Abbreviations: ALP=alkaline phosphat ase; ALT= alanine aminotransferase ; AST= aspartate aminotransferase ; 
BUN=blood urea nitrogen; GGT=gamma glutamyl transpeptidase ; HPF=high power field; MCV=mean 
corpuscular volume; RBC=red blood cell; SARS -CoV -2=severe acute respi[INVESTIGATOR_6507] 2 ; 
WBC=white blood cell
NB. In case a participant shows an AST orALT ≥ 3 × ULN together with total  bilirubin 
≥ 2 × ULN please refer to Appendix D.Actions requi red in cases of increases in liver 
biochemistry  and eval uation of  Hy’s Law , for further instructions.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 65of 1238.2.5 Other Safety Assessments
[IP_ADDRESS] Pregnancy Test
The fo llowing tests are applicable to female participants only and will be conducted at the 
timepo ints specified in the SoA  (Secti on1.3).
Serum  β-HCG: To be done at screening Visit 1 only , for wom en of childbearing potential
(analyzed at central laboratory ).
Urine pregnancy  test: To be performed at the study center for women of childbearing 
potenti alat each treatm ent visi t (bef ore study  intervent ion administration on Visit 3 to 
Visit 6) using a di pstick. A posi tive urine test result must be confirmed wit h serum β -
HCG (analyzed at central laboratory ).
[IP_ADDRESS] Weight and Height
Weight and height will be measured, and BMI calculated in accordance with the SoA  
(Secti on1.3).
The pa rticipant ’s weight will be recorded in pounds /kg; height will be recorded in 
inches/ meters .
[IP_ADDRESS] Serology
Hepati tis B surface ant igen and hepat itis C ant ibody
To be done at screening Visit 1 only (Secti on1.3)
; test to be performed at central 
laboratory .
HIV-1 and HIV -2 antibodies
To be done at screening Visit 1 only (Secti on1.3); test to be pe rform ed at central  
laboratory .
Instructi ons for sam ple collect ion, processing, storage, and shipment can be found in the 
separate Laboratory  Manual  provided to the study  centers.
[IP_ADDRESS] SARS -CoV -[ADDRESS_942867]
Local  viral testing t o be performed at screening Visi t 1 to confirm exclusio n criterion27
(Secti on1.3).
Results of local negat ive viral SARS -Cov-[ADDRESS_942868] be recorded in the eCRF .
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 66of 1238.[ADDRESS_942869] ion.
The definit ions of an AE or SAE can be found in Appendix E.
Adverse events will be reported by  [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant 's legally author ized representative) . 
The invest igator and any designees are responsible for detecting, document ing,and recording 
events that meet the definit ion of an AE.
8.3.[ADDRESS_942870] igator shall, without undue delay , report the SAE to the sponsor .
8.3.2 Follow- up of AEs and SAEs
Any AEs that are unreso lved at the participant ’s last AE assessment or other assessment/visit 
as appropri atein the study  are fo llowed up by [CONTACT_476669], but without further recording in the eCRF. [COMPANY_008] retains the right to request 
additional information for any  participant with ongoing AE(s)/SAE(s) at the end of the study , 
if judged nece ssary .
Adverse event variables
'The following variables will be collected for each AE;
AE (verbat im)
The date when the AE started and stopped
Maximum intensit y
Whether the AE is serious or not
Invest igator causalit y rating against the study  intervent ion(s)(yes or no)
Action taken with regard to study  intervent ion(s)
AE caused participant ’s withdrawal fro m study  (yes or no)
Outcom e
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 67of 123In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for SAE
Date invest igator became aware o f SAE
AE is seri ous due to
Date of hospi[INVESTIGATOR_18543]
Date of discharge
Probable cause of death
Date of death
Autopsy  performed
Causalit y assessment in relat ion to study procedure(s)
Causalit y assessment to other medicat ion
8.3.[ADDRESS_942871] igator should assess causal relationship between study  interventi onand each AE, 
andanswer ‘yes’ or ‘no’ to the question ‘Do y ou consi der that there is a reasonable possibilit y 
that the event may have been caused by  [CONTACT_592730]?’
For SAEs , causal  relationship shoul dalso be assessed for other medicat ion and study  
procedures . Note that for SAEs that could be associated with any study  procedure the causal 
relationship is implied as ‘yes’.
A guide to the interpretation of the causalit y questi on is found in
 Appendix Eto the CSP.
8.3.4 Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by [CONTACT_592731]: ‘Have y ou/the child had any  health problems since 
the previous visit/you were last asked? ’, or reveal ed by  [CONTACT_695017]. When co llecting AEs, the recording of diagnoses is preferred (when 
possible) to recording a list of signs and symptoms . However, if a diagnosis is known and 
there are other signs or symptoms that are not generally part of the diagnosis, the diagnosis 
and each sign or symptom will be recorded separately.
8.3.5 Adverse Events Based on Examinations and Tests
The results from the CSP mandated laboratory  tests and vi tal signs will be summari zed in the 
CSR . 
Deteri oration as com pared to baseline in CSP mandated laboratory  values, vital si gns and 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 68of 123other safet y assessments shoul d therefore only  be reported as AEs if they fulfi ll any of the 
SAE cri teria, are the reason for discont inuat ion of treatment with the study  intervent ionor are 
considered to be clinically relevant as judged by [CONTACT_20603] (which may include but not 
limited to considerat ion as to whether treatment or non- planned visits were required or other 
action was taken wit h the study  intervent ion, eg, dose adjustment or drug interruption).
If deteri oration in a laboratory  value/vital sign is associated with clinical signs and symptoms, 
the sign or symptom  will be reported as an AE and the associated laboratory  resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible the reporting invest igator
uses t he clinical, rather than the laboratory  term  (eg,anemia versus low hemoglobin value) . In 
the absence of clinical signs or symptoms, clinically relevant deteriorations in non -mandated 
param eters shoul d be reported as AE(s).
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE unless unequivocally 
related to the disease under study .
8.3.[ADDRESS_942872] towards improving the understanding o f 
the study  intervent ion. An AESI may be serious or non -serious. For thi s study ,AESIs include:
Anaphylactic reactions
Immune com plex disease (Ty pe 3hypersensit ivity reacti ons)
Malignancy
Helmint h infect ions
Severe infect ions which are defined as:
SAEs or
Requi ring treatm ent wi th systemic antiviral medications, intravenous antibiotics or 
medicat ions for helmint h parasit ic infect ion or
Requi ring a perm anent discont inuat ion of study  intervent ion
Injec tion si te reacti ons
Opportuni stic infect ions
Guillain -BarréSyndrome
8.3.7 Hy’s Law
Cases where a participant shows elevations in liver biochemistry  may requi re further 
evaluat ion and occurrences of AST or ALT ≥ 3 × ULN together with total bilirubin ≥ 2 × ULN 
may need to be reported as SAEs . Please refer to Appendix Dfor further instruction on cases 
Cli nical St u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D 5 1 8 0 C 0 0 0 3 1 
C O N FI D E N TI A L A N D P R O P RI E T A R Y 6 9 of 1 2 3 of  i ncreases i n li ver bi oc he mistr y  a n d e val uat i o n of H y ’s La w .
8. 3. [ADDRESS_942873] 
ti g ht ness, d y s p nea , breat hless ness a n d p hle g m, will be rec or de d as A Es o nl y w he n: 
T he si g n or s y m pt o m is seri o us acc or di n g t o defi niti o ns, see A p pe n di x E 2 .
T he parti ci pa nt disc o nt i n ues t he st u d y d ue t o t he si g n or s y m pt o m .
T he si g n or s y m pt o m is ne w t o t he partici pa nt or n ot c o nsiste nt wit h t he partici pa nt’s 
pre -e xist i n g ast h ma hist or y ( defi ne d as wit hi n 1 year of Visit 1) as j u d ge d b y t he 
i n vesti gat or. 
 s h o ul d be rec or de d as a n A E or S A E o nl y if it f ulfills a n y o f t h e a b o ve 
cri teria. 
8. 3. [ADDRESS_942874] u d y  pr oce d ure(s) . All S A Es will be rec or de d i n t he eC R F .
If a n y S A E occ urs i n t he c o urse of t he st u d y , i n vesti gat or s or ot her site pers o n nel will i nf or m 
t h e a p pr o priate Pare xel re prese ntati ves wit hi n o ne da y  ie, i m me diatel y b ut n o l ater  t h a n [ADDRESS_942875] i g at or /st u d y site staff h o w t o pr ocee d .C CI 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 70of 123For further guidance on the definit ion of a SAE, see Appendix E 2of the CSP.
The reference document for definit ion of expectedness/listedness is the I nvestigator ’s 
Brochure for the [COMPANY_008] drug. 
8.3.10 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to [COMPANY_008] except for:
If the pregnancy  is discovered before the study  participant has received any study  
intervent ion
[IP_ADDRESS] Maternal Exposure
If a participant beco mes pregnant during the course of the study , study  intervent ion shoul d be 
discontinued immedia tely.
Pregnancy itself is not regarded as an AEunless there is a suspi[INVESTIGATOR_24510] n that the invest igational 
product under study  may have interfered with the effect iveness of a contraceptive medicat ion. 
Congenital a nomalies/birth defects and spontaneous miscarriag es shoul d be reported and 
handled as SAEs . Elective aborti ons wi thout com plicat ions should not be handled as AEs . The 
outcom e of all pregnancies (spontaneous miscarriage, elective terminat ion, ectopic pregnancy , 
norm al birth or congeni tal anomaly/birth def ect) shoul d be f ollowed up and documented even 
if the participant was di scontinued from the study .
If any pregnancy  occurs in the course of the study , then the investigator or other site personnel 
informs the appropriate Parexel representatives within 1day, ie,immediately but no later  
than [ADDRESS_942876] igator to ensure that all relevant 
inform ation is provided to the [COMPANY_008] Pat ient Safet y data entry  site within 1 or  
5calendar  days for SAEs (see Section 8.3.9 and within 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.
The PREGREP module in the eCRF is used to report the pregnancy  and the paper -based 
PREGOUT moduleis used to report the outcome of the pregnancy .
[IP_ADDRESS] Paternal Exposure 
Pregnancy of the participant ’s partners i s not considered to be a n AE. However, the outcome 
of all pregnancies (spontaneous miscarriage, elect ive terminat ion, ectopic pregnancy , normal  
birth or congenital anomaly), occurring from  the date of the first dose until 16 weeks 
(5half-lives) after the last administration o f study  intervent ion, if possible, be fo llowed up and 
docum ented in the Pregnancy  Report Form . Consent fro m the partner m ust be obtained before 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 71of 123the Pregnancy  Report F orm is com pleted . 
8.3.[ADDRESS_942877] igator to ensure that all relevant 
inform ation is completed within 1(Initial Fatal/Life -Threatening or fo llow-up Fatal /Life -
Threatening) or 5(other serious init ial and fo llow-up) calendar  days ifthere is an SAE 
associ ated wi th the m edicat ion error (see Section 8.3.9 ) and within [ADDRESS_942878] (APFS) are being provided for use in this 
study . In order to fulfil regulatory  reporting obligations worldwide, the invest igator is 
responsible for the detection and documentation of events meet ing the definit ions of m edical  
device deficiency that occur during th e study  with the device const ituent of the study  drug 
combinat ion product.
The definit ion of a deficiency in the device const ituent of a com binat ion product (APFS) is an 
inadequacy  of a medical device wit h respect to its ident ity, qualit y, durabilit y, reliability, 
safet y, or perform ance. Medical  device deficiencies include malfunct ions, use errors, and 
issues wit h information supplied by [CONTACT_3455] . For simplicit y, the term  medical device 
deficiency will be used for deficiency in the device constituen t of a combinat ion product.
NOTE: Addit ional guidance, including expanded definit ions, can be found in
 Appendix Fof 
the protocol. 
The [COMPANY_008] Report Form will be used to collect the deficiency  as per the Parexel study -
specific Invest igator Manual .
[IP_ADDRESS] Time Period for Detecting Medical Device Deficiencies
Medical device incidents or malfunct ions of the medical device will be detected, 
docum ented, and reported during all periods of the study  in which the medical device is 
used.
If the invest igator learns of any medical device deficiency at any t ime after a participant 
has been discharged from the study , and such incident is considered reasonably related to 
a medical device provided for the study , the invest igator will pro mptly notify  the sponsor.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 72of 123The m ethod of docum enting medical device deficiency is provided in Appendix Fand the 
Parexel study -specific Investigator Manual .
[IP_ADDRESS] Follow -up of Medical Device Deficiencies
Follow-up applies to all participants, including those who discont inue study  intervent ion.
The invest igator is responsible for ensuring t hat follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the deficiency.
New or updated informat ion will be recorded on the originally co mpleted form wit h all 
changes signed and dated by  [CONTACT_17062].
[IP_ADDRESS] Prompt Reporting of Medical Device Deficiencies to Sponsor
Deficiencies associated with the device const ituent part of the combinat ion product 
shoul d be reported to the Sponsor.
Medical device deficiencies will be reported to the S ponsor within 24 hou rs after the 
investigator determines that the event meets the protocol definit ion of a medical device 
deficiency.
The [COMPANY_008] Report Form will be sent to the sponsor via email
Medical device deficiency wit h an associated adverse event
oAEMailbo [EMAIL_13285]
o[COMPANY_008] complaint representative(s), as per the Parexel study -specific 
Invest igator Manual
NOTE: For  AEs and SAE ’s, the eCRF m ust al so be popul ated -see Section 8.3.9 .
Medical Device Deficiency  without an associ ated adverse or serious adverse event
o[COMPANY_008] complaint representative(s), as per the Invest igator Manual
The Sponsor will be the contact [CONTACT_355658].
[IP_ADDRESS] Regulatory Reporting Requirements for Device Deficiencies
The invest igator will pro mptly report all medical device deficiencies occurring with any 
medical device provided for use i n the study  in order for the sponsor to fulfil the legal 
responsibilit y to notify appropriate regulatory  authori ties and other entit ies about certain 
safet y informat ion relating to medical devices being used in clinical studies.
The invest igator, or respon sible person according to local requirements (eg, the head o f 
the medical inst itution), will co mply with the applicable local regulatory  requi rements 
relating to the reporting o f medical device deficiencies to the IRB/IEC.
For further guidance on the defin itions, see Appendix Fof the CSP.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 73of 1238.4 Overdose
For thi s study , any  dose of study  intervent iongreater than 700mgSC within a 2-week peri od
will be con sidered an overdose.
There i s currently no specific treatment in the event of overdose of study  intervent ion and 
possible symptoms of an overdose are not established.
An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
An overdose without associated symptoms is only  reported on the Overdose eCRF 
module.
If an overdose on an [COMPANY_008] study  interventi onoccurs in the course of the study , the 
investigator or other site personnel inform appropriate Parexel representatives immediately , 
but no later  than [ADDRESS_942879] igator to ensure that all relevant 
inform ation is provided to the [COMPANY_008] Pat ient Safet y data entry  site 
within one or 
5calendar  days for overdoses associated with an SAE (see Section 8.3.9 ) and within 30days
for all other overdoses.
8.[ADDRESS_942880] confident iality. For further details on Handling o fHum an Bi ological 
SamplesseeAppendix G.
Samples will  be stored for a m aximum  of 15 y ears from the date of the i ssue of the CSR in 
line with consent and local requirements , after which they  will be destroyed /repatri ated. 
Pharmacokinet icsamples will be disposed of after the Bioanaly tical Report finalizat ion or 
6 months after issuance of the draft Bioanalyt ical Report (whichever is earlier), unless 
consented for future analyses. 
Pharmacokinet ic samples may be disposed of or anonymi zed by  [CONTACT_76435]. Addit ional 
analyses may be conducted on the anonymi zed, pool ed PK samples to further 
evaluate and validate the analyt ical method. Any  resul ts from such analyses may be 
reported separately  from the CSR.
Remaining ADA sample aliquots will be retaine d at [COMPANY_008] or its designee for a 
maximum o f 15 years fo llowing issue of the CSR . Addit ional use includes but is not 
limited to further characterizat ion of any ADAs, confirmat ion and/or requalificat ion of 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 74of 123the assay as well as addit ional assay  devel opment work. The results from future analysis 
will not be reported in the CSR .
8.5.1 Pharmacokinetics
Serum samples will be co llected for measurement of serum concentrati ons of tezepel umab as 
specified in the SoA (Secti on1.3).Samples will be collected, labelled, stored, and shipped as 
detailed in the Laboratory  Manual.
[IP_ADDRESS] Determination of Drug Concentration
Samples for determination of tezepelumab concentrati on in serum will be assayed by 
[CONTACT_122637] o f Ast raZeneca, using an appropriate ly 
validated bioanalyt ical method . 
Full details of the analyt ical method used will be described in 
a separate Bioanalyt ical Report.
Drug concentration informat ion that may/woul dunblind the study will not be reported to 
investigat ive sites or blinded personnel until the study has been unblinded (see Sect ion6.3.4
for maintaining the study  blind) .
Incurred sample reproducibilit y analysis, if any , will  be perform ed al ongside the bioanalysis 
of the test samples . The results from the evaluat ion, if perform ed,will be reported in a 
separate Bioanaly tical Report.
8.5.[ADDRESS_942881] si tes operated by  [CONTACT_695018] , using an 
appropriately  validated bi oanaly tical method. Full  details of the m ethods used will be 
described in a separate Bioanaly tical Report.
ADA  samples may  also be further tested for characterizat ion of the ADA  response.
Samples will  be collected, l abelled, stored, and shipped as detailed in the Laboratory  Manual.
8.5.3 Pharmacodynamics
Samples for the analysis of peripheral blood eosinophils will be performed in a central 
laboratory  as part of the routi ne hematol ogy assessment.
8.6 Human  Biological Sample Biomarkers
Biomarker research is not applicable in this study .
8.7 Optional Genomics Initiative Sample
Optional Genomics Ini tiative research is not applicable in this study .
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 75of 1238.8 Health Economic sOR Medical Resource Utilization and Health 
Economic s
Health Economics /Medical  Resource Utilization and Healt h Economics parameters are not 
evaluated in this study .
[ADDRESS_942882] ification is based on the desired precisio n of the estimate of the ratio of 
the GMT s (as GMT vaccine / GMT tezepelumab+vaccine ). With 50 participants per arm , the 90% CI for 
the GMT ratio would be 0.67 to 1.48, assuming an observed rat io of 1, and that the log (post -
dose HAI antibody  titer or post -dose MN antibody titer) is normally distributed with a 
standard deviat ion (SD) of 1.2 on the natural log scale ( Langley et al  2013 )
.
9.3 Populations for Analyses
Antibody  endpoints to the influenza vaccine —strain -specific HAI and MN ant ibody  GMFRs 
and GMT s—will be analyzed using the vaccine immunogenicit y analysis set. All remaining 
efficacy analyse s will be performed using an ITT approach based on the full analysis set. 
Demographic and baseline characterist ics will be presented for both the full analysis set and 
the vaccine immunogenicit y analysis set . Safet y object ives and ADA  will be analyzed base d 
on the Safet y analysis set. The populat ionanalysis set s are defined in
 Table10.
Table10
Populations for  Analysis
Population /Analysis set Description
All participant analysis set All participants screened for the study will be included in the 'All participant 
analy sis set' and will be used for reporting of disposition and screening 
failures.
Full (ITT) analy sis set All participants randomized and receiving any study intervention will be 
included in the 'Full analysis set', irrespective of their CSP adherence and 
continued participation in the study. 
Participants will be analyzed according to their randomized treatment, 
irrespective of whether or not they have prematurely discontinued, 
according to the ITT principle. 
Participants who withdraw informed consent /assent to participate in the 
study will be included up to the date of their study termination.
Vaccine immunogenicity 
analy sis setAll randomized participants who received the influ enza vaccine plus at least 
[ADDRESS_942883] -dose HAI or MN 
antibody measurements ,had no influenza infection prior to Visit 7
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 76of 123Table10 Populations for  Analysis
Population /Analysis set Description
(Week 16), and had no protocol deviation ,judged to have the potential to 
interfere with the gen eration or interpretation of an antibody response ,will 
be included in the 'vaccine immunogenicity analysis set '.
The analy ses conducted using this analysis set will be based on the actual 
treatment received. Protocol deviations will be reviewed by [CONTACT_695019] (Visit 7 [Week 16 ]).
Safety analysis set All participants who received at least 1 dose of study intervention will be 
included in the safety analysis set. 
Participants will be classified according to the treatment they actually 
received. A participant who has on one or several occasions received active 
treatment will be classified as active. All safety and ADA summaries will be 
based on this analysis set.
PK analysis set All participants who receiv ed tezepelumab and from whom PK blood 
samples were obtained and assumed not to be affected by [CONTACT_695020] 'PK analysis set'.
Those participants who had at least [ADDRESS_942884] dose will be included in the PK analysis dataset. All PK 
summaries will be based on this analysis set.
Abbreviations: ADA=anti -drug antibody; CSP=clinical study protocol; HAI=hemagglutination -inhibition; 
ITT=intent to treat; MN=microneutralization; PK=pharmac okinetic.
Primary Analyses Estimands
Table11provi des the param eters to follow for each set of primary  analyses .Please note : If 
influenza vaccine administration is delayed, so me participants ’ assessments at W eek 12 and 
Week 16 may  be performed at l ater timepo ints.
Table11 Primary Analysis Estimands
Primary Endpoint s Parameters
 Post-dose strain -specific 
hemagglutination-inhibition (HAI) 
antibody geometric mean fold rises 
(GMFRs) from Week 12 (pre-dose 
antibody measure )to Week16(EOT)
 Post-dose strain -specific 
microneutralization (MN) antibody 
GMFRs from Week 12 (pre-dose 
antibody measure) to Week 16(EOT)
 Post-dose strain -specific serum HAI 
antibody geometric mean titers (GMTs) 
obtained at Week 16 (EOT)Population: Vaccine immunogenicity analysis set, defined as 
all randomized participants who received the influenza vaccine 
plus at least [ADDRESS_942885]-dose HAI or MN antibody measurements, had no 
influenza infection prior to Visit 7 (Week 16),and had no 
protocol deviation judged to have the potential to interfere 
with the generation or interpretation of an antibody response.
Intercurrent Events :
Treatment discontinuation: All data up to timepoint of post -
dose antibody measurements will be included for participants 
in the vaccine immunogenicity analysis set.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 77of 123Table11 Primary Analysis Estimands
Primary Endpoint s Parameters
 Post-dose strain -specific serum MN 
antibody GMTs obtained at Week 16
(EOT)Initiation of other medication: All data up to timepoint of post -
dose antibody measurements will be included for participants 
in the vaccine immunogenicity analysis set.
Summary Measure: Least square g eometric mean ratio 
estimates for placebo vs. tezepelumab and corresponding 90% 
CIs
.
 Post-dose strai n-specific antibody 
response at Week 16 (EOT) with 
antibody response defined as a ≥ 4-fold 
rise in HAI antibody titer from 
Week 12 (pr e-dose antibody measure) 
to Week 16(EOT)
 Post-dose strain -specific antibody 
response at Week 16 (EOT) with 
antibody respo nse defined as a ≥ 4-fold 
rise in MN antibody titer from 
Week 12 (pr e-dose antibody measure) 
to Week 16(EOT)
 Post-dose strain -specific HAI antibody 
titer ≥40 at Week 16(EOT)
 Post-dose strain -specific MN antibody 
titer ≥40 at Week 16(EOT)Population: Vaccine immunogenicity analysis set, defined as 
all randomized participants who received the influenza vaccine 
plus at least [ADDRESS_942886]-dose HAI or MN antibody measurements, had no 
influenza infection prior to Visi t 7 (Week 16),and had no 
protocol deviation judged to have the potential to interfere 
with the generation or interpretation of an antibody response.
Intercurrent Events:
Treatment discontinuation: All data up to timepoint of post -
dose antibody measureme nts will be included for participants 
in the vaccine immunogenicity analysis set.
Initiation of other medication: All data up to timepoint of post -
dose antibody measurements will be included for participants 
in the vaccine immunogenicity analysis set.
Summary Measure: Number and % of participants in each 
treatment group meeting the specified threshold and 
corresponding 90% CI.
Clinical Study P rotocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 78of 1239.[ADDRESS_942887] participant (enrolled in the 2021/2022 flu season) completes Visit7
(Week 16 ), and the final database lock and analysis will be conducted once all participants
have co mpleted the follow-up period, V isit 8 (Week28).All an alyses of the primary  
objectives and selected safet y objectives will be perform ed based on the primary database lock 
data.
The SAP will be final ized and signed- off prior to the primary  database l ock.Itwill include a 
more technical and detailed descript ion of the statistical analyses described in this sect ion. 
This sect ion is a summary of the planned statist ical analyses of the most important endpoints 
including primary  and secondary  endpoints.
9.4.[ADDRESS_942888] availab le versio n of SAS®(SAS Institute Inc., Cary , North 
Carolina, US), version 9.[ADDRESS_942889] ives will be evaluated for the double -blind treatment period, defined as the 
period after administration of randomized study  intervent ion at W eek 0 and the conclusio n of 
Week16 (EOT ) Visit, inclusive.
The tezepelu mab versus placebo humoral immune responses fo llowing seasonal influenza 
virus vaccinat ion will be assessed by [CONTACT_695021].
[IP_ADDRESS] Primary Endpoint (s)
Post-dose strain -specific HAI ant ibody  GMFRs from Week 12 (pre-dose antibody 
measure) to Week 16(EOT).
Post-dose strain -specific MN ant ibody  GMFRs from Week 12 (pre-dose antibody 
measure) to Week 16(EOT) .
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 79of 123Post-dose strain -specific serum HAI ant ibody  GMTs obtained at Week 16(EOT) .
Post-dose strain -specific serum MN ant ibody  GMTs obtained at Week 16(EOT) .
Post-dose strain -specific ant ibody  response at Week 16 (EOT) with antibody response 
defined as a ≥ 4-fold rise in HAI ant ibody  titer from Week 12 (pre-dose antibody 
measure) to Week 16(EOT) .
Post-dose strain -specific ant ibody  response at Week 16 (EOT) with antibody response 
defined as a ≥ 4-fold rise in MN ant ibody  titer from Week 12 (pre-dose antibody 
measure) to Week 16(EOT) .
Post-dose strain -specific HAI ant ibody  titer ≥ 40 at Week 16(EOT) .
Post-dose strain -specific MN ant ibody  titer ≥ 40 at Week 16(EOT) .
As the HAI assay may not work for one of the influenza virus strains (Influenza A  H3N2 ), the 
corresponding MN result for that strain will only be used . Hence, both the HAI and MN 
resul ts will  serve as the dual  primary  endpoints for this stu dysuch that results fro m both 
assay scan be used for the analyse s of the primary obj ective. This dual endpo int approach 
allows for a broader characterizat ion of the immune response and flexibilit y in case the results 
for either assay are missing.
Analysis Methods for Efficacy Variables
The analys es of the primary endpo ints will use the vaccine immunogenicit y analysis set . If 
inform ed consent /assent to the study  was wi thdrawn, all data up until the date of withdrawn 
inform ed consent /assent will be included. The full analysis set will be used for the other non -
primary  efficacy  analyses .
Analysis methods for  antibody endpoints
Geom etric mean fo ld rises for the HAI and MN antibody measurements are defined as:
GMFR = ant ilogz(mean [ logex])
Where x is the post -dose (EOT) HAI or MN antibody titer fo ld rise from W eek12 (pre-dose 
antibody  measure) and e is the natural logarithm.
Geom etric mean ti ters for the HAI and MN ant ibody  measurements are defined as:
GMT = antilog z(mean [ logey])
Where y is the HAI or MN antibody  titer and e is the natural logarithm.
The analysis of the anti -influenza ant ibody  response endpo ints–strain -specific GMFRs and 
GMT s
–will be performed on the vaccine immunogenicit y analysis set. Geometric m ean fo ld 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 80of 123rises and GMT s will be summarized by [CONTACT_694991] , and the least square 
geom etric mean ratio of GMFRs and GMT s between treatment groups (influenza vaccine 
divided by [CONTACT_694992]) will be calculated via an ANCOV A model on 
the log-transformed variable, adjusting for treatment group and age stratum (adolescents aged 
12to17 or y oung adul ts aged 18 to 21). The least square geometric mean ratio will be 
provi ded wi th associ ated 90% CI.
The ant ibody  response to the quadrivalent influenza vaccine strain is defined as a ≥ 4-fold rise 
in HAI or a ≥ 4-fold rise in MN from W eek12 (pre-dose antibody  measure) to Week16
(EOT) . The proportion of participants who experience a post -dose antibody response at 
Week16 (EOT) for HAI and the proportion of participants who experience a post- dose 
antibody  response at W eek 16 (EOT) for MN and corresponding 90% Clopper -Pearson exact 
CIswill be summarized by  [CONTACT_694993] . 
The proporti on of  parti cipants who achieve a post- dose HAI antibody  titer ≥ [ADDRESS_942890] -dose MN ant ibody t iter ≥ 40 at Week16 (EOT) 
and corresponding 90% Clopper -Pearson exact CI swill be summarized by [CONTACT_695022] .
No interim blinded review is planned.
[IP_ADDRESS] Secondar y Endpoint (s)
Calculation or Derivation of PK Variables
Due to the limited sampling schedule, the PK assessment will be primarily based on the 
observed serum trough concentrations.
Analysis Methods for PK Variables
The PK analyses will be performed by a third-party  vendor under the guidance of [COMPANY_008] 
Research and Development.
Tezepelumab serum concentrations will be summarized using descriptive statist ics at each 
visit.
Calculation or Derivation of Tezepelumab Immunogenicity Variables
ADA  assessments will be conducted utilizing a tiered approach (screen, confirm, t iter).
Analysis Method for Tezepelumab Immunogenicity Variables
ADA  to tezepel umab will be summarized using descript ive statist ics at each visit by  [CONTACT_103466].
Cli nical St u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D 5 1 8 0 C 0 0 0 3 1 
C O N FI D E N TI A L A N D P R O P RI E T A R Y 8 1 of 1 2 3 9. 4. 3 S afet y 
9. 4. 3. 1 Safet y En d p oi nt(s) 
C alc ul ati o n or Deri v ati o n of Safet y Vari a ble(s) 
T he f o ll o wi n g safet y  data will  b e c ollecte d: vital si g ns, p h ysical e xa mi nat i o n, he mat ol o g y , 
ser u m  c he mistr y , uri nal ysis, a n d re p orte d A Es. 
C ha n ge fr o m baseli ne ( W ee k 0) t o eac h p ost -treat me nt visit w here sc he d ule d assess me nts 
were m a de will be calc ulate d f or rele va nt meas ure me nts. A d verse e ve nts will be s u m marize d 
b y mea ns of descri pt i ve statist ic s a n d q ualitat i ve s u m maries. 
A n al ysis Met h o ds f or S afet y V ari a bles 
A d verse e ve nts will be c o de d usi n g t he Me d D R A versi o n i n f o rce at t h e pri mar y data base 
l o c k. T he defi nit i o n of o n -treat m e nt a n d o n -st u d y  f or A E a nal yses will be gi ve n i n t he S A P .
T he n u m ber a n d perce nta ge of parti ci pa nts wi t h  o n -treat me nt a n d o n -st u d y  A Es will  b e
ta b ul ate d se paratel y b y  preferre d ter m  a n d s yste m or ga n class. A n e ve nt t hat occ urre d o ne or C CI 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 82of 123more times during a period will contribute 1 observat ion to the numerator of the proportion. 
Thedeno minato r of the proportion will co mprise all participants in the safet y popul ation. On -
treatm entAEs will also be summarized by  [CONTACT_2236]/severi ty and separately , by
[CONTACT_20084] y/relatedness (as determined by [CONTACT_3170]). Should a participant report the same
preferred term/system organ class within mult iple intensit y/severit y or causalit y/relatedness
categori es, the participant ’s worst occurrence (most severe/most related) will be tabulated. 
SeriousAEs, AEs leading to discont inuat ion from study  interventi on, and commo nly 
occurring AEs will be summarized
in a generally similar manner . Adverse events, SAEs, AEs 
leading to death, and AEs leading to discont inuat ion of study  intervent ionwill be summarized 
for each treatm ent group as applicable.
An overall summary o f on-treatm ent AEs will be presented by [CONTACT_1570].
AEs of special  interest (AESIs), as defined in Section 8.3.6 will also be summarized
descript ively by [CONTACT_1570].
Laboratory  data will be summarized by [CONTACT_338428] (baseline 
tomost extrem e post -baseline value) and by [CONTACT_694994] (means, medi ans, quartiles, ranges). The incidence of clinically 
notabl elaboratory  abnorm alities will  be summarized.
Vital signs data will be summarized by [CONTACT_695023]. The incidence of clinically notable vital signs abnorm alities will  be
summarized. 
9.5 Interim Analyses 
There i s neither an unblinded data review nor interim analysis planned for this study prior to 
primary  database l ock.
9.6 Data Monitoring Committee
Not Applicable.
10 SUPPORTING DOCUMENTA TION AND OP ERATIONAL 
CONSIDERATIONS
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 83of 123Appendix AAnaphylaxis: Signs and Symptoms, Management
A [ADDRESS_942891] inguishable: immuno logic (IgE -mediated and non -IgE-mediated [eg, IgG and immune 
complex mediated]) and nonimmunologic ( Johansson et al 2004 ). The clinical criteria for 
defining anaphylaxis for this study are listed in Appendix A 2. A guide to the si gns and 
symptoms and management of acute anaphylaxis is provided in Appendix A
3. Appropri ate 
drugs, such as epi[INVESTIGATOR_238], ant ihistamines, corticosteroids, etc, and medical equipment to treat 
anaphylactic reactions must be immediately available at study sites, and study  personnel 
shoul d be trained to recognize and treat anaphylaxis according to local guidelines.
If an anaphylact ic react ion occurs, a blood sample will be drawn fro m the participant as soon 
as possible after the event, at 60 minutes ± 30 minutes after the event, and at discharge for 
analysis of serum try
ptase.
A 2 Clinical Criteria for Defining Anaphylaxis and Immune Com plex 
Disease
Anaphylaxis
In adults, anaphylaxis is highly likely when any one of the fo llowing 3 cri teria is fulfilled:
1Acute onset of an illness (minutes to several hours) with invo lvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruri tus or flushing, swo llen lips -tongueuvula)
AND AT LEAST ONE OF THE FOLLOWING
(a)Respi[INVESTIGATOR_33097] (eg, dyspnea, wheeze- bronchospasm, stridor, reduced PEF, 
hypoxemia).
(b)Reduced BP or associated symptoms of end -organ dy sfunct ion (eg, hy potoni a 
[collaps e], syncope, incont inence).
2Two or more of the fo llowing that occur rapi[INVESTIGATOR_17176] a likely allergen for that 
subject (minutes to several hours):
(a)Involvement of the skin -mucosal t issue (eg, generalized hives, itch -flush, swollen 
lips-tongue-uvul a).
(b)Respi[INVESTIGATOR_33097] (eg, dyspnea, wheeze- bronchospasm, stridor, reduced PEF, 
hypoxemia).
(c)Reduced BP or associated symptoms (eg, hy potonia [coll apse], syncope, 
incont inence).
(d)Persi stent gastrointestinal symptoms (eg, crampy  abdominal  pain, vomi ting).
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 84of [ADDRESS_942892] (minutes to several hours): 
Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease fro m that 
subject’s baseline.
Immune Complex Disease
Immune com plex disease or Hy persensi tivity Type 3 is evoked by [CONTACT_695024]-
antibody  or anti gen-antibody -complement com plexes on cell surfaces, with subsequent 
involvement of breakdown products of complement, platelets, and polymorphonuclear 
leukocy tes, and development of vasculit is;serum  sickness and nephri tis is comm on.
A 3 Signs and Symptoms and Management of Acute Anaphylaxis
Anaphylaxis is an acute and potentially lethal mult i-system  allergic reaction in which so me or 
all of the following si gns and symptoms occur:
Diffuse ery thema
Pruritus
Urticaria and/or angioedema
Bronchospasm
Laryngeal edema
Hypotensi on
Cardi ac arrhy thmias
Feeling of impending doom
Unconsciousness
Shock
Other earlier or concomitant signs and symptoms can include:
Itchy  nose, ey es, pharynx, genitalia, palms, and soles
Rhinorrhea
Change in voice
Metallic taste
Nausea, vo miting, di arrhea, abdominal cramps and bloating
Light headedness
Headache
Uterine cramps
Generalized warmt h
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 85of 123A [ADDRESS_942893] , breathing, ci rculation, and adequacy  of mentati on
2Administer epi[INVESTIGATOR_96702]  5-15 minutes, in appropriate doses, as 
necessary , depending on the presenting signs and symptoms of anaphylaxis, to control 
signs and symptoms and prevent progression to more severe symptoms such as 
respi [INVESTIGATOR_36645], hypotension, shock and unconsciousness.
Possibly appr opriate, subsequent measur es depending on r esponse to epi[INVESTIGATOR_238]
(a)Place participant in recumbent posit ion and elevate lower extremit ies.
(b)Establish and maintain airway.
(c)Administer oxy gen.
(d)Establish venous access.
(e)Norm al saline IV for fluid replacement.
Specific measures to consider  after  epi[INVESTIGATOR_96703], wher e appr opriate
(a)Consider epi[INVESTIGATOR_96704] n.
(b)Consider H 1and H 2antihistamines.
(c)Consider nebulized β2 agonist [eg, albuterol (salbutamo l)] for bronchospasm 
resistant to epi[INVESTIGATOR_238].
(d)Consider systemic corticosteroids.
(e)Consider vasopressor (eg, dopamine).
(f)Consider glucagon for subject taking β -blocker.
(g)Consider atropi[INVESTIGATOR_694979].
(h)Consider transportation to an emergency  depart ment or an intensive care facilit y.
(i)For cardi opulm onary arrest during anaphylaxis, high -dose epi[INVESTIGATOR_244871], if necessary .
Adapted from: Kemp SF , Lockey  RF, Simons FE; W orld Allergy Organizat ion ad hoc 
Committee on Epi[INVESTIGATOR_96707]. Epi[INVESTIGATOR_238]: the drug of cho ice for anaphylaxis. A  
statement of the W orld Allergy Organizat ion. Allergy . 2008;63(8):1061-70.
A 5 References
Johansson et al 2004
Johansson SG, Bieber T , Dahl  R, Fri edmann PS, Lanier BQ, Lockey  RF, et al .A revised 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 86of 123nomenclature for allergy for global use: report of the no menclature review co mmittee of world 
allergy organization. J Allergy Clin Immuno l. 2004;113:832 -6.
Clinical Study Proto col– 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 87of 123Appendix BChanges Related to Mitigatio n of Study Disruptions Due to 
Cases of Civil Crisis, Natural Disaster, or Public Health 
Crisis
Note: Changes below should be implemented only during study disruptions due to any of or a 
combinat ion of civil crisis, natural disaster, or public healt h crisis(eg, during quarant ines and 
resul ting site closures, regional travel restrictions and considerat ions if site personnel or study  
participants beco me infected with SARS -CoV-2or similar pandemic infection) during which 
participants may not wi sh to or m ay be unable to visit the study  site for study visits. These 
changes should only be implemented if allowable by [CONTACT_271133]/regi onal guidelines and following 
notification fro m the sponsor and instructions on how to perform these procedures will be 
provi ded at the tim e of implementati on.
Please note that during civil crisis, natural disaster, or public healt h crisis, so me study  
assessments and procedures may  not be conducted due to internat ional or local po licies or 
guidelines, hospi[INVESTIGATOR_122572] ’s safet y. If in doubt, pl ease contact [CONTACT_695025].
B 1 Reconsent of Study Participants During Study Interruptions
During study  interrupti ons, i t may not be possible for the participants to com plete study  visits 
and assessments on -site and al ternat ive means for carrying out the visit s and assessments may  
be necessary , eg, rem ote visits. Reconsent should be obtained for the al ternative m eans of 
carrying out visits and assessments and shoul d be obtained prior to performing the procedures 
described in Sections B 2to B 5. Local and regi onal regul ations and/or guidelines regarding 
reconsent of study  participants shoul d be checked and fo llowed. Reconsent m ay be verbal if 
allowed by  [CONTACT_96728] (note, i n the case of verbal reconsent the ICF should 
be signed at the participant ’snext contact [CONTACT_72953]). V isiting the study  sites for the 
sole purpose of obtaining reconsent should be avo ided. 
B [ADDRESS_942894] be undertaken to confirm eligibilit y using the same 
rando mizat ion number as for the participant.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 88of 123B [ADDRESS_942895] On -site Visit (where applicable)
A qualified HCP from the study site or TPV service will visit the participants ho me / or other 
remote locati on as per l ocal standard of procedures, as applicable , only during safet y 
follow-up (after V isit 7). Supplies will be provided for a safe and efficient visit. The qualified 
HCP will be expected to collect informat ion per the CSP .
B
[ADDRESS_942896] On -site Visit (where applicable)
In thi s appendix, the term telemedicine visit refers to remote contact [CONTACT_695026]-up (after V isit 7).
During a civil crisis, natural disaster, or public health crisis, on -site visi ts may  be replaced by  
a telemedicine visit if allowed by  [CONTACT_5737]/regional guidelines. Having a telemedicine contact 
[CONTACT_592756] , conco mitant m edicat ion to be reported and 
docum ented.
B
5 Data Capture During Telemedicine or Home / Remote Visits
Data collected during telemedicine or home / remote visits will be captured by [CONTACT_122654], or by [CONTACT_695027].
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 89of 123Appendix CRegulatory, Ethical, and Study Oversight Considerations
C 1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the CSP and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical 
Sciences (CIOMS) International Ethical Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The CSP, CSP amendments, ICF, I nvest igator’s Brochure , and other relevant documents 
(eg,advertisements) must be submitted to an IRB/IEC by [CONTACT_317791]/IEC before the study  is initiated.
Any amendments to the CSP will require IRB /IEC and applicable Regulatory  Authori ty
approval  before implementati on of  changes made to the study  design, except for changes 
necessary  to eliminate an immediate hazard to study  parti cipants.
[COMPANY_008] will be responsible for obtaining the required aut horizations to conduct the 
study  from the concerned Regulatory  Authori ty. This responsibilit y may be delegated to a 
CRO but the accountabilit y remains wi th [COMPANY_008].
The invest igator will be responsible for providing oversight of the conduct of the stud y at 
the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, 
European Regulati on 536/2014 for clinical studies (if applicable), European Medical 
Device Regulation 2017/745 for clinical device research (if applicable), and all other 
applicable local regulat ions
Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_32847] a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of
a study  intervent ion under clinical invest igation are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply with US-specific regulatory  requi rements rel ating 
to safet y reporti ng to the regul atory  authori ty, IRB/IEC, and investigators.
For all studies except those utilizing medical devices, invest igator safet y reports must be 
prepared for S[LOCATION_003]R according to local regulatory  requi rements and sponsor policy an d 
forwarded to invest igators as necessary.
European Medical Device Regulat ion 2017/745 for clinical device research (if 
applicable), and all other applicable local regulat ions
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 90of 123An invest igator who receives an invest igator safety report describing a SAE or o ther 
specific safet y informat ion (eg,summary or list ing of SAEs) fro m the sponsor will review 
and then file it along with the [Invest igator’s Brochure or state other documents] and will 
notify the IRB/IEC, if appropriate according to local requirements.
C [ADDRESS_942897] igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appr opriate regul atory  authori ties. Investi gators 
are responsible for providing information on financial interests during the course of the study 
and for 1 y ear after com pletion of  the study .
C 3 Informed Consent Process
The invest igator or his/her representative will explain the nature of the study  to the 
participant or his/her parent/ legally author ized representative and answer all quest ions 
regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntaryand they are f ree to 
refuse to par ticipate and m ay wi thdraw thei r informed consent /assent at any  time and for 
any reason during the study . Parti cipants or thei r parent/ legally author ized representative 
will be required to sign a statement of informed consent /assent that meets the 
requi reme nts of 21CFR 50, local regulati ons, ICH gui delines, Heal th Insurance 
Portabilit y and Accountabilit y Act (HIPAA) requirements, where applicable, and the 
IRB/IEC or study  center.
The m edical  record m ust include a statem ent that wri tten inform ed consent /asse ntwas 
obtained before the participant was enro lled in the study and the date the written informed 
consent /assent was ob tained. The author ized person obtaining the informed 
consent /assent must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  
author ized representati ve.
Parti cipants who are re -screened are required to sign a new ICF.
C 4 Data Protection
Parti cipants will be assigned a unique ident ifier by [CONTACT_456]. Any part icipant records or 
datasets that are transferred to the sponsor will contain the ident ifier only; part icipant 
names or any  information which would make the participant ident ifiable will not be 
transferred.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 91of 123The parti cipant must be inform ed that hi s/her personal  study -related data will  be used by  
[CONTACT_456] i n accordance with local data protection law. The level of disclo sure and use 
of their data must also b e explained to the parti cipant in the informed consent /assent.
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by 
[CONTACT_17080] y Assurance auditors or other author ized personnel appo inted by  [CONTACT_103], by  [CONTACT_6667]/IEC members, and by [CONTACT_32857].
C 5 Committees Structure
The safet y of all [COMPANY_008] clinical studies is clo sely monitored on an ongoing basis by 
[CONTACT_695028] h Pati ent Safet y. Issues ident ified will be addressed; 
for instance, this could invo lve amendments to the CSP and letters to invest igators.
C 6 Dissemination of Clinical Study Data
A descri ption of this clinical study will be available on
http://astrazenecagrouptrials.pharmacm.com and http://www .clinica ltrials.gov as will the 
summary of the main study  resul ts when they  are available. The clinical study and/or 
summary of main study  resul ts may also be available on other websites according to the 
regul ations of the countries in which the main study is cond ucted.
C 7 Data Quality Assurance
All participant data relat ing to the study  will be recorded on eCRF unless transmitted to 
the sponsor or designee electronically ( eg,laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  [CONTACT_122642].
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF.
The invest igator m ust permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect a ccess to source data documents.
Moni toring details describing strategy  (eg,risk-based init iatives in operations and qualit y 
such as Ri sk Management and Mit igation Strategies and Analyt ical Risk-Based 
Moni toring), m ethods, responsibilit ies and requirements, including handling of 
nonco mpliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in the Mon itoring Plan .
The sponsor or designee is responsible for the data management of this study  includin g 
qualit y checking of the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals ( eg,
Contract Research Organizations).
Study  monitors will perform  ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_178702], com plete, and verifiable fro m 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 92of 123source documents; that the safet y and ri ghts of  participants are being protecte d; and that 
the study  is being conducted in accordance with the currently approved CSP and any 
other study  agreem ents, ICH GCP, and all applicable regu latory requi rements.
Records and documents, including signed ICFs, pertaining to the conduct of this stud y 
must be retained by [CONTACT_41176] 15years after study  com pletion unless local 
regul ations or inst itutional policies requi re a l onger retenti on peri od. No records m ay be 
destroy ed during the retention period without the written approval of the spo nsor. No 
records m ay be transferred to another location or party  without wri tten notificat ion to the 
sponsor .
C 8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Sour ce documents are filed at the invest igator’s site.
Data entered in the eCRF that are transcribed from source documents must be consistent 
with the source documents or the discrepancies must be explained. The investigator may  
need to request previous medica l records or transfer records, depending on the study . 
Also, current medical records must be available.
Definit ion of what constitutes source data can be found in the Moni toring Plan.
C [ADDRESS_942898] igator may init iate study site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by [CONTACT_11004]:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP guidelines
Inadequate recruit ment of participants by  [CONTACT_476681] – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 93of 123Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investigator s, the IECs/IRBs, the regulatory  authorit ies, and any contract research 
organizat ion(s) used in the study  of the reason for terminat ion or suspensio n, as specified by 
[CONTACT_122644]. The invest igator shall pro mptly inform the participant 
and should assure appropriate participant therapy  and/or follow-up .
Parti cipants from  terminated si tes may have the opportunit y to be transferred to another site to 
continue the study .
C
10 Publication Policy
The results of this study  may be published or presented at scient ific meet ings. If this is 
foreseen, the invest igator agrees to submit all manuscripts or abstracts to the sponsor 
before submissio n. This allows the sponsor to protect proprietary  information and to 
provi de comments.
The sponsor will co mply wit h the requirements for publication o f study  resul ts.In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publicat ion of multicenter studi es only  in thei r entirety  and not as individual site data. In 
this case, a co -ordinat ing invest igator will be designated by [CONTACT_695029].
Authorship will be determined by  [CONTACT_73008] h Internat ional 
Committee of Medical Journal Editors authorship requirements.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 94of 123Appendix DActions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hy’s Law
D 1 Introducti on
This appendix describes the process to be fo llowed in order to ident ify and appropriately 
report Potential Hy ’s Law (PHL) cases and Hy ’s Law (HL) cases. It is not intended to be a 
comprehensive gui de to the m anagement of el evated liver biochemistries. 
During the course of the study  the invest igator will remain vigilant for increases in liver 
biochemistry . The investigator is responsible for determining whether a participant meets 
potenti al PHL  criteria at any  point during the study .
All sources of l aboratory  data are appropri ate for the determinat ion of PHL  and HL  events; 
this includes samples taken at scheduled study  visits and other vi sits including central  and all 
local laboratory  evaluat ions even if co llected outside of the study  visit s; for exam ple,PHL 
criteria coul d be m et by  [CONTACT_96724] a central  laboratory  and/or elevated TBL  from 
a local laboratory . 
The invest igator will also review AE data (for example, for AEs that may indicate elevat ions 
in liver bio chemistry ) for possible PHL  event s.
The invest igator participates, together with [COMPANY_008] clinical project representatives, in 
review and assessment of cases meet ing PHL  criteria to agree whether HL  criteria are m et. 
Hy’s Law criteria are met if there is no alternat ive explanat ion for the elevati ons in liver 
biochemistry  other than DILI) caused by [CONTACT_695030]. 
The invest igator is responsible for recording data pertaining to PHL/HL  cases and for 
reporting SAEs and AEs according to the outcome of the review and assessment in l ine with 
standard safet y reporting processes.
D 2 Definitions
Potential Hy’s Law
AST or ALT ≥ 3 × ULN together  with TBL ≥ 2× ULN at any  point during the study  
following the start of study  medicat ionirrespect ive of an increase in ALP .
Hy’s Law
AST or ALT ≥
3×ULN together  with TBL ≥ 2×ULN, where no other reason, other than the 
study  interventi on, can be found to explain the combinat ion of increases, eg, elevated ALP 
indicat ing cholestasis, viral hepat itis, another drug. 
For PHL  and HL  the el evation in transa minases must precede or be coincident with (ie, on the 
same day ) the el evati on in TBL, but there is no specified timeframe within which the 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 95of 123elevations in transaminases and TBL  must occur .
D 3 Identification of Potential Hy’s Law Cases
In order to i dentify  case s of PHL  it is important to perform a comprehensive review of 
laboratory  data for any  parti cipant who m eets any of the fo llowing identificat ion criteria in 
isolation or in combinat ion:
ALT ≥ 3 × ULN
AST ≥ 3 × ULN
TBL ≥ 2 × ULN
Central Laboratories Being Used:
When a participant meets any of the PHL  identification criteria, in iso lation or in co mbinat ion, 
the central  laboratory  will immediately send an alert to the investigator (also sent to 
[COMPANY_008] representative). 
The invest igator will also remain v igilant for any  local  laboratory  reports where the PHL  
ident ificat ion criteria are met, where this is the case the invest igator will:
Notify  the [COMPANY_008] representative
Request a repeat of the test (new blood draw) by  [CONTACT_531440]
Com plete the appropri ate unscheduled laboratory  eCRF m odule(s) wi th the 
original  local laboratory  test resul t
When the identificat ion criteria are m et from central  or local laboratory  resul ts the invest igator 
will wit hout del ay:
Determine whether the pa rticipant m eets PHL cri teria (see Section D 2for 
definit ion) by  [CONTACT_42574] l aboratory  reports from  all previ ous visi ts (including both 
central  and l ocal laboratory  resul ts)
D 4 Follow -up
D4.1 Potential Hy’s Law Criteria not met
If the participant does not meet PHL  criteria the investigator will:
Perform  follow-up on subsequent laboratory  resul ts according to the guidance 
provi ded in the CSP.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 96of 123D4.2 Potential Hy’s Law Criteria met
If the participant does meet PHL  criteria the investigator will:
Notify  the [COMPANY_008] representative who will then inform the central Study  Team  
Within [ADDRESS_942899] igator will report the case as an SAE of 
Potenti al Hy’s Law; seri ous cri teria ‘Im portant m edical event’ and causalit y assessment 
‘yes/related’ according to CSP process for SAE reporting.
For parti cipants that met PHL criteria prior to starting study  intervent ion, the invest igator 
is not required to submit a PHL SAE unless there is a significant change*in the 
participant’s condit ion.
The Parexel Medical Monitor contacts the investigator, to provide guidance, discuss and 
agree an approach for the study  parti cipants’ fo llow-up (including any further laboratory  
testing) and the continuous review of data .
Subsequent to this contact [CONTACT_33157]:
Moni tor the parti cipant until liver bio chemistry  param eters and appropri ate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated. Completes fo llow-up SAE Form as required.
Invest igate the etio logy of the event and perform diagnostic investigat ions as 
discussed wi th the Parexel Medical Monitor . This includes deciding which the tests 
available in the Hy’s Law lab ki t shoul d be used.
Com plete the 3 Liver eCRF Modules as informat ion beco mes available .
*A ‘significant ’ change in the participant ’s condi tion refers to a clinically  relevant change 
in any of the individual liver biochemistry  parameters (AL T, AST or total  bilirubin) in 
isolation or in combinat ion, or a clinically  relevant change in associated symptoms. The 
determinat ion of whether there has been a significant change will be at the discret ion of the 
investigator, this may be in consultat ion with theParexel Medical Monitor if there is any 
uncertaint y.
D 5 Review and Assessment of Potential Hy’s Law Cases
The instructions in this section shoul d be fo llowed for all cases where PHL  criteria are met.
As soon as possible after the biochemistry  abnormalit y wasinitially detected, the Parexel 
Medical Monitor contacts the invest igator in order to review available data and agree on 
whether there is an alternat ive explanat ion for meeting PHL  criteria other than DILI caused by 
[CONTACT_592730], to ensure timely analysis and reporting to health authorit ies wit hin [ADDRESS_942900] matter ex perts as appropriate. 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 97of 123According to the outcome of the review and assessment, the invest igator will fo llow the 
instructi ons bel ow.
Wher e ther e is an agr eed alternative explanation for the ALT or AST and TBL elevat ions, a 
determinat ion of whether the altern ative explanat ion is an AE will be made and subsequent ly 
whether the AE meets the criteria for a SAE:
If the alternat ive explanat ion is notan AE, record the alternative explanation on the 
appropriate eCRF.
If the alternat ive explanat ion is an AE/SAE: update the previously submitted Potential 
Hy’s Law SAE and AE eCRFs accordingly wit h the new informat ion (reassessing event 
term; causalit y and seri ousness cri teria) fo llowing the [COMPANY_008] standard processes.
If it is agreed that there is no explanat ion that would explain the AL T or AST and TBL 
elevations other than the study  intervent ion:
Send updated SAE (report term ‘Hy’s Law’) according to [COMPANY_008] standard 
processes. 
 The ‘Medically  Important’ seri ous cri terion shoul d be used if no other serious
criteria apply .
 As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If, there i s an unavo idable delay , of over 15 cal endar day s in obtaining the informat ion 
necessary  to assess whether or not th e case meets the criteria for HL, then it is assumed that 
there is no alternat ive explanation unt il such time as an informed decisio n can be made:
Provi des any  further update to the previously submitted SAE of Potential Hy’s Law, 
(report term now ‘Hy’s Law case’) ensuring causalit y assessment i s related to study 
intervent ion and seriousness criteria is medically important, according to CSP process for 
SAE reporting.
Continue fo llow-up and review according to agreed plan. Once the necessary  
supplementary  information is obtained, repeat the review and assessment to determine 
whether HL criteria are still met. Update the previously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review and 
amending the reported term if an al ternat ive explanat ion for the liver biochemistry  
elevations is determined.
D 6 Actions Required When Potential Hy’s Law Criteria are Met 
Before and After Starting Study Intervention 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 98of 123This sect ion is applicable to participants who meet PHL criteria on study  intervent ion, having 
previously met PHL  criteria at a study  visit pri or to starti ng study  interventi on.
At the first on -study  intervent ion occurrence of PHL criteria being met the invest igator will 
determine if there has been a significan t change in the participants ’ condi tion com pared wi th 
the last visit where PHL  criteria were met 
If there is no significant change no action is required
If there is a significant change, notify the [COMPANY_008] representative, who will 
inform  the central  Study Team , then foll ow the subsequent process described in 
Secti on D 4.2
D 7 Actions Required for Repeat Epi[INVESTIGATOR_33099]’s Law
This sect ion isapplicable when a participant meets PHL  criteria on study  intervent ion and has 
already met PHL  criteria at a previous on study  intervent ion visit .
The requi rement to conduct fo llow-up, revi ew and assessment of a repeat occurrence(s) of 
PHL is based on the nature of the alternative cause identified for the previous occurrence.
The invest igator should determine the cause for the previous occurrence of PHL  criteria being 
met and answer the fo llowing quest ion:
Was the al ternat ive cause for the previous occurrence of PHL  criteria being met found 
to be the di sease under study  eg, chronic or progressing malignant disease, severe 
infect ion or liver ?
If No: follow the process described in Sect ion D4.2for reporting PHL  as an SAE
If Yes: Determine if there has been a significant change in the participant ’s condi tion#
compared wi th when PHL  criteria were previously met
If there is no significant change no action is requi red
If there is a significant change#follow the process described in Section D4.2for 
reporting PHL as an SAE
A ‘significant ’ change in the participant ’s condi tion refers to a clinically  relevant change in 
any of the individual liver biochemistry  param eters (AL T, AST or total bilirubin) in iso lation 
or in co mbination, or a clinically relevant change in associated symptoms. The dete rminat ion 
of whether there has been a significant change will be at the discretion o f the invest igator , this 
may be in consultat ion with the Study  Physician if there is any uncertaint y.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 99of 123D 8 Laboratory Tests
Hy’s Law Lab Kit for Central Laboratories 
Additional standard chemistry and coagulation 
testsGGT
LDH
Prothrombin time
INR
Viral hepatitis IgM anti -HAV 
HBsAg
IgM and IgG anti -HBc
HBV DNAa
IgG anti -HCV
HCV RNAb
IgM anti -HEV
HEV RNA
Other viral infections IgM & IgG anti -CMV
IgM & IgG anti -HSV
IgM & IgG anti -EBV
Alcoholic hepatitis Carbohydrate deficient transferrin ( CD-
transferrin)
Autoimmune hepatitis Antinuclear antibody (ANA)
Anti-Liver/Kidney Microsomal Ab (Anti -LKM)
Anti-Smooth Muscle Ab (ASMA)
Metabolic diseases alpha -1-antitrypsin
Ceruloplasmin
Iron
Ferritin
Transferrin
Transferrin saturation
aHBV DNA is only recommended when IgG anti -HBc is positive
bHCV RNA is only recommended when IgG anti -HCV is positive or inconclusive 
D 9 References
Aithal et al, 2011
Aithal et al 2011,Clinical Pharmaco logy and Therapeutics 89(6):806 -815.
FDA Guidance for Industry, July 2009
FDA  Guidance for Industry  (issued July 2009) ‘Drug -induced liver injury: Premarket ing 
clinical evaluat ion’. Available fro m; https://www .fda.gov/regulatory -informat ion/search -fda-
guidance -docum ents/drug -induced -liver-injury -premarket ing-clinical -evaluati on.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 100of 123Appendix EAdverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
E [ADDRESS_942901] a causal 
relationship with this treatment . An AE can therefore be any unfavorable and unintended sign 
(eg, an abnormal labo ratory  finding), symptom (for example nausea, chest pain), or disease 
temporally  associ ated wi th the use of a m edicinal product, whether or not considered related 
to the m edicinal product . 
The term  AE is used to include both serious and non -serious AEs an d can include a 
deteri oration of  a pre -exist ing medical occurrence . An AE may occur at any  time, including 
run-in or washout periods, even if no study intervent ionhas been administered.
E 2 Definition of Serious Adverse Events
AnSAEis an AE occurring during any  study  period (ie,run-in, treatment, washout, 
follow-up), that fulfil ls one or m ore of the fo llowing cri teria:
Results in death
Is immediately life -threatening
Requi res in -patienthospi [INVESTIGATOR_694980] 
Results in persistent or significant disabilit y or incapaci ty
Is a congenital anomaly or birth defect
Is an important medical event that may jeopardi ze the participant or may requi re medical  
treatm ent to prevent one of the outcomes listed above
Adverse Events (AEs) for malignant tumors reported during a study  shoul d generally  be 
assessed as Serious AEs. If no other seri ousness criteria apply , the ‘important medical event’ 
criterion shoul d be used. In certain situat ions, however, medical judgment on an individual 
event basis should be applied to clarify that the malignant tumor event should be assessed and 
reported as a non-serious AE. For exam ple, if the tum or is included as medical history  and 
progression occurs during the study , but the progressio n does not change treatment and/or 
prognosi s of the m alignant tum or, the AE m ay not fulfil lthe attri butes for being assessed as 
serious, al though reporti ng of the progression of the malignant tumoras an AE is valid and 
shoul d occur . Also, some types of malignant tumors, which do not spread remotely  after a 
routi ne treatm ent that does not require hospi[INVESTIGATOR_3094], may be assessed as non-serious; 
examples in adults include Stage 1 basal cell carcino ma and S tage 1A1 cervical cancer 
removed via cone biopsy .
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 101of 123Life-threatening
‘Life-threatening ’ means that the participant was at immediate risk of death fro m the AE as i t 
occurred or it is suspected that use or continued use of the product would result in the 
participant ’s death . ‘Life-threatening ’ does not m ean that had an AE occurred in a more severe 
form it might have caused death ( eg,hepatit is that resolved wit hout hepatic failure).
Hospi[INVESTIGATOR_694981] a n SA E, although the reasons for it 
may be ( eg,bronchospasm, laryngeal edema) . Hospi[INVESTIGATOR_33094]/or surgical operations 
planned before or during a study  are not consi dered AEs if the illness or disease existed before 
the participant was enro lled in the study , provi ded that i t did not deterior ate in an unexpected 
way during the study .
Important Medical Event or Medical Treatment
Medical and scientific judg ment should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life- threatening or resul t in 
death, hospi [INVESTIGATOR_059], disabilit y or incapaci ty but may jeopard izethe participant or may 
requi re medical treatm ent to prevent one or more outcomes listed in the definit ion of seri ous. 
These should usually be considered as serious.
Simply stoppi[INVESTIGATOR_33095]; medical 
judgment must be used.
Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatm ent
Hepatotoxicit y caused by [CONTACT_33153] l (acetamin ophen) overdose requiring treatment with 
N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias ( eg,neutropenia or anemia requiring blood transfusio n, etc.) or 
convulsio ns that do not result in hosp italization
Development of drug dependency or drug abuse
Intensity Rating Scale:
Mild (awareness of sign or symptom, but easily tolerated)
Moderate (di scomfort sufficient to cause interference with normal act ivities)
Severe (incapacitat ing, with inabilit yto perform  norm al activities)
It is important to dist inguish between serious and severe AEs . Severit y is a measure of 
intensity whereas seri ousness is defined by [CONTACT_73010] E 2. An AE of severe 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 102of 123intensity need not necessarily be considered serious . For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not a SAE unless it meets the cr iteria 
shown in Appendix E 2. On the other hand, a stroke that results in only a limited degree of 
disabili ty may be considered a mild stroke but wou ld be a SAE when it satisfies the criteria 
shown in Appendix
 E 2.
E
3 A Guide to Interpreting the Causality Question
When making an assessment of causali ty consi der the foll owing f actors when deciding if there 
is a ‘reasonable possibilit y’that an AE m ay have been caused by [CONTACT_33641].
Time Course . Exposure to suspect drug . Has the participant actually received the suspect 
drug? Did the AE occur in a reasona ble temporal relat ionship to the administration of the 
suspect drug?
Consistency wit h known drug profile . Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
properties?
De-challenge experience . Did the AE resolve or improve on stoppi[INVESTIGATOR_122570]?
No al ternative cause . The AE cannot be reasonably explained by [CONTACT_33154], other drugs, other host or environmental factors.
Re-challenge experi ence. Did the AE reoccur if the suspected drug was reintroduced after 
having been stopped? [COMPANY_008] would not normally reco mmend or support a re-
challen ge.
Laboratory  tests . A specific laboratory invest igation (if performed) has confirmed the 
relationship .
In difficult cases, other factors could be considered such as:
Is this a recogn ized feature of overdose of the drug?
Is there a known mechanism?
Caus ality of ‘related ’ is made if fo llowing a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the individual case . The expression 
‘reasonable possibilit y’ of acausal  relati onship is meant to convey , in general, that there are 
facts (evidence) or arguments to suggest a causal relat ionship.
The causalit y assessment i s perform ed based on the available data including enough 
inform ation to m ake an informed judgment . With no available facts or arguments to suggest a 
causal relat ionship, the event(s) will be assessed as ‘not rel ated’.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 103of 123Causal relat ionship in cases where the disease under study  has deteri orated due to l ack of 
effect shoul d be classified as no reasonable possibilit y.
E 4 Medication Error
For the pur poses of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for an [COMPANY_008] study  intervent ionthat either causes harm to the 
participant or has the potential to cause harm to the participant . 
A medicat ion error i s not l ack of  efficacy of the drug, but rather a human or process related 
failure while the drug is in control of the study  site staf f or parti cipant.
Medicat ion error includes situat ions where an error . 
Occurred
Was i dentified and intercepted b efore the participant received the drug
Did not occur, but circumstances were recogni zedthat coul d have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name [CONTACT_33165] n
Dispensing error eg, medication prepar ed incorrectly , even if i t was not actually  given to 
the participant
Drug not administered as indicated, for example, wrong route or wrong site of 
administration
Drug not taken as indicated eg, tablet disso lved in water when it should be taken as a 
solid t ablet 
Drug not stored as instructed eg, kept in the fridge when it should be at room temperature 
Wrong participant received the medicat ion (excluding IRT/RTS Merrors)
Wrong drug administered to participant (excluding IRT/RTS Merrors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IRT/RTS M -including those which lead to one of the 
above listed events that would otherwise have been a medication error 
Parti cipant acci dentally  missed drug dose(s) eg, forgot to take medication
Accidental  overdose (will be captured as an overdose)
Parti cipant f ailed to return unused medicat ion or empt y packaging
Errors related to background and rescue medicat ion, or standa rd of  care m edicat ion in 
open l abel studi es, even if an [COMPANY_008] product 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 104of 123Medication errors are not regarded as AEs but AEs may occur as a consequence of the medication 
error .
Clinical Study Protoco l – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 105of 123Appendix FMedical Device AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs and 
Medical Device Deficiencies: Definitions and Procedures for 
Recording, Evaluating and Follow -up 
This appendix supports the activit ies described in section 8.3.12
The definit ions and procedures detailed in this appendix are in accordance wit h 
International Organizat ion for Standardizat ion [ZIP_CODE] and European Medical Device 
Regulation (MDR) 2017/745 for clinical device research (if applic able).
Both the invest igator and the Sponsor will co mply with all local reporting requi rements 
for medical devices.
The detecti on and docum entati on procedures described in this protocol apply  to all  
Sponsor medical devices provided for use in the study .See Secti on 6.1.[ADDRESS_942902] of 
sponsor m edical devices.
For simplicit y, medical device will be used to cover device const ituent parts of 
combinat ion products and standalone medical device whether invest igational or approved.
F 1 Definition of Medical Device AE and ADE
Medical Device AE and ADE Definition
An AE is any  untoward m edical occurrence in a clinical study  parti cipant, users, or other 
persons, tem porally associ ated wi th the use of study  intervent ion, whether or not 
considered related to the invest igational medical device. A medical device AE can 
therefore be any  unfavorable and unintended sign (including an abnormal laboratory  
finding), symptom, or disease (new or exacerbated) temporally associated with the use of 
an invest igational medical device. This definit ion includes events related to the 
investigat ional medical device or comparator and events related to the procedures 
involved.
An adverse device effect (ADE) is defined as an AE related to the use of an 
investigat ional medical device. This definit ion includes any AE result ing from 
insufficient or inadequate instructions for use, deployment, implantation, installat ion, or 
operati on, or any  malfunct ion of the invest igational medical device as well as any event 
resul ting fro m use error or from intentional misuse of the invest igational medical device.
F 2 Definition of Medical Device SAE, SADE and [LOCATION_003]DE
A Medical Device SAE isany medical device adverse event that: 
a.Led to death .
b.Led to serious deterioration in the healt h of the participant, that either resulted in:
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 106of 123A life-threatening illness or injury. The term “life -threatening” in the definit ion of 
“serious” refers to an event in which the parti cipant was at ri sk of death at the time of the 
event. It does not refer to an event, which hypothetically might have caused death if it 
were m ore severe.
A permanent impairment of a body  structure or a body  function.
Inpat ient or prolonged hospi[INVESTIGATOR_1916]. Planned hospi [INVESTIGATOR_95658] a pre -exist ing 
condi tion, or a procedure required by [CONTACT_760], without serious deterioration in healt h, 
is not considered an SAE.
Medical or surgical intervent ion to prevent life -threatening illness or injury  or pe rmanent 
impairment to a body  structure or a body  function.
Chronic disease (MDR 2017/745).
c.Led to fetal distress, fetal death, or a congenital anomaly or birth defect .
SADE definition
A serious adverse device effect (SADE) is defined as an adverse medical device effect 
that has resulted in any o f the consequences characterist ic of an SAE (eg, needle stick 
requi ring surgical intervent ion or battery  leakage chemical burn causing scaring).
Any medical device deficiency that might have led to an SAE if appropri ate acti on had 
not been taken, intervent ion had not occurred, or circumstances had been less fortunate.
Unanticipated SADE ([LOCATION_003]DE) definition
An unant icipated serious adverse device effect ([LOCATION_003]DE) (also ident ified as UADE in 
[LOCATION_002] Regulat ions 21 C FR 813.3), is defined as a serious adverse medical device 
effect that by  [CONTACT_5942], incidence, severit y, or outcom e has not been i dentified in the 
current version of the risk analysis report (see Sectio n 2.3).
F 3 Definition of Medical Device Deficiency
Medical Device Deficiency Definition
A medical device deficiency is an inadequacy of a medical device wit h respect to its 
ident ity, qualit y, durabili ty, reliabili ty, safet y, or perform ance. Medi cal device 
deficiencies include malfunctions, use errors, and inadequacy in the informat ion supplied 
by [CONTACT_941] m anufacturer including labelling .
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 107of 123F 4 Recording and Follow -up of AE and/or SAE and Medical Device 
Deficiencies
AE, SAE, and Medical Device Deficiency Recording
When an AE/SAE/medical device deficiency occurs, it is the responsibilit y of the 
investigator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, 
and diagnostics report s) related to the event.
The invest igator will then record all relevant AE/SAE/medical device deficiency 
inform ation in the participant’s medical records, in accordance with the invest igator’s 
norm al clinical pract ice and on the appropriate form.
It is notacceptable for the invest igator to send photocopi[INVESTIGATOR_10914]’s medical 
records to Sponsor in lieu of complet ion of the AE/SAE/medical device deficiency form.
There m ay be instances when copi[INVESTIGATOR_63475] b y 
Sponsor. In this case, all part icipant identifiers, with the exception o f the participant 
number, will be redacted on the copi[INVESTIGATOR_244877] n to 
Sponsor.
The invest igator will attempt to establish a diagnosis of the event base d on si gns, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
For m edical device deficiencies, it is very  important that the invest igator describes any 
correc tive or remedial act ions taken to prevent recurrence of the deficiency.
A remedial act ion is any action other than routine maintenance or servicing o f a medical 
device where such act ion is necessary to prevent recurrence of a medical device 
deficiency. Thi s includes any  amendment to the medical device design to prevent 
recurrence.
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE/SAE/m edical  device 
deficiency reported during the study  and assign it to one of the foll owing categori es: 
Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal disco mfort 
and not interfering with everyday act ivities.
Moderate: An event that causes sufficient discomfort and interferes wit h norm al 
everyday act ivities.
Severe: An event that prevents normal every day activi ties. An AE that is assessed as 
severe should not be confused with an SAE. “Severe” is a category  used for rating the 
intensity of an event; both AEs and SAEs can be assessed as severe.
An event is defined as ‘seri ous’ when i t meets at l east 1 of the predefined outcomes as 
described in the definit ion of an SAE, notwhen it is rated as severe.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 108of 123Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE/medical device deficiency.
A “reasonable possibilit y” of a relationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relat ionship, cannot be ruled out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be conside red and invest igated.
The invest igator will also consult the I nvest igator’s Brochure or Product Information in 
his/her assessment.
For each AE/SAE/medical device deficiency , the investi gator must document in the 
medical notes that he/she has reviewed the AE/SAE/medical device deficiency and has 
provi ded an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has minimal 
inform ation to include in the in itial report to Sponsor. However, it is very important that 
the invest igator always make an assessment of causalit y for every  event before the init ial 
transmissio n of the SAE data to Sponsor.
The invest igator may change his/her opi[INVESTIGATOR_3078] n of causalit y in light of follow-up inform ation 
and send an SAE fo llow-up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  
reporting requirements.
Follow -up of AE/SAE/Medical Device Deficiency
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by [CONTACT_19514]/or causalit y of the AE/SAE/medical device deficiency as fully as 
possible. This may include addit ional laboratory  tests or invest igations, histopathological 
examinat ions, or consultation with other health care professio nals.
If a participant dies during participation in the study or during a recognized fo llow
-up 
period, the invest igator will provide Sponsor with a copy of any post -mortem findings 
including histopathology .
New or updated informat ion will be recorded in the originally co mpleted form.
The invest igator will submit any updated SAE data to Sponsor within 24 hou rs of receipt 
of the inform ation.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 109of 123Appendix G Handling of Human Biological Samples
G [ADDRESS_942903] igator at each center keeps full traceability of co llected bio logical sam ples fro m the 
participants while in storage at the center until shipment or disposal (where appropriate) and 
records relevant processing information related to the samples whilst at site.
The sample receiver keeps full traceabilit y of the sam ples while in s torage and during use unt il 
used or disposed of or until further shipment and keeps record of receipt of arrival and onward 
shipment or disposal.
[COMPANY_008] or delegated representatives will keep oversight of the ent ire life cycle through 
internal  procedu res, m onitoring of study  sites, auditing or process checks, and contractual 
requi rements of external laboratory  provi ders
Samples retained for further use will be stored in the [COMPANY_008] -assigned bi obanks or other 
sample archive facilit ies and will be tr acked by [CONTACT_601096] T eam during for 
the rem ainder of the sam ple life cycle.
G 2 Withdrawal of Informed Consent for Donated Biological Samples 
[COMPANY_008] ensures that bio logical samples are returned to the source or destroyed at the end 
of a specified period as described in the informed consent.
If a participant withdraws consent to the use of donated biolo gical  samples, the sam ples will 
be disposed of/destroy ed/repatriated, and the action documented. If samples are already  
analyzed ,AstraZene ca is not obliged to destroy  the resul ts of this research.
Following wi thdrawal  of consent for bio logical samples, further study  partici pation shoul d be 
considered in relat ion to the wi thdrawal  processes outlined in the informed consent.
The invest igator:
Ensures participant’s withdrawal of informed consent to the use of donated samples is 
highlighted immediately to [COMPANY_008] or delegate.
Ensures that relevant human bio logical samples from  that parti cipant, if stored at the 
study  site, are immediately  identified, disposed of as appropriate, and the action 
docum ented.
Ensures that the participant and [COMPANY_008] are informed about the sample disposal.
[COMPANY_008] ensures the organizat ion(s) ho lding the samples is/are informed about the 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 110of 123withdrawn consent im mediately and that samples are disposed of or repatriated as appropriate, 
and the action is documented and study  site is notified.
G [ADDRESS_942904] SAMPLES
Internatio nal Airline Transportation Associat ion (IA TA) 
(https://www .iata.org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infect ious 
substances into 3 categories: Category  A, Category B or Exempt
Category A Infectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal disease in 
otherwi se healt hy humans or animals. 
Category A Pathogens are, eg, Ebola, Lassa fever virus. Infect ious substances meet ing these 
criteria which cause disease in humans or both in humans and animals must be assigned to 
UN2814. Infect ious substances which cause disease only in animals must be assigned to 
UN2900.
Category B Infectious Substances are infect ious Substances that do not meet the criteria for 
inclusio n in Category  A. Category  B pathogens are, eg, Hepatitis A, C, D, and E viruses. They 
are assigned the fo llowing UN number and proper shippi[INVESTIGATOR_72919]:
UN 33 73 – Biological Substance, Category  B
are to be packed in accordance with UN [ADDRESS_942905] to these R egulati ons unless they  
meet the criteria for inclusio n in another class.
Clinical study samples will fall into Category  B or exempt under IATA regulat ions
Clinical study  samples will routinely  be packed and transported at ambient temperature in 
IATA 650 co mpliant packaging 
(https://www.iata.org/whatwedo/cargo/dgr/Documents/DGR -60-EN-PI650.pdf)
Biological samples transported in dry  ice requi re addi tional dangerous goods specificat ion 
for the dry  ice content
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 111of 123Appendix HMaintenance Therapy Equivalence Table
Asthma Thera py Total Daily Dose ( μg/day)
Inhaled CorticosteroidaMedium High
Beclomethasone dipropi[INVESTIGATOR_16847] (pMDI, standard 
particle, HFA)>500-1000 >1000
Beclomethasone dipropi[INVESTIGATOR_16847] (DPI [INVESTIGATOR_301674], 
extrafine particle, HFA)>200-400 >400
Budesonide (DPI, or pMDI, standard particle, HFA) >400-800 >800
Ciclesonide (pMDI, extrafine particle, HFA) >160-320 >320
Fluticasone furoate (DPI, eg Arnuity®Ellipta®
Breo®)100 200
Fluticasone propi[INVESTIGATOR_16847] (DPI) >250-500 >500
Fluticasone propi[INVESTIGATOR_16847] (pMDI, standard particle, 
HFA)>250-500 >500
Mometasone furoate (DPI) Depends on DPI [INVESTIGATOR_16897] –see product 
information
Mometasone furoate (pMDI, standard particle, 
HFA) >200-400 >400
Inhaled Corticosteroid in ICS/LABA 
combinationaMedium High
Beclomethasone dipropi[INVESTIGATOR_16847] (eg. Fostair®) >200-400 >400
Fluticasone propi[INVESTIGATOR_96701] (eg. Seretide®, 
Advair®)>250-500 >500
Fluticasone furoate (eg. Relvar®Ellipta®, Breo®
Ellipta®)92-100 184-200
Budesonide, if as delivered dose (eg. Symbicort®) >400-640 >640
Mometasone Furoate (eg. Dulera®) >220-400 >400
aThe ICS doses were derived from GINA 2021 and the ICS/LABA combinations were derived from GINA 
2017, 2018, and 2021 and using prescribing information.
Abbreviations: DPI=dry powder inhaler; HFA =hydrofluoroalkane propellant; ICS =inhaled corticosteroid; 
LABA=long -acting β2 agonist ; pMDI =pressurized metered dose inhaler .
ICS by  [CONTACT_301719] a spacer.
Cli nical St u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D [ADDRESS_942906] 
A L P al kali ne p h os p hatase 
A L T ala ni ne a mi n otra nsferase/tra nsa mi nase 
A N C O V A a nal y sis of c o varia nce 
A P F S Access orize d pre -fille d s yri n ge 
A S T as partate a mi n otra nsferase/tra nsa mi nase 
B A L F br o nc h oal ve olar la va ge fl ui d 
B D br o nc h o dilat or 
B MI b o d y mass i n de x 
B U N bl o o d urea nitr o ge n 
C D C Ce nters f or Disease C o ntr ol a n d Pre ve nti o n 
C H O C hi nese ha mster o var y 
CI c o nfi de nce i nter val 
C O VI D - [ADDRESS_942907] u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D [ADDRESS_942908] a n ati o n 
G M F R ge o metric mea n f ol d rise 
G M T ge o metric mea n titer 
H AI he ma g gl uti nati o n -i n hi biti o n 
H C G h u ma n c h ori o nic g o na d otr o pi n 
H C P healt h care pr o vi der 
HI V h u ma n i m m u n o deficie nc y vir uses 
H L H y’s La w 
H P F hi g h p o wer fiel d 
I A T A I nter nati o nal Airli ne Tra ns p ortati o n Ass ociati o n 
I C F i nf or me d c o nse nt f or m 
I C H I nter nati o nal C o u ncil f or Har m o nisati o n 
I C S i n hale d c ortic oster oi ds 
I D i de ntificati o n 
I E C I n de pe n de nt Et hics C o m mittee 
I g A i m m u n o gl o b uli n A
I g E i m m u n o gl o b uli n E 
I g G i m m u n o gl o b uli n G 
I g G [ADDRESS_942909] u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D [ADDRESS_942910]; 
O C S or al c ortic oster oi ds 
P H L p ote ntial H y’s La w 
PI [INVESTIGATOR_32449] i n vesti gat or 
P K p har mac o ki netic 
Q [ADDRESS_942911] o me c or o na vir us 2 
S C s u bc uta ne o us 
S o A Sc he d ule of Acti vities 
T 2 t y p e 2 
T B L t otal bilir u bi n 
T h 2 T hel per t y pe 2 
T P V t hir d part y ve n d or 
T S L P t h y mic str o mal l y m p h o p oieti n 
U L N u p per li mit of n or mal 
U S A/ U S U n ite d States of A merica/ U nite d States 
U S A D E u na ntici pate d a d verse de vice effect 
W B C w h ite bl o o d cell C CI 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 115of 123Appendix JProtocol Amendment History
The Protocol Amendment Summary  of Changes T able for the cu rrent am endment, 
Amendment [ADDRESS_942912] ly before the T able of Contents.
Amendment 1 (07 Sep 2021)
Overall Rationale for  the Amendment:
The Clinical Study  Protocol  (CSP), V ersion 1.0, dated 02 June 2021, was updated with the 
following changes:
Section # and Name [CONTACT_415587]/Non -su
bstantial
Title Page Text was deleted. As [COMPANY_010] is not a co -sponsor of 
study conduct, their name [CONTACT_695035]. This is 
consistent with other AZ run 
tezepelumab clinical studies.Non-substantial
Synopsis; Section 
[IP_ADDRESS] Primary 
EndpointsAnaly sis will be 
summarized by 
[CONTACT_695031].To add additional details. Non-substantial
Synopsis; Section 
[IP_ADDRESS] Primary 
EndpointsText was updated. To clarify that there are four 
strains of the influenza vaccineNon-substantial
Section 1.3 Schedule 
of Activities, Table 2Text related to serum 
antibody testing being 
done prio r to influenza 
vaccination was 
deleted.To add clarity that serum 
antibody testing is done not only 
prior to influenza vacc ine, but 
also 4 weeks later.Non-substantial
Section 1.3 Schedule 
of Activities, Table 2, 
footnote gText was updated. To clarify that unscheduled study 
interventio n visits may be done 
prior to V6, if needed.Non-substantial
Section 1.3 Schedule 
of Activ ities, Table 2, 
footnote h; Section 6.6 
Dose ModificationText was updated. To clarify that unscheduled study 
interventio n visits may be done 
prior to V6, if needed.Non-substantial
Section 3 Objectives 
and Endpoints‘Not controlled’ was 
updated to ‘not w ell-
controlled’Correction of ‘not controlled’ to 
‘not well -controlled’ based on 
Juniper et al 2006 referenceNon-substantial
Section 5.2.1 Study 
EligibilityExclusion criterion #5 
regarding allergy to 
eggs was updated.To clarify that if cell based 
vaccine is used, this is not 
considered an exclusion criterion.Non-substantial
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 116of 123Section # and Name [CONTACT_415587]/Non -su
bstantial
Section 5.2.1 Study 
EligibilityExclusion criterion #18 
regarding COVID -19 
vaccine was updated.To accommodate changing 
enviro nment with booster 
COVID -19 vaccines 
recommended for high-pr iority 
groups including people with 
underlying health conditions.Non-substantial
Section [IP_ADDRESS] 
Management of Study 
Intervention Related 
ReactionsLung function 
assessment was 
removed. Correction of Error: Lung 
function assessments are not 
performed at V3 and V4.Non-substantial
Section 6.5 
Concomitant Therapy, 
Table 7Scheduled 
inactivated/killed 
vaccines, including the 
COVID -[ADDRESS_942913] 
Discontinuation visit 
and End of Study visit 
was added.To clarify that study participants 
should continue in the study even 
if study intervention is 
prematurely withdrawn.Non-substan tial
Section 7.2 Participant 
Withdrawal from the 
Study‘End of Treatment’ 
visit was updated to 
‘Investigational 
Product 
Discontinuation’ visit.To clarify that upon withdrawal, 
an IPD visit needs to be 
conducted.Non-substantial
Section 7.[ADDRESS_942914] u d y Pr ot oc ol – 3 . 0 Astra Ze neca 
Teze pel u ma b –D 5 1 8 0 C 0 0 0 3 1 
C O N FI D E N TI A L A N D P R O P RI E T A R Y 1 1 7 of 1 2 3 Secti o n # a n d N a me Descri pti o n of 
C h a n ge Brief R ati o n ale S u bst a nti al/ N o n -s u 
bst a nti al 
Secti o n 8. 1. 2. [ADDRESS_942915] w or di n g t o pr ot oc ol 
re q uire me nts -s pir o metr y is 
perf or me d o nl y d uri n g scree ni n g. N o n -s u bsta ntial 
  
  
Secti o n 8. 2. 4 Cli nical 
Safet y La b orat or y 
Assess me nts La n g ua ge re gar di n g 
rec or di n g t he date, ti me 
of c ollecti o n, a n d 
res ults bei n g rec or de d 
o n t he a p pr o priate 
electr o nic case re p ort 
f or m, was delete d. Ot her t ha n f or se vere i nfecti o ns, 
i nf or mati o n re gar di n g l ocal 
la b orat o r y  tests d o ne o utsi de of 
t he Sc he d ule of Acti vities are n ot 
c ollecte d i n t he electr o nic case 
re p ort f or m. N o n -s u bsta ntial 
 
  
 
  
 
 
   
 
  
  
  
   
  
 
I n a d dit i o n, mi n or f or matti n g a n d e dit orial re visi o ns were ma de t hr o u g h o ut t he pr ot oc ol. C CI 
C CI 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 118of [ADDRESS_942916] cells. J Exp Med. 2007;204:253 -8.
Antonicelli et al 2004
Antoni celli L, Bucca C, Neri  M, De Benedetto F , Sabbatani P , Bonifazi F , et al . Asthma 
severit y and medical resource utilizat ion. Eur Respir J. 2004;23(5):723 -9.
Asthma and Allergy Foundation of America 2017
Asthma and Allergy Foundat ion of America. Allergic Asthma. A vailable at: 
http://www .aafa.org/display .cfm?id=8&sub=16. Accessed 23Apr2021 .
Asthma and Allergy Foundation of America 
Asthma and Allergy Foundat ion of America. Asthma Facts and Figures. A vailable at: 
https://www .aafa.org/asthma -facts/ . Accessed 29 April 2021.
Barnes and Kuitert 1996
Barnes NC, Kuitert LM. Risk of sever e life threatening asthma. Thorax 1996 
Nov;51(11):1073.
Brightling et al 2008
Brightling C, Berry M, Amrani Y . Targeting TNF -alpha: a novel therapeut ic approach for 
asthma. J Allergy Clin Immuno l. 2008;121(1):5-10.
CDC Asthma 2021
Centers for Disease Contr ol and Prevent ion (CDC). Flu & People wi th Asthma. Available at:
https://www .cdc.gov/flu/highrisk/asthma.ht m.Accessed 07May 2021.
CDC Influenza 2021
Centers for Disease Control and Prevent ion (CDC). Key Facts About Seasonal Flu V accine . 
Available at: https://www .cdc.gov/flu/prevent/keyfacts.htm . Accessed 18May 2021.
CINQAERO SmPC 2021
CINQAERO (reslizumab). Summary or Product Characterist ics. Teva B.V . Haarlem, The 
Netherl ands. Revised June 2021
. Available at: 
https://www .ema.europa.eu/en/documents/product -inform ation/cinqaero -epar-product -
inform ation_en.pdf. Accessed 31Jan2022.
CINQAIR US PI 2020
CINQAIR (reslizumab). Prescribing informat ion. Teva Respi[INVESTIGATOR_442072], W est Chester, P A, 
[LOCATION_003]; Revise d February  2020. A vailable at: 
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 119of 123https://www .cinqair .com /globalassets/cinqair/prescribinginformation.pdf . Accessed 
23Apr2021.
Corren et al 2017
Corren J, Parnes JR, W ang L, Mo M, Roseti SL, Griffit hs JM, et al. T ezepelumab in Adult s 
with Uncontrolled Asthm a. N Engl  J Med. 2017;377(10):936
-946.
CSGA 1997
The Collaborative Study  on the Genetics of Asthma (CSGA). A genome -wide search for 
asthma suscept ibilit y loci in ethnically diverse populat ions. Nat Genet. 1997;15(4):389-92.
DUPI[INVESTIGATOR_694950] 2020
DUPI[INVESTIGATOR_24786] (dupi[INVESTIGATOR_12458]) solut ion for injection. Summary  of Product Characterist ics. Sano fi-
Avent is Groupe. Revised January  2021 . Available at: 
https://www .ema.europa.eu/en/documents/product -inform ation/dupi[INVESTIGATOR_12460] -epar-product -
inform ation_en.pdf . Accessed 23Apr2021.
DUPI[INVESTIGATOR_694951] 2019
DUPI[INVESTIGATOR_24786] (dupi[INVESTIGATOR_12458]) inject ion for subcutaneous use. [LOCATION_002] Prescribing 
Inform ation. Regeneron Pharmaceut icals, Inc. Revised January  2021 . Available at: 
https://www .regeneron.com/downloads/dupi[INVESTIGATOR_12460]_fpi.pdf . Accessed 23Apr2021.
FASENRA SmPC 2019
FASENRA  (benralizumab) for injection. Summary of Product Characterist ics. [COMPANY_008] 
AB. Revised August 20 20. A vailable at: https://www .ema.europa.eu/en/documents/product -
inform ation/fasenra -epar-product -informat ion_en.pdf. Accessed 23Apr2021 .
FASENRA US PI 2019
FASENRA  (benralizumab) inject ion, for subcutaneous use. [LOCATION_002] Prescribing 
Inform ation. [COMPANY_008] Pharmaceut icals LP. Revised February  2021 . Available at: 
https://den8dhaj6zs0e.cloudfront.net/50fd68b9 -106b-4550- b5d0 -12b045f8b184/3647bed4 -
ce91-4fe7-9bc5 -32dbee73f80a/3647bed4 -ce91 -4fe7-9bc5 -
32dbee73f80a_viewable_rendit ion__v .pdf. Accessed 23Apr2021.
FDA [ADDRESS_942917] ion 2021 -
2022 
Northern Hemisphere, FDA  Vaccines and Related Biological Products Advisory  Committee 
(3/5/2021). Available at: https://www .fda.gov/media/146448/download . Accessed 
07May 2021.
Froidure et al 2016
Froidure A, Mouthuy J, Durham SR, Chanez P , Sibi lle Y, Pi[INVESTIGATOR_96691] C. Asthma phenotypes and 
IgE responses. Eur Resp J. 2016;47:304 -
19.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 120of 123Gauvreau et al 2014
Gauvreau GM, O'By [CONTACT_695032], Boul etL-P, W angY, Cockcroft D, BiglerJ, et al . Effects of an 
anti-TSLP ant ibody  on allergen- induced asthmat ic responses. N Engl J Med. 
2014;370(22):[ADDRESS_942918] ivated by [CONTACT_695033]40L  induce proallergic cytotoxic T cells. J 
Exp Med. 2003;197(8):1059-63.
GINA 2021
Global Strategy  for Asthma Management and Prevent ion, Gl obal Init iative for Asthma 
(GINA). Updated 2021. A vailable fro m: https://ginasthma.org/wp -
content/uploads/2021/05/GINA -Main -Report -2021 -V2-WMS.pdf
Global Asthma Network 2018
Global Asthm a Network. The Global Asthma Report 2018. Available fro m: 
http://globalasthmareport.org/. Accessed 23Apr2021.
Graham et al 2019
Graham BL, Steenbruggen I
, Miller MR, Barj aktarevic IZ, Cooper BG, Hall GL, et al .
Standardi zation of Spi[INVESTIGATOR_96656] 2019 Update. An Official American Thoracic Societ y and 
European Respi[INVESTIGATOR_271058]. Am J Respir Crit Care Med. 
2019;15;200(8):e70 -e88.
Hannoun et al 2004
Hannoun C, Megas F , Pi[INVESTIGATOR_5784]  J. Immunogenicit y and pr otective efficacy o f influenza 
vaccination. Virus Res. 2004;103(1 -2):[ADDRESS_942919] ion with influenza A2 and B viruses. 
J Hyg (Lond). 1972;70(4):767 -77.
Juniper et al 2005
Juniper EF , Svensson K, Mörk AK, Ståhl E. Measurement properties and interpretation of 
three shortened versions of the asthma control questionnaire. Respir Med. 2005;99:553 -58.
Juniper et al 2006
Juniper EF , Bousquet J, Abetz L, Bateman ED. The GOAL  Committee. Identifying ‘well-
controlled ’ and ‘not well -controlled ’ asthma using the Asthma Control Quest ionnaire. Respir 
Med. 2006;100:616 -21.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 121of 123Krammer 2019
Krammer F . The human ant ibody  response to influenza A  virus infection and vaccinat ion. Nat 
Rev Immuno l. 2019;19(6):383 -397.
Kroger et al 2011
Kroger AT, Sumay  CV, Pi[INVESTIGATOR_34513], Atkinson WL. General reco mmendat ions on 
immunizat ion: Reco mmendat ions of the Advisory Committee on Immunizat ions Pract ices 
(ACIP). Morbidit y and Mortalit y Weekly  Report (MMWR). 201 1;60(RR02):1 -60.
Langley et al 2013
Langley  JM, Matinez AC, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, et al. 
Immunogenicit y and safet y of an inactivated quadrivalent influenza vaccine c andidate: A 
Phase III randomised controlled trial in children. J Infect Dis. 2013;208:[ADDRESS_942920] ice paramete r: 2010 update. J Allergy Clin 
Immunol. 2010;126(3):477- 80.e1 -42.
Menzies -Gow et al 2021
Menzies -Gow A, Corren J, Bourdin A, Chupp G, Israel E, W echsler ME, et al. Tezepelumab in 
Adults and Ado lescents with Severe, Uncontrolled Asthma. N Engl J Med. 
2021;384(19):1800 -1809.
NHANES III 2010
Centers for Disease Control and Prevent ion. NHANES III. Spi[INVESTIGATOR_694982]. 
Office of Informat ion Service, CDC/National Center for Health Statist ics. 2010 Nov . 
Available at: http://www .cdc.gov/nchs/nhanes/nh3rrm.ht m.
NUCALA SmPC 2019
NUCALA  (mepolizumab) Summary  of Product Characteri stics. Gl axoSmi thKline Trading 
Services Limited. Revised March 2021. Available at: 
https://www .ema.europa.eu/en/documents /product -inform ation/nucala
-epar-product -
inform ation_en.pdf. Accessed 23Apr2021.
NUCALA US PI 2019
NUCALA  (mepolizumab). US Prescribing information. GlaxoSmithKline, Research Triangle 
Park, NC, [LOCATION_003]; -Revised September 2020 . Available at:
 
https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Informat ion/Nucala/pdf/
NUCALA -PI-PIL-IFU-COMBINED.PDF . Accessed [ADDRESS_942921] ion in asthma: an overview . J Allergy Clin Immuno l. 2005;116(3):477 -86.
Clinical Study Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 122of 123Quanjer et al 2012
Quanjer PH, Stanojevic S, Cole TJ, Baur X, L  Hall GL, Culver B, et al. Mult i ethnic reference 
values for spi[INVESTIGATOR_96694] 3 -95 year age range: the glo bal lung funct ion 2012 equations. 
2012;40(6):[ADDRESS_942922] T , Liu Mr, Travis M, et al. Human thymic 
strom al lymphopoi etin preferent ially stim ulates myelo id cells. J Immuno l. 2001;167(1):336-
43.
Serra -Batlles et al 1998
Serra -Batlles J, Plaza V , Morej ón E, Com ella A, Brugués J. Costs of asthma according to the 
degree of severi ty. Eur Respi r J. 1998;12(6): 1322 -6.
Sicca et al 2020
Sicca F , Martinuzzi D, Montomo li E, Huckriede A. Comparison of influenza -specific 
neutralizing ant ibody  titers determined using different assay  readouts and hemagglut ination 
inhibit ion titers:good correlation but poor agreement. V accine. 2020;38(11):2527-2541.
Simpson et al 2006
Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subt ypes in asthma: assessment 
and ident ificat ion using induced sputum. Respi[INVESTIGATOR_310366]. 2006;1 1(1):[ADDRESS_942923] G, Hom ey B, et al . Hum an epi [INVESTIGATOR_694983] -mediated allergic inflammat ion by [CONTACT_96783] . Nat Immunol .
2002;3:673 -80.
Swedin et al 2017
Swedin L, Saarne T , Rehnberg M, Glader P , Niedzielska M, Johansson G, et al. Patient 
stratificat ion and the unmet need in asthma. Pharmacol Ther . 2017;169:13-34.
TEZSPI[INVESTIGATOR_694984] 2021
TEZSPI[INVESTIGATOR_21392] (tezepelumab -ekko) Prescribing Informat ion. [COMPANY_010] Inc., One [COMPANY_010] Center 
Drive, Thousand Oaks, CA  [ZIP_CODE] -1799. Revised December 2021. Available at: 
https://www .accessdata.fda.gov/drugsatfda_docs/label/2021/761224s000lbl.pdf . Accessed 
31Jan2022.
Tough et al [ADDRESS_942924] inguish those 
who die from asthma fro m communit y control s with asthma. J Asthma. 1998;35(8):657
-65.
Turner et al 1998
Turner MO, Noertjo jo K, V edal S, Bai  T, Crump S, Fitzgerald JM. Risk factors for near -fatal 
Clinical Stu dy Protocol – 3.0 [COMPANY_008]
Tezepelumab –D5180C00031
CONFIDENTIAL AND PROPRIETARY 123of 123asthma. A case-control  study  in hospi [INVESTIGATOR_694985]. Am J Respir Crit Care Med. 
1998;157(6 Pt 1):1804 -9.
XOLAIR SmPC 2019
XOLAIR (omalizumab). Summary of Product Characterist ics. [COMPANY_001] Europharm Limited, 
Dublin, Ireland. Revised August 2020 . Available at: 
https://www .ema.europa.eu/en/documents/product -inform ation/xolair-epar-product -
inform ation_en.pdf . Accessed 23Apr2021 .
XOLAIR US PI 2019
XOLAIR (omalizumab). Prescribing informat ion. Novarti s Pharm aceut icals Corporation, East 
Hanover, NJ, [LOCATION_003]; revised April 2021 . Available at: 
https://www .gene.com/d ownl oad/pdf/xol air_prescribing.pdf .
 Accessed 23Apr2021.
Wenzel 2016
Wenzel SE. Em ergence o f biomolecular pathways to define novel asthma phenoty pes. T ype-
2 
immunit y and bey ond. Am J Respir Cell Mo l Biol. 2016;55:1 -4.
Ying et al 2005
Ying S, O ’Connor B, R atoff J, Meng Q, Mallett K, Cousins D, et al. Thymic stromal 
lymphopoi etin expressio n is increased in asthmat ic airways and correl ates wi th expressio n of 
Th2 attracting chemokines and disease severit y. J Immunol . 2005;174: [ADDRESS_942925], Leong M, Cole J, Mallory  RM, Shih VH, Olsson RF , Benralizumab does not 
impair ant ibody  response to seasonal influenza vaccinat ion in ado lescent and y oung adul t 
patients wi th moderate to severe asthma: results from the Phase IIIb ALIZE tri al. J Asthm a 
Allergy . 2018;1 1:181 -192.
Ziegler et al 2013
Ziegler SF , Roan F , Bell  BD, Stokl asek T A, Kitajima M, Han H. The bio logy of thymic 
strom al lymphopoi etin (TSLP). Adv Pharmaco l.2013;66:[ADDRESS_942926] ati o n of t he electr o nic si g n at ure 
D oc u me nt N a me: d 5 1 8 0c 0 0 0 3 1-cs p- v 3 
D oc u me nt Title: D [ADDRESS_942927] u d y Pr ot oc ol versi o n 3 
D oc u me nt I D: 
Versi o n L a bel: 4. 0 C U R R E N T L A T E S T A P P R O V E D 
Ser ver D ate 
( d d- M M M- y y y y H H: m m ‘ U T C’ Z) Si g ne d b y Me a ni n g of Si g n at ure 
2 3- Fe b- 2 0 2 2 1 3: 0 9 U T C C o nte nt A p pr o val 
2 3- Fe b- 2 0 2 2 1 1: 4 0 U T C C o nte nt A p pr o val 
2 3- Fe b- 2 0 2 2 2 2: 0 7 U T C C o nte nt A p pr o val 
N otes: ( 1) D oc u me nt details as st ore d i n  , a n Astra Ze neca d oc u me nt ma na ge me nt s yste m. P P D 
P P D 
P P D C CI 
C CI 